

# Diagnosis and management of dementia with Lewy bod

Neurology

89, 88-100

DOI: [10.1212/wnl.0000000000004058](https://doi.org/10.1212/wnl.0000000000004058)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Familial Occurrence of Dementia and Parkinsonism. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 288-295.	0.7	22
2	Evaluation of Probable or Possible Dementia with Lewy Bodies Using 123I-HMP Brain Perfusion SPECT, 123I-MIBG, and 99mTc-MIBI Myocardial SPECT. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1641-1650.	2.8	25
3	Boston naming performance distinguishes between Lewy body and Alzheimer's dementias. <i>Archives of Clinical Neuropsychology</i> , 2007, 22, 925-931.	0.3	25
4	Spatial Perseveration in Dementia with Lewy Bodies. <i>Behavioural Neurology</i> , 2007, 18, 235-236.	1.1	3
5	Invited Article: Nervous system pathology in sporadic Parkinson disease. <i>Neurology</i> , 2008, 70, 1916-1925.	1.5	471
6	Patterns and stages of $\alpha$ -synucleinopathy. <i>Neurology</i> , 2008, 70, 1042-1048.	1.5	226
7	Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 667-670.	0.9	70
8	Patterns of motor and non-motor features in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 846-850.	0.9	52
9	P1.190 Detection of Lewy body disease in patients with late-onset depression, anxiety and psychotic disorder with myocardial meta-iodobenzylguanidine scintigraphy. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S78.	1.1	0
10	Les troubles cognitifs de la maladie d'Alzheimer et des syndromes apparentés: pourquoi et comment les explorer?. <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2009, 9, 183-190.	0.1	0
11	Parkinsonismo farmacológico frente a demencia con cuerpos de Lewy. <i>Neurología</i> , 2010, 25, 459-461.	0.3	1
12	Pharmacological Parkinsonism vs. Dementia with Lewy Bodies. <i>Neurología (English Edition)</i> , 2010, 25, 459-461.	0.2	0
14	Parkinson's disease: Insights from non-traditional model organisms. <i>Progress in Neurobiology</i> , 2010, 92, 558-571.	2.8	60
15	Did Immanuel Kant have dementia with Lewy bodies and REM behavior disorder?. <i>Sleep Medicine</i> , 2010, 11, 586-588.	0.8	5
16	High Resolution Imaging of the Medial Temporal Lobe in Alzheimer's Disease and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1129-1140.	1.2	42
17	Neuropathological Alterations in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a006189-a006189.	2.9	2,365
19	CSF Amyloid- $\beta$ Peptides in Neuropathologically Diagnosed Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 383-391.	1.2	26
20	Epidemiological Neuropathology: The MRC Cognitive Function and Aging Study Experience. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 359-372.	1.2	106

#	ARTICLE	IF	CITATIONS
21	CSF Tau, A $\beta$ 42, and MHPG Differentiate Dementia with Lewy Bodies from Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 377-384.	1.2	36
22	An extended registration framework for the triple registration of IBZM SPECT, DATSCAN SPECT and MRI brain images to support the evaluation of brain dopamine receptor scintigraphies. , 2011, 2011, 8025-8.		0
23	The Neuropsychological Profile of Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006171-a006171.	2.9	392
24	Cortical Thinning in Subcortical Vascular Dementia with Negative 11C-PIB PET. Journal of Alzheimer's Disease, 2012, 31, 315-323.	1.2	37
25	Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia. Journal of Alzheimer's Disease, 2012, 33, 117-131.	1.2	40
26	Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. Journal of Parkinson's Disease, 2012, 2, 57-65.	1.5	38
27	Striatal Amyloid Plaque Density Predicts Braak Neurofibrillary Stage and Clinicopathological Alzheimer's Disease: Implications for Amyloid Imaging. Journal of Alzheimer's Disease, 2012, 28, 869-876.	1.2	65
28	From Molecule to Clinic and Community for Neurodegeneration: Research to Bridge Translational Gaps. Journal of Alzheimer's Disease, 2012, 33, S385-S396.	1.2	5
29	Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 505-510.	0.9	58
30	Clinicopathologic Study of Alzheimer's Disease: Alzheimer Mimics. Journal of Alzheimer's Disease, 2013, 35, 799-811.	1.2	43
32	Using Cerebrospinal Fluid Marker Profiles in Clinical Diagnosis of Dementia with Lewy Bodies, Parkinson's Disease, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 63-73.	1.2	39
34	Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration. Journal of Parkinson's Disease, 2013, 3, 415-459.	1.5	68
35	Resting State Cortical Electroencephalographic Rhythms in Covert Hepatic Encephalopathy and Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 707-725.	1.2	8
36	Longitudinal Stability of Cerebrospinal Fluid Biomarker Levels: Fulfilled Requirement for Pharmacodynamic Markers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 807-822.	1.2	35
37	Cerebrospinal Fluid A $\beta$ 1-40 Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels. Journal of Alzheimer's Disease, 2013, 36, 759-767.	1.2	79
38	Amyloid Pathology Influences A $\beta$ 1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2013, 35, 137-146.	1.2	45
39	The New Qualitative Scoring MMSE Pentagon Test (QSPT) as a Valid Screening Tool between Autopsy-Confirmed Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 823-832.	1.2	28
40	Dementia and Systemic Disease. , 2014, , 1263-1277.		0

#	ARTICLE	IF	CITATIONS
41	Physical Activity Reduces the Risk of Dementia in Mild Cognitive Impairment Subjects: A Cohort Study. Journal of Alzheimer's Disease, 2014, 39, 833-839.	1.2	71
42	Lyme Neuroborreliosis and Dementia. Journal of Alzheimer's Disease, 2014, 41, 1087-1093.	1.2	45
43	Psychiatric Disorders Impacting Critical Illness. Critical Care Nursing Clinics of North America, 2014, 26, 115-138.	0.4	7
44	Malattia a corpi di Lewy. EMC - Neurologia, 2014, 14, 1-8.	0.0	0
45	Age-Associated Changes of Brain Copper, Iron, and Zinc in Alzheimer's Disease and Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2014, 42, 1407-1413.	1.2	59
46	Hippocampal Sclerosis of Aging is a Key Alzheimer's Disease Mimic: Clinical-Pathologic Correlations and Comparisons with both Alzheimer's Disease and Non-Tauopathic Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2014, 39, 691-702.	1.2	83
47	1H-Proton Magnetic Resonance Spectroscopy Differentiates Dementia with Lewy Bodies from Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 40, 953-966.	1.2	14
48	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2014, 41, 313-327.	1.2	307
49	Amyloid- $\beta^2$ Oligomers Relate to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 35-43.	1.2	52
50	Apolipoprotein E4 Affects Topographical Changes in Hippocampal and Cortical Atrophy in Alzheimer's Disease Dementia: A Five-Year Longitudinal Study. Journal of Alzheimer's Disease, 2015, 44, 1075-1085.	1.2	11
51	I716F A $\beta$ 2PP Mutation Associates with the Deposition of Oligomeric Pyroglutamate Amyloid- $\beta^2$ and $\beta^2$ -Synucleinopathy with Lewy Bodies. Journal of Alzheimer's Disease, 2015, 44, 103-114.	1.2	13
52	Cognitive impairment, dementia, and occupational therapy interventions. , 2016, , 245-265.		2
53	Dementia with Lewy bodies advances. Neurology, 2017, 89, 18-19.	1.5	4
54	Neuroleptic malignant syndrome following quetiapine treatment in a patient with dementia with Lewy bodies. Asian Journal of Psychiatry, 2017, 30, 173-174.	0.9	6
55	Diagnosis and Management of Cognitive and Behavioral Changes in Dementia With Lewy Bodies. Current Treatment Options in Neurology, 2017, 19, 42.	0.7	14
56	Clinical and radiological diversity in genetically confirmed primary familial brain calcification. Scientific Reports, 2017, 7, 12046.	1.6	16
57	What Can Quantitative Gait Analysis Tell Us about Dementia and Its Subtypes? A Structured Review. Journal of Alzheimer's Disease, 2017, 60, 1295-1312.	1.2	59
58	Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias. Archives of Clinical Neuropsychology, 2017, 32, 786-801.	0.3	27

#	ARTICLE	IF	CITATIONS
59	The Oligomer Hypothesis in $\alpha$ -Synucleinopathy. <i>Neurochemical Research</i> , 2017, 42, 3362-3371.	1.6	53
60	Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 73.	2.0	26
61	Alzheimer's Disease: Past, Present, and Future. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 818-831.	1.2	389
62	Hallucinations Are Real to Patients With Dementia. <i>Gerontology and Geriatric Medicine</i> , 2017, 3, 233372141772110.	0.8	1
63	Alzheimer's Disease-Related Dementias Summit 2016: National research priorities. <i>Neurology</i> , 2017, 89, 2381-2391.	1.5	109
64	Cingulate island sign temporally changes in dementia with Lewy bodies. <i>Scientific Reports</i> , 2017, 7, 14745.	1.6	37
65	Dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 310-311.	1.5	3
67	How far can biomarkers take us in neurodegenerative disorders?. <i>Brain</i> , 2017, 140, 3067-3068.	3.7	3
68	Dementia with Lewy Bodies. , 2017, , 89-102.		0
69	UK lags far behind Europe on diagnosis of dementia with Lewy bodies. <i>BMJ: British Medical Journal</i> , 2017, 358, j3319.	2.4	6
71	Accumulation of 123I-hoflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-Naïve Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 321.	1.7	4
72	Evidence-Based Review of Therapeutic Approaches in Dementia with Lewy Bodies. , 2017, 07, .		0
73	Cognitive profile in prodromal disease (dementia) with Lewy bodies. <i>Psychologie &amp; Neuropsychiatrie Du Vieillissement</i> , 2017, 15, 434-442.	0.2	4
74	Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. <i>F1000Research</i> , 2017, 6, 1604.	0.8	35
75	Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 247-268.	1.2	50
76	Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2018, 90, 299-300.	1.5	2
77	Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2018, 90, 298-299.	1.5	0
78	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 503-510.	2.2	52

#	ARTICLE	IF	CITATIONS
79	Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer's Disease Versus Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 699-711.	1.2	17
80	Integrated neurodegenerative disease autopsy diagnosis. <i>Acta Neuropathologica</i> , 2018, 135, 643-646.	3.9	12
81	Pharmacological interventions for psychosis in Parkinson's disease patients. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 499-505.	0.9	26
82	Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies. <i>Movement Disorders</i> , 2018, 33, 1130-1138.	2.2	36
83	Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis. <i>Clinical Neurophysiology</i> , 2018, 129, 1209-1220.	0.7	43
84	How does dementia with Lewy bodies start? prodromal cognitive changes in REM sleep behavior disorder. <i>Annals of Neurology</i> , 2018, 83, 1016-1026.	2.8	76
85	Patterns of carer distress over time in mild dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 987-993.	1.3	12
86	The clinical relevance of cognitive impairment in REM sleep behavior disorder. <i>Neurology</i> , 2018, 90, 909-910.	1.5	4
88	EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2018, 67, 75-83.	1.5	21
89	PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1519-1525.	1.2	24
90	Lewy Body Disease: Clinical and Pathological 'Overlap Syndrome' Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 24.	2.0	40
91	Negative 11C-PIB PET Predicts Lack of Alzheimer's Disease Pathology in Postmortem Examination. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 79-85.	1.2	1
92	When Post-Traumatic Stress Disorder and Charles Bonnet Syndrome Become Lewy Body Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 911.	0.6	2
93	Biomarkers study in atypical dementia: proof of a diagnostic work-up. <i>Neurological Sciences</i> , 2018, 39, 1203-1210.	0.9	3
94	Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2018, 90, 300-300.	1.5	2
95	FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. <i>NeuroImage: Clinical</i> , 2018, 18, 167-177.	1.4	108
96	Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimer's and Parkinson's diseases. <i>Clinical Neurophysiology</i> , 2018, 129, 766-782.	0.7	45
97	Author response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2018, 90, 300-301.	1.5	12

#	ARTICLE	IF	CITATIONS
98	Dementia. American Journal of Medicine, 2018, 131, 1161-1169.	0.6	314
99	Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Annals of Neurology, 2018, 83, 522-531.	2.8	150
100	The role of biomarkers and imaging in the clinical diagnosis of dementia. Age and Ageing, 2018, 47, 641-643.	0.7	27
101	Progress and Challenges in the Diagnosis of Dementia: A Critical Review. ACS Chemical Neuroscience, 2018, 9, 446-461.	1.7	22
102	Editors' note: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 2018, 90, 298-298.	1.5	0
103	Alpha event-related synchronization after eye closing differs in Alzheimer's disease and dementia with Lewy bodies: a magnetoencephalography study. Psychogeriatrics, 2018, 18, 202-208.	0.6	1
104	Daytime sleepiness in dementia with Lewy bodies is associated with neuronal depletion of the nucleus basalis of Meynert. Parkinsonism and Related Disorders, 2018, 50, 99-103.	1.1	22
105	Neuropathology correlates of cognitive assessments. Irish Journal of Medical Science, 2018, 187, 835-844.	0.8	1
106	Clinicopathological and <sup>123</sup> I-â€‹FP-â€‹CIT SPECT correlations in patients with dementia. Annals of Clinical and Translational Neurology, 2018, 5, 376-381.	1.7	11
107	Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies. Psychological Medicine, 2018, 48, 2384-2390.	2.7	66
108	Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 143-152.	1.2	44
109	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiology of Aging, 2018, 65, 18-40.	1.5	61
110	The Added Value of Dynamic 18F-Florbetapir PET in the Assessment of Dementia With Lewy Bodies. Clinical Nuclear Medicine, 2018, 43, e85-e86.	0.7	2
111	Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives. Neurology and Therapy, 2018, 7, 13-22.	1.4	8
112	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 2-20.	0.9	77
113	Tau Imaging in Parkinsonism: What Have We Learned So Far?. Movement Disorders Clinical Practice, 2018, 5, 118-130.	0.8	14
114	Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?. BMC Medicine, 2018, 16, 34.	2.3	232
115	Cognitive fluctuations in Parkinson's disease dementia: blood pressure lability as an underlying mechanism. Journal of Clinical Movement Disorders, 2018, 5, 1.	2.2	8

#	ARTICLE	IF	CITATIONS
116	Functional Disconnectivity during Inter-Task Resting State in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 105-120.	0.7	9
117	Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden. <i>BMC Geriatrics</i> , 2018, 18, 50.	1.1	16
118	Clinical prevalence of Lewy body dementia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 19.	3.0	135
119	Improving the identification of dementia with Lewy bodies in the context of an Alzheimer's-type dementia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 27.	3.0	43
120	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 71-84.	1.5	12
121	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1470-1486.	3.3	19
122	CSF biological antioxidant potentials may differentiate neurodegenerative diseases-A preliminary report. <i>Neurology and Clinical Neuroscience</i> , 2018, 6, 45-47.	0.2	2
123	Brain FDG-PET: clinical use in dementing neurodegenerative conditions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1467-1469.	3.3	2
124	Title is missing!. <i>Journal of Otolaryngology of Japan</i> , 2018, 121, 8-13.	0.1	0
125	Letter to the Editor Regarding: Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives. <i>Neurology and Therapy</i> , 2018, 7, 161-163.	1.4	2
126	Author's Response to the Letter to the Editor Regarding: Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives. <i>Neurology and Therapy</i> , 2018, 7, 165-167.	1.4	1
129	Clinical imaging in dementia with Lewy bodies. <i>Evidence-Based Mental Health</i> , 2018, 21, 61-65.	2.2	21
130	Electroencephalographic derived network differences in Lewy body dementia compared to Alzheimer's disease patients. <i>Scientific Reports</i> , 2018, 8, 4637.	1.6	44
131	Are we missing dementia with Lewy bodies?: a case report. <i>Australasian Psychiatry</i> , 2018, 26, 381-383.	0.4	1
132	CT-based attenuation correction and resolution compensation for I-123 IMP brain SPECT normal database: a multicenter phantom study. <i>Annals of Nuclear Medicine</i> , 2018, 32, 311-318.	1.2	7
133	18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. <i>Scientific Reports</i> , 2018, 8, 4717.	1.6	59
134	REM Sleep Behavior Disorder and Alzheimer's Disease: Definitely No Relationship?. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1-11.	1.2	35
135	Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB consortium. <i>Neurology</i> , 2018, 90, 299-299.	1.5	0



#	ARTICLE	IF	CITATIONS
136	Lewy Body Dementia. , 2018, , 297-312.		3
137	Mild Cognitive Impairment in Parkinsonâ€™s Diseaseâ€”What Is It?. Current Neurology and Neuroscience Reports, 2018, 18, 17.	2.0	57
138	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
139	Dementia with Lewy Bodies and Parkinson Disease Dementia: It is the Same Disease!. Parkinsonism and Related Disorders, 2018, 46, S6-S9.	1.1	46
140	Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 358-366.	0.9	106
141	The diagnosis of dementias: a practical tool not to miss rare causes. Neurological Sciences, 2018, 39, 615-627.	0.9	14
142	Propagation of alpha-synuclein pathology from the olfactory bulb: possible role in the pathogenesis of dementia with Lewy bodies. Cell and Tissue Research, 2018, 373, 233-243.	1.5	36
143	Dementia with Lewy bodies and Parkinsonâ€™s disease-dementia: current concepts and controversies. Journal of Neural Transmission, 2018, 125, 615-650.	1.4	200
144	Imaging and CSF analyses effectively distinguish CJD from its mimics. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 461-466.	0.9	69
145	MicroRNA expression patterns in human anterior cingulate and motor cortex: A study of dementia with Lewy bodies cases and controls. Brain Research, 2018, 1678, 374-383.	1.1	23
146	Utility of Autonomic Function Tests to Differentiate Dementia with Lewy Bodies and Parkinson Disease with Dementia from Alzheimer Disease. European Neurology, 2018, 79, 27-32.	0.6	14
147	Neuropathology of Parkinson disease. Parkinsonism and Related Disorders, 2018, 46, S30-S33.	1.1	363
148	Development and validation of a screening instrument for cognitive fluctuation in patients with neurocognitive disorder with Lewy bodies (NCDLB): the Mayo Fluctuations Scale-Thai version. Annals of General Psychiatry, 2018, 31, e000001.	1.1	1
149	Rapidly Progressive Dementia. , 2018, , .		1
150	Diagnostic value of Alzheimer's biomarkers in cerebrospinal fluid in dementia with Lewy body. Psychologie & Neuropsychiatrie Du Vieillissement, 2018, 16, 174-180.	0.2	2
152	Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain, 2018, 141, 3415-3427.	3.7	95
153	Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimerâ€™s Disease: A Case Report. Journal of Alzheimer's Disease, 2018, 66, 1363-1369.	1.2	5
154	Autopsied centenarian case of Alzheimer's disease combined with hippocampal sclerosis, TDPâ€™43, and Î±â€™synuclein pathologies. Neuropathology, 2018, 38, 653-659.	0.7	0

#	ARTICLE	IF	CITATIONS
155	The D'Épistage Cognitif de Qu'Ébec: A New Clinician'™s Tool for Early Recognition of Atypical Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 310-321.	0.7	13
156	Cervical skin denervation associates with alpha'€synuclein aggregates in Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1394-1407.	1.7	39
157	Brains for Dementia Research: Evolution in a Longitudinal Brain Donation Cohort to Maximize Current and Future Value. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1635-1644.	1.2	24
158	Clinical-Neuropathological Correlations of Alzheimer'™s Disease and Related Dementias in Latino Volunteers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1539-1548.	1.2	11
159	Psychiatric Manifestation in Patients with Parkinson's Disease. <i>Journal of Korean Medical Science</i> , 2018, 33, e300.	1.1	58
160	Î±'€Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. <i>Movement Disorders</i> , 2018, 33, 1724-1733.	2.2	79
161	Multiparametric MR imaging of Parkinsonisms at 3 tesla: Its role in the differentiation of idiopathic Parkinson'™s disease versus atypical Parkinsonian disorders. <i>European Journal of Radiology</i> , 2018, 109, 95-100.	1.2	24
162	Occipital and Cingulate Hypometabolism are Significantly Under-Reported on 18-Fluorodeoxyglucose Positron Emission Tomography Scans of Patients with Lewy Body Dementia. , 2018, 08, .		2
163	Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics. <i>PLoS Biology</i> , 2018, 16, e2006265.	2.6	44
164	Comparison of brain perfusion patterns in dementia with Lewy bodies patients with or without cingulate island sign. <i>Geriatrics and Gerontology International</i> , 2019, 19, 197-202.	0.7	5
165	MR approaches in neurodegenerative disorders. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2018, 108, 1-16.	3.9	23
166	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <i>Annals of Neurology</i> , 2019, 85, 259-271.	2.8	88
167	Structural Brain Correlates of Attention Dysfunction in Lewy Body Dementias and Alzheimer'™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 347.	1.7	12
168	Role of myocardial 123I-mIBG innervation imaging in the diagnosis of neurodegenerative diseases. <i>Clinical and Translational Imaging</i> , 2018, 6, 449-458.	1.1	6
169	Utility of Amyloid PET Scans in the Evaluation of Patients Presenting with Diverse Cognitive Complaints. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1599-1608.	1.2	3
170	Young Onset Dementia. , 2018, , .		2
172	Cerebrospinal fluid 5-HIAA concentrations correlate with cardiac uptake of 123I-MIBG during myocardial scintigraphy in drug na'€ve Parkinson'™s disease. <i>Journal of Neural Transmission</i> , 2018, 125, 1511-1514.	1.4	2
173	A new visual rating scale for loflupane imaging in Lewy body disease. <i>NeuroImage: Clinical</i> , 2018, 20, 823-829.	1.4	14

#	ARTICLE	IF	CITATIONS
174	Voxel-wise deviations from healthy aging for the detection of region-specific atrophy. <i>NeuroImage: Clinical</i> , 2018, 20, 851-860.	1.4	18
175	Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. <i>Nature Neuroscience</i> , 2018, 21, 1332-1340.	7.1	728
176	Molecular Imaging of the Cholinergic System in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 211-250.	0.9	40
177	Skin $\alpha$ -synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study. <i>Scientific Reports</i> , 2018, 8, 14246.	1.6	75
178	Phenoconversion from Idiopathic Rapid Eye Movement Sleep Behavior Disorder to Lewy Body Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 506-511.	0.8	19
180	Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Current Psychiatry Reports</i> , 2018, 20, 117.	2.1	39
181	Tau PET imaging evidence in patients with cognitive impairment: preparing for clinical use. <i>Clinical and Translational Imaging</i> , 2018, 6, 471-482.	1.1	3
182	Forgetting Rate on the Recency Portion of a Word List Differentiates Mild to Moderate Alzheimer's Disease from Other Forms of Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 461-470.	1.2	11
183	Traumatic Brain Injury and Age of Onset of Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 717-723.	1.2	20
184	Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 551-563.	1.2	46
185	Association of visual hallucinations with very mild degenerative dementia due to dementia with Lewy bodies. <i>PLoS ONE</i> , 2018, 13, e0205909.	1.1	1
186	An Informant-Based Simple Questionnaire for Language Assessment in Neurodegenerative Disorders. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 207-216.	0.7	10
187	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. <i>Molecular Neurodegeneration</i> , 2018, 13, 53.	4.4	75
189	Sex ratio in dementia with Lewy bodies balanced between Alzheimer's disease and Parkinson's disease dementia: a cross-sectional study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 92.	3.0	33
190	Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. <i>Frontiers in Neuroscience</i> , 2018, 12, 612.	1.4	340
191	Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2018, 136, 873-885.	3.9	69
192	Discriminative Accuracy of [ <sup>18</sup> F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1151.	3.8	298
193	Hallucinations in Neurological Disorders. , 2018, , 99-130.		0

#	ARTICLE	IF	CITATIONS
194	Diagnostic challenges in rapidly progressive dementia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 761-772.	1.4	29
195	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2018, , 1-26.		0
197	Advances in the pharmacotherapeutic management of dementia with Lewy bodies. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1643-1653.	0.9	9
198	High-Definition Transcranial direct current stimulation (HD-tDCS) for auditory hallucinations in dementia—A case series. <i>Asian Journal of Psychiatry</i> , 2018, 37, 102-105.	0.9	5
199	Technical note: can resting state functional MRI assist in routine clinical diagnosis?. <i>BJR   case Reports</i> , 2018, 4, 20180030.	0.1	2
200	REM sleep behaviour disorder. <i>Nature Reviews Disease Primers</i> , 2018, 4, 19.	18.1	290
201	Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2018, 6, 84.	2.4	79
202	HIV Dementia with a Decreased Cardiac $^{123}\text{I}$ -metaiodobenzylguanidine Uptake Masquerading as Dementia with Lewy Bodies. <i>Internal Medicine</i> , 2018, 57, 3007-3010.	0.3	3
203	Sleep disorders in the elderly: a growing challenge. <i>Psychogeriatrics</i> , 2018, 18, 155-165.	0.6	292
204	<i>APOE</i> $\epsilon$ 4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2018, 14, 1137-1147.	0.4	39
205	Influence of Lewy Pathology on Alzheimer's Disease Phenotype: A Retrospective Clinico-Pathological Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1317-1323.	1.2	18
206	$^{123}\text{I}$ -MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1167-1173.	0.9	44
207	Associations between ZnT3, tau pathology, agitation, and delusions in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1146-1152.	1.3	11
208	In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. <i>Lancet Neurology</i> , The, 2018, 17, 618-628.	4.9	228
209	Lysosomes, autophagosomes and Alzheimer pathology in dementia with Lewy body disease. <i>Neuropathology</i> , 2018, 38, 347-360.	0.7	5
210	Semi-quantitative dopamine transporter standardized uptake value in comparison with conventional specific binding ratio in $^{123}\text{I}$ FP-CIT single-photon emission computed tomography (DaTscan). <i>Neurological Sciences</i> , 2018, 39, 1401-1407.	0.9	3
211	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. <i>Autophagy</i> , 2018, 14, 1404-1418.	4.3	87
212	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. <i>NeuroImage: Clinical</i> , 2018, 19, 939-947.	1.4	31

#	ARTICLE	IF	CITATIONS
213	The brain metabolic signature of visual hallucinations in dementia with Lewy bodies. <i>Cortex</i> , 2018, 108, 13-24.	1.1	18
214	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain <sup>18</sup> F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. <i>European Journal of Neurology</i> , 2018, 25, 1201-1217.	1.7	153
215	Roles of cardiac sympathetic neuroimaging in autonomic medicine. <i>Clinical Autonomic Research</i> , 2018, 28, 397-410.	1.4	17
217	Behavioral and psychological symptoms in Lewy body disease: a review. <i>Psychologie &amp; Neuropsychiatrie Du Vieillessement</i> , 2018, 16, 87-95.	0.2	2
218	EEG Characteristics of Dementia With Lewy Bodies, Alzheimer's Disease and Mixed Pathology. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 190.	1.7	48
219	Amsterdam Dementia Cohort: Performing Research to Optimize Care. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1091-1111.	1.2	228
221	Characteristics of facial expression recognition ability in patients with Lewy body disease. <i>Environmental Health and Preventive Medicine</i> , 2018, 23, 32.	1.4	2
222	Current Status of <sup>18</sup> F-FDG PET Brain Imaging in Patients with Dementia. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 362-367.	0.4	19
223	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 111.	1.7	29
224	Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 123.	1.7	43
225	Parkinson's Disease Dementia and Dementia with Lewy Bodies Have Similar Neuropsychological Profiles. <i>Frontiers in Neurology</i> , 2018, 9, 123.	1.1	31
226	Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. <i>Frontiers in Neurology</i> , 2018, 9, 156.	1.1	136
227	Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2018, 9, 265.	1.1	32
228	Are We Ready for Detecting $\alpha$ -Synuclein Prone to Aggregation in Patients? The Case of $\alpha$ -Protein-Misfolding Cyclic Amplification and $\alpha$ -Real-Time Quaking-Induced Conversion as Diagnostic Tools. <i>Frontiers in Neurology</i> , 2018, 9, 415.	1.1	66
229	Incidence and Comorbidity of Dementia with Lewy Bodies: A Population-Based Cohort Study. <i>Behavioural Neurology</i> , 2018, 2018, 1-6.	1.1	13
230	Minor Hallucinations in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 543-549.	1.2	7
231	A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment. <i>Neurology and Therapy</i> , 2018, 7, 249-263.	1.4	27
232	In Silico, in Vitro, and in Vivo Evaluation of New Candidates for $\alpha$ -Synuclein PET Imaging. <i>Molecular Pharmaceutics</i> , 2018, 15, 3153-3166.	2.3	40

#	ARTICLE	IF	CITATIONS
233	The Pentagon Copying Test and the Clock Drawing Test as Prognostic Markers in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 308-317.	0.7	5
234	REM Sleep Behavior Disorder (RBD) in Dementia with Lewy Bodies (DLB). <i>Behavioural Neurology</i> , 2018, 2018, 1-10.	1.1	26
235	Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology. <i>Neurobiology of Aging</i> , 2018, 71, 171-178.	1.5	25
236	Î±-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons. <i>Acta Neuropathologica Communications</i> , 2018, 6, 35.	2.4	62
237	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1509-1525.	3.3	81
238	The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 3.	3.0	76
239	MRI of non-Alzheimer's dementia: current and emerging knowledge. <i>Current Opinion in Neurology</i> , 2018, 31, 405-414.	1.8	10
241	Self- and Informant-Reported Memory Complaints: Frequency and Severity in Cognitively Intact Individuals and those with Mild Cognitive Impairment and Neurodegenerative Dementias. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1011-1027.	1.2	17
242	Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: Implications for in-vivo diagnostics. <i>Acta Neuropathologica Communications</i> , 2018, 6, 75.	2.4	47
243	Relative survival in patients with dementia with Lewy bodies and Parkinson's disease dementia. <i>PLoS ONE</i> , 2018, 13, e0202044.	1.1	29
244	Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The <scp>DIAMOND</scp> Lewy study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1293-1304.	1.3	31
245	The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 67.	2.0	69
246	Evaluating combinations of diagnostic tests to discriminate different dementia types. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 509-518.	1.2	19
247	Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification. <i>NeuroImage: Clinical</i> , 2018, 20, 153-160.	1.4	21
248	<i>APOE</i> Î¼4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. <i>Neurology</i> , 2018, 91, e1182-e1195.	1.5	122
249	Diagnostic biomarkers for Parkinson's disease at a glance: where are we?. <i>Journal of Neural Transmission</i> , 2018, 125, 1417-1432.	1.4	65
250	Metabolic Risk Factors of Alzheimer's Disease, Dementia with Lewy Bodies, and Normal Elderly: A Population-Based Study. <i>Behavioural Neurology</i> , 2018, 2018, 1-8.	1.1	9
251	Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity?. <i>Cell and Tissue Research</i> , 2018, 373, 149-160.	1.5	44

#	ARTICLE	IF	CITATIONS
252	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. <i>Lancet Neurology</i> , The, 2018, 17, 597-608.	4.9	101
253	Raman Spectroscopy to Diagnose Alzheimer's Disease and Dementia with Lewy Bodies in Blood. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2786-2794.	1.7	62
254	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018, 141, 2181-2193.	3.7	448
255	Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular Dementias. <i>Focus (American Tj ETQq1 1 0.784314 ggBT /Over</i>	0.4	0
256	Diffuse Lewy body disease manifesting as corticobasal syndrome. <i>Neurology</i> , 2018, 91, e268-e279.	1.5	37
257	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 505-513.	1.2	16
258	Diagnosis (2): Disorders Causing Dementia and Cognitive Impairment. , 2018, , 279-296.		0
259	Testing Hippocampal Memory in Prodromal Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 349-353.	1.2	9
260	Diagnosis (1): Cognitive Syndromes, Comorbidities, No Diagnosis, and Wrong Diagnosis. , 2018, , 241-277.		0
261	Non-Alzheimer's contributions to dementia and cognitive resilience in The 90+ Study. <i>Acta Neuropathologica</i> , 2018, 136, 377-388.	3.9	112
262	Neuroimaging in Lewy body dementia. <i>Journal of Neurology</i> , 2019, 266, 1-26.	1.8	45
263	Is Braak staging valid for all types of Parkinson's disease?. <i>Journal of Neural Transmission</i> , 2019, 126, 423-431.	1.4	73
264	Objective intestinal function in patients with idiopathic REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 28-34.	1.1	18
265	Cerebrospinal Fluid Total and Phosphorylated $\tau$ -Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy. <i>Molecular Neurobiology</i> , 2019, 56, 3476-3483.	1.9	26
266	Deep Learning With EEG Spectrograms in Rapid Eye Movement Behavior Disorder. <i>Frontiers in Neurology</i> , 2019, 10, 806.	1.1	67
267	Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 317-325.	1.2	18
268	Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases. <i>Current Psychiatry Reports</i> , 2019, 21, 79.	2.1	38
269	Cerebrospinal Fluid, Imaging, and Physiological Biomarkers in Dementia With Lewy Bodies. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 421-432.	0.9	5

#	ARTICLE	IF	CITATIONS
270	Fluctuating cognition in the Lewy body dementias. <i>Brain</i> , 2019, 142, 3338-3350.	3.7	27
271	Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. <i>Nature Reviews Neurology</i> , 2019, 15, 501-518.	4.9	734
272	Effects of single and combined immunotherapy approach targeting amyloid $\beta$ protein and $\alpha$ -synuclein in a dementia with Lewy bodies-like model. <i>Alzheimer's and Dementia</i> , 2019, 15, 1133-1148.	0.4	18
273	Classification of Clinically Diagnosed Alzheimer's Disease Associated with Diabetes Based on Amyloid and Tau PET Results. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 261-271.	1.2	21
274	Current radiotracers to image neurodegenerative diseases. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 17.	1.8	28
275	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2019, , 1251-1275.		1
276	Acute presentation of dementia with Lewy bodies. <i>Clinical Medicine</i> , 2019, 19, 327-330.	0.8	9
278	Characteristic asymmetric limbic and anterior temporal atrophy in demented patients with pathologically confirmed argyrophilic grain disease. <i>Neuroradiology</i> , 2019, 61, 1239-1249.	1.1	15
279	Vulnerability of multiple large-scale brain networks in dementia with Lewy bodies. <i>Human Brain Mapping</i> , 2019, 40, 4537-4550.	1.9	24
280	Otras demencias degenerativas. Demencia con cuerpos de Lewy, demencia en la enfermedad de Parkinson, demencia frontotemporal y demencia vascular. <i>Medicine</i> , 2019, 12, 4347-4356.	0.0	0
281	Parkinson's-adapted cognitive stimulation therapy: a pilot randomized controlled clinical trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641985221.	1.5	18
282	Diagnosis and Management of Autonomic Dysfunction in Dementia Syndromes. <i>Current Treatment Options in Neurology</i> , 2019, 21, 38.	0.7	22
283	REM sleep without atonia and the relation with Lewy body disease. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 90-98.	1.1	21
284	Assessment of Amyloid Deposition in Patients With Probable REM Sleep Behavior Disorder as a Prodromal Symptom of Dementia With Lewy Bodies Using PiB-PET. <i>Frontiers in Neurology</i> , 2019, 10, 671.	1.1	5
285	Plasma YKL-40 in the spectrum of neurodegenerative dementia. <i>Journal of Neuroinflammation</i> , 2019, 16, 145.	3.1	40
286	Hallucinations, somatic-functional disorders of PD $\alpha$ -DLB as expressions of thalamic dysfunction. <i>Movement Disorders</i> , 2019, 34, 1100-1111.	2.2	57
287	Neuropsychological, electrophysiological, and neuroimaging biomarkers for REM behavior disorder. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1069-1087.	1.4	30
288	Animal models of synucleinopathies and how they could impact future drug discovery and delivery efforts. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 969-982.	2.5	4



#	ARTICLE	IF	CITATIONS
289	Living with dementia with Lewy bodies: an interpretative phenomenological analysis. <i>BMJ Open</i> , 2019, 9, e024983.	0.8	15
290	Potential Clinical Applications and Future Prospect of Wireless and Mobile Electroencephalography on the Assessment of Cognitive Impairment. <i>Bioelectricity</i> , 2019, 1, 105-112.	0.6	5
291	Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. <i>Brain</i> , 2019, 142, 2813-2827.	3.7	121
292	Traumatic Brain Injury and Risk of Long-Term Brain Changes, Accumulation of Pathological Markers, and Developing Dementia: A Review. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 629-654.	1.2	60
293	Resting State Dynamic Functional Connectivity in Neurodegenerative Conditions: A Review of Magnetic Resonance Imaging Findings. <i>Frontiers in Neuroscience</i> , 2019, 13, 657.	1.4	80
294	A Clinical Approach to Diagnosing Encephalopathy. <i>American Journal of Medicine</i> , 2019, 132, 1142-1147.	0.6	40
295	Empiric Methods to Account for Pre-analytical Variability in Digital Histopathology in Frontotemporal Lobar Degeneration. <i>Frontiers in Neuroscience</i> , 2019, 13, 682.	1.4	13
296	The Charles Bonnet Syndrome: a Systematic Review of Diagnostic Criteria. <i>Current Treatment Options in Neurology</i> , 2019, 21, 41.	0.7	24
297	The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease. <i>Neurobiology of Disease</i> , 2019, 132, 104545.	2.1	13
298	Neuropathological Changes in Dementia With Lewy Bodies and the Cingulate Island Sign. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 717-724.	0.9	15
299	Upper limb movements in dementia with Lewy body: a quantitative analysis. <i>Experimental Brain Research</i> , 2019, 237, 2105-2110.	0.7	3
300	Delusions and visual hallucinations in a patient with Parkinson's disease with dementia showing pronounced Lewy body pathology in the nucleus basalis of Meynert. <i>Neuropathology</i> , 2019, 39, 319-323.	0.7	11
301	Diagnostic Test Accuracy Studies in Dementia. , 2019, , .		18
302	Cognitive Assessment. , 2019, , 27-40.		0
305	Dementia with Lewy Bodies. , 2019, , 88-100.		0
306	Frontotemporal Dementia. , 2019, , 101-111.		0
307	Clinical Scenarios. , 2019, , 291-302.		0
309	Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease. <i>Neurology</i> , 2019, 93, e476-e484.	1.5	23

#	ARTICLE	IF	CITATIONS
310	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1516-1523.	1.4	35
311	Mixed Small Vessel Disease in a Patient with Dementia with Lewy Bodies. <i>Brain Sciences</i> , 2019, 9, 159.	1.1	3
312	Trajectories of neuropsychiatric symptoms over time in healthy volunteers and risk of MCI and dementia. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1865-1873.	1.3	9
313	Promoting independence in Lewy body dementia through exercise (PRIDE) study: Protocol for a pilot study. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100466.	0.5	1
314	Clinical drug development for dementia with Lewy bodies: past and present. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 951-965.	1.9	32
315	Increased weighting on prior knowledge in Lewy body-associated visual hallucinations. <i>Brain Communications</i> , 2019, 1, fcz007.	1.5	45
316	Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 84.	3.0	28
317	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4674.	1.8	26
318	Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 1062.	1.6	50
319	Mutations in CHCHD2 cause $\alpha$ -synuclein aggregation. <i>Human Molecular Genetics</i> , 2019, 28, 3895-3911.	1.4	48
320	Amyloid- $\beta$ peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 83.	3.0	23
321	Dynamic functional connectivity changes in Lewy body disease. <i>Brain</i> , 2019, 142, e68-e68.	3.7	3
322	DAT imaging and myocardial MIBG scintigraphy for Lewy body diseases: A clinical neuroimaging study. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 334-340.	0.2	2
323	[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series. <i>Acta Neuropathologica Communications</i> , 2019, 7, 164.	2.4	33
324	Behavioral symptomatology and psychopharmacology of Lewy body dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 165, 59-70.	1.0	9
325	A comparison of machine learning classifiers for dementia with Lewy bodies using miRNA expression data. <i>BMC Medical Genomics</i> , 2019, 12, 150.	0.7	22
326	Science of performing diagnostic tests. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 11-13.	1.1	3
327	Clinical and Imaging Characteristics Associated with Color Vision Impairment in Lewy Body Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1233-1240.	1.2	6

#	ARTICLE	IF	CITATIONS
328	Psychotic disorders in late life: a narrative review. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531988279.	1.2	32
329	Diagnosis of Dementia and Cognitive Impairment. <i>Diagnostics</i> , 2019, 9, 180.	1.3	3
330	Association of innervation-adjusted alpha-synuclein in arrector pili muscles with cardiac noradrenergic deficiency in autonomic synucleinopathies. <i>Clinical Autonomic Research</i> , 2019, 29, 587-593.	1.4	8
331	Diagnosis and Management of Dementia: Review. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1589.	3.8	675
332	α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2120-2126.	1.7	87
333	Neuromelanin-sensitive MRI in the differential diagnosis of elderly white matter lesion from Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 322-325.	0.2	1
334	Preferential tau aggregation in von Economo neurons and fork cells in frontotemporal lobar degeneration with specific MAPT variants. <i>Acta Neuropathologica Communications</i> , 2019, 7, 159.	2.4	34
335	Two distinct pathological substrates associated with MMSE-pentagons item deficit in DLB and AD. <i>Neuropsychologia</i> , 2019, 133, 107174.	0.7	12
336	Cardiovascular Disease, Diabetes Mellitus, and Hypertension in Lewy Body Disease: A Comparison with Other Dementia Disorders. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 851-859.	1.2	13
337	In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 289-296.	0.7	9
338	A Stage-Based Approach to Therapy in Parkinson's Disease. <i>Biomolecules</i> , 2019, 9, 388.	1.8	41
339	Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression. <i>Acta Neuropathologica Communications</i> , 2019, 7, 142.	2.4	49
340	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019, 8, 28.	3.6	70
341	Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension. <i>Neurology</i> , 2019, 93, e1339-e1347.	1.5	16
342	Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85+. <i>Acta Neuropathologica</i> , 2019, 138, 771-782.	3.9	46
343	Depressive Symptoms and Cognitive Improvement in Patients with Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 899-905.	1.2	1
344	The bivariate distribution of amyloid-β <sup>2</sup> and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	3.7	129
345	Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. <i>Drug Discovery Today</i> , 2019, 24, 2307-2314.	3.2	33

#	ARTICLE	IF	CITATIONS
346	Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?. Alzheimer's and Dementia, 2019, 15, 1367-1377.	0.4	40
347	Regional Structural Hippocampal Differences Between Dementia with Lewy Bodies and Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 775-783.	1.5	8
348	Visual hallucinations in Alzheimer's disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but may be associated with reduced cholinergic input to these areas. Alzheimer's Research and Therapy, 2019, 11, 80.	3.0	14
349	Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review. Neurology and Therapy, 2019, 8, 289-305.	1.4	16
351	Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. Journal of Neuropathology and Experimental Neurology, 2019, 78, 891-899.	0.9	44
352	Intriguing Mixed Pathologic Features in a Case of Dementia With Lewy Bodies. Journal of Osteopathic Medicine, 2019, 119, 632-636.	0.4	1
353	Cardiac 123I-MIBG normal uptake values are population-specific: Results from a cohort of controls over 60 years of age. Journal of Nuclear Cardiology, 2021, 28, 1692-1701.	1.4	14
354	&lt;p&gt;Differentiation Between Dementia With Lewy Bodies And Alzheimer's Disease Using Voxel-Based Morphometry Of Structural MRI: A Multicenter Study&lt;/p&gt;. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2715-2722.	1.0	13
355	PD and DLB: Brain imaging in Parkinson's disease and dementia with Lewy bodies. Progress in Molecular Biology and Translational Science, 2019, 165, 167-185.	0.9	7
356	Going beyond the mean: Intraindividual variability of cognitive performance in prodromal and early neurodegenerative disorders. Clinical Neuropsychologist, 2019, 33, 369-389.	1.5	43
357	A Human Neuroimaging Perspective on Sleep in Normative and Pathological Ageing. Current Sleep Medicine Reports, 2019, 5, 1-12.	0.7	1
358	Young-Onset Dementia with Lewy Bodies. Case Reports in Neurology, 2019, 10, 363-368.	0.3	1
360	Dementia with Lewy bodies: an update and outlook. Molecular Neurodegeneration, 2019, 14, 5.	4.4	203
361	Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial. Alzheimer's Research and Therapy, 2019, 11, 9.	3.0	24
362	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. Neurobiology of Aging, 2019, 77, 112-127.	1.5	33
363	Pharmacological Management of Dementia with Lewy Bodies. Drugs and Aging, 2019, 36, 309-319.	1.3	62
364	Neuroimaging in dementia. Clinical radiological correlation. Radiologia, 2019, 61, 66-81.	0.3	4
365	Imaging in prodromal dementia with Lewy bodies: Where do we stand?. International Journal of Geriatric Psychiatry, 2019, 34, 635-646.	1.3	10

#	ARTICLE	IF	CITATIONS
366	123I-MIBG scintigraphy utility and cut-off value in a clinically representative dementia cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 79-84.	1.1	22
367	Impact of a combination of quantitative indices representing uptake intensity, shape, and asymmetry in DAT SPECT using machine learning: comparison of different volume of interest settings. <i>EJNMMI Research</i> , 2019, 9, 7.	1.1	13
368	Sex differences in mixed neuropathologies in community-dwelling older adults. <i>Brain Research</i> , 2019, 1719, 11-16.	1.1	38
369	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 7803.	1.6	33
370	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	3.7	33
371	The Cingulate Island Sign on FDG-PET vs. IMP-SPECT to Assess Mild Cognitive Impairment in Alzheimer's Disease vs. Dementia with Lewy Bodies. <i>Journal of Neuroimaging</i> , 2019, 29, 712-720.	1.0	18
372	Prevalence and clinical features of dual diseases of Alzheimer's disease and dementia with Lewy bodies: A neuroimaging-based study. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 196-199.	0.2	1
373	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
374	Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update". Hypokinetic-rigid movement disorders. <i>Journal of Neural Transmission</i> , 2019, 126, 933-995.	1.4	28
375	A comparison of the prevalence of orthostatic hypotension between older patients with Alzheimer's Disease, Lewy body dementia, and without dementia. <i>Experimental Gerontology</i> , 2019, 124, 110628.	1.2	30
376	Simultaneous tonic and phasic REM sleep without atonia best predicts early phenoconversion to neurodegenerative disease in idiopathic REM sleep behavior disorder. <i>Sleep</i> , 2019, 42, .	0.6	31
377	Deep-learning-based imaging-classification-identified cingulate island sign in dementia with Lewy bodies. <i>Scientific Reports</i> , 2019, 9, 8944.	1.6	52
378	Visual impairment in aging and cognitive decline: experience in a Memory Clinic. <i>Scientific Reports</i> , 2019, 9, 8698.	1.6	32
379	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , 2019, 15, 1081-1103.	0.4	16
380	The prevalence and clinical features of epileptic seizures in a memory clinic population. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2019, 71, 83-92.	0.9	23
381	Clinical profiles of late-onset psychiatric patients exhibiting incidental REM sleep without atonia. <i>Journal of Neural Transmission</i> , 2019, 126, 1095-1104.	1.4	7
382	Association of <i>MAPT</i> H1 subhaplotypes with neuropathology of lewy body disease. <i>Movement Disorders</i> , 2019, 34, 1325-1332.	2.2	15
383	Cognitive decline in association with hyposmia in idiopathic rapid eye movement sleep behavior disorder: a prospective 2-year follow-up study. <i>European Journal of Neurology</i> , 2019, 26, 1417-1420.	1.7	10

#	ARTICLE	IF	CITATIONS
384	Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS ONE, 2019, 14, e0217566.	1.1	31
385	Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study. Journal of Alzheimer's Disease, 2019, 70, 597-609.	1.2	13
386	Treatment of psychiatric disturbances in hypokinetic movement disorders. Expert Review of Neurotherapeutics, 2019, 19, 965-981.	1.4	8
387	Frailty in Older Adults with Mild Dementia: Dementia with Lewy Bodies and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2019, 9, 176-183.	0.6	28
388	Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease. BMC Neurology, 2019, 19, 113.	0.8	11
389	Î±-Synuclein pathology in Parkinson's disease and related Î±-synucleinopathies. Neuroscience Letters, 2019, 709, 134316.	1.0	177
390	Overlap Between Frontotemporal Dementia and Dementia with Lewy Bodies: A Treviso Dementia (TREDÈM) Registry Case Report. Journal of Alzheimer's Disease, 2019, 69, 839-847.	1.2	4
391	Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 389-397.	1.2	30
392	Increased prevalence of granulovacuolar degeneration in C9orf72 mutation. Acta Neuropathologica, 2019, 138, 783-793.	3.9	19
393	LRP10 variants in Parkinson's disease and dementia with Lewy bodies in the South-West of the Netherlands. Parkinsonism and Related Disorders, 2019, 65, 243-247.	1.1	14
394	Increased Cortical Thickness in Attentional Networks in Parkinson's Disease with Minor Hallucinations. Parkinson's Disease, 2019, 2019, 1-6.	0.6	9
395	FDG-PET in suspected dementia with Lewy bodies: a case report. BMC Geriatrics, 2019, 19, 150.	1.1	0
396	End-of-life experiences in dementia with Lewy bodies: Qualitative interviews with former caregivers. PLoS ONE, 2019, 14, e0217039.	1.1	21
397	Diagnosis and treatment of cognitive impairment. Zeitschrift Fur Gerontologie Und Geriatrie, 2019, 52, 309-315.	0.8	14
398	Parkinson's-adapted cognitive stimulation therapy: feasibility and acceptability in Lewy body spectrum disorders. Journal of Neurology, 2019, 266, 1756-1770.	1.8	16
399	Stimulation over the cerebellum with a regular figure-of-eight coil induces reduced motor cortex inhibition in patients with progressive supranuclear palsy. Brain Stimulation, 2019, 12, 1290-1297.	0.7	23
400	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
401	Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players. Acta Neuropathologica, 2019, 138, 389-399.	3.9	108

#	ARTICLE	IF	CITATIONS
403	Functional movement disorders in neurogeriatric inpatients. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2019, 52, 324-329.	0.8	10
404	Use of Cholinesterase Inhibitors in Non-Alzheimerâ€™s Dementias. <i>Drugs and Aging</i> , 2019, 36, 719-731.	1.3	27
405	Prevalence of Mild Behavioral Impairment and Risk of Dementia in a Psychiatric Outpatient Clinic. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 505-513.	1.2	78
406	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019, 16, 593-600.	1.3	41
407	Physician's Field Guide to Neuropsychology. , 2019, , .		2
408	Hippocampal CA1 subfield predicts episodic memory impairment in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101824.	1.4	47
409	GBA and APOE Î¼4 associate with sporadic dementia with Lewy bodies in European genome wide association study. <i>Scientific Reports</i> , 2019, 9, 7013.	1.6	53
410	Extrastriatal dopaminergic and serotonergic pathways in Parkinsonâ€™s disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1642-1651.	3.3	38
411	Antibodies against alphaâ€™synuclein: tools and therapies. <i>Journal of Neurochemistry</i> , 2019, 150, 612-625.	2.1	53
412	Comprehensive Quantitative Spatiotemporal Gait Analysis Identifies Gait Characteristics for Early Dementia Subtyping in Community Dwelling Older Adults. <i>Frontiers in Neurology</i> , 2019, 10, 313.	1.1	25
413	â€œCanâ€™t seem to keep my mind to itâ€ did Arthur Millerâ€™s Salesman have dementia with Lewy bodies?. <i>Journal of Neurology</i> , 2019, 266, 1806-1808.	1.8	0
414	Parkinson's and Lewy body dementia CSF biomarkers. <i>Clinica Chimica Acta</i> , 2019, 495, 318-325.	0.5	38
416	Early diagnosis of Lewy body disease in elderly individuals with subjective cognitive decline. <i>Journal of the Neurological Sciences</i> , 2019, 401, 128-129.	0.3	1
417	Frontal atrophy as a marker for dementia conversion in Parkinson's disease with mild cognitive impairment. <i>Human Brain Mapping</i> , 2019, 40, 3784-3794.	1.9	41
418	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 45.	3.0	19
419	Corticobasal syndrome with visual hallucinations and probable REM-sleep behavior disorder: an autopsied case report of a patient with CBD and LBD pathology. <i>Neurocase</i> , 2019, 25, 26-33.	0.2	3
420	Assessment of cognitive profile as a prodromal marker of the evolution of rapid eye movement sleep behavior disorder. <i>Sleep</i> , 2019, 42, .	0.6	22
421	Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1244-1250.	1.3	31

#	ARTICLE	IF	CITATIONS
422	Neurochemical Aspects of Lewy Body Dementia. , 2019, , 113-150.		0
423	Impaired Color Discriminationâ€”A Specific Marker of Hallucinations in Lewy Body Disorders. Journal of Geriatric Psychiatry and Neurology, 2019, 32, 257-264.	1.2	11
424	Autonomic Dysfunction in Î±-Synucleinopathies. Frontiers in Neurology, 2019, 10, 363.	1.1	87
425	Immune Signaling in Neurodegeneration. Immunity, 2019, 50, 955-974.	6.6	217
426	Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinsonâ€™s disease with cognitive decline. Acta Neuropathologica Communications, 2019, 7, 61.	2.4	47
427	Glucocerebrosidase mutations and phenoconversion of REM sleep behavior disorder to parkinsonism and dementia. Parkinsonism and Related Disorders, 2019, 65, 230-233.	1.1	26
428	Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies â€” current issues and future directions. Journal of Neurochemistry, 2019, 150, 467-474.	2.1	98
429	Extreme sleep pattern in Lewy body dementia: a hypothalamic matter?. BMJ Case Reports, 2019, 12, e228177.	0.2	3
430	Prevalence and severity of symptoms suggestive of gastroparesis in prodromal dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2019, 34, 990-998.	1.3	3
431	Lewy Body Dementia Associationâ€™s Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research and Therapy, 2019, 11, 23.	3.0	9
432	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. American Journal of Geriatric Psychiatry, 2019, 27, 998-1018.	0.6	82
433	Rare histotype of sporadic Creutzfeldt-Jakob disease, clinically suspected as corticobasal degeneration. BMJ Case Reports, 2019, 12, e228305.	0.2	6
434	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. Journal of Alzheimer's Disease, 2019, 68, 1151-1159.	1.2	9
435	Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study. Journal of Alzheimer's Disease, 2019, 68, 723-733.	1.2	21
436	Neurodegenerative Diseases and Ageing. Sub-Cellular Biochemistry, 2019, 91, 75-106.	1.0	8
437	Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. Alzheimer's Research and Therapy, 2019, 11, 20.	3.0	67
438	Frontotemporal dementia is the leading cause of â€œtrueâ€”/T+ profiles defined with $A\beta_{42}/A\beta_{40}$ ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169.	1.2	8
439	A Quarter Century of APOE and Alzheimerâ€™s Disease: Progress to Date and the Path Forward. Neuron, 2019, 101, 820-838.	3.8	338



#	ARTICLE	IF	CITATIONS
440	Risk of dementia after Parkinson's disease in Taiwan: a population-based retrospective cohort study using National Health Insurance claims. <i>BMJ Open</i> , 2019, 9, e025274.	0.8	6
441	Systemic peptide mediated delivery of an siRNA targeting $\alpha$ -syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease. <i>Neurobiology of Disease</i> , 2019, 127, 163-177.	2.1	30
442	Tandem gait abnormality in Parkinson disease: Prevalence and implication as a predictor of fall risk. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 83-87.	1.1	6
444	18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease. , 2019, , 37-48.		1
445	Epilepsy and Aging. <i>Clinical Handbooks in Neuropsychology</i> , 2019, , 401-425.	0.1	1
446	A proteomic signature for dementia with Lewy bodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 270-276.	1.2	18
447	The Optimal Short Version of Montreal Cognitive Assessment in Diagnosing Mild Cognitive Impairment and Dementia. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1055.e1-1055.e8.	1.2	18
448	Amygdala sign, a FDG-PET signature of dementia with Lewy Bodies. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 300-303.	1.1	8
449	Causes and outcomes of hospitalization in Lewy body dementia: A retrospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 106-111.	1.1	18
450	Prodromal Parkinson's Disease: The Decade Past, the Decade to Come. <i>Movement Disorders</i> , 2019, 34, 665-675.	2.2	120
451	123I-FP-CIT striatal binding ratios do not decrease significantly with age in older adults. <i>Annals of Nuclear Medicine</i> , 2019, 33, 434-443.	1.2	8
452	Dementia with Lewy bodies: Challenges in the diagnosis and management. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 291-303.	1.3	28
453	Peripheral inflammation in mild cognitive impairment with possible and probable Lewy body disease and Alzheimer's disease. <i>International Psychogeriatrics</i> , 2019, 31, 551-560.	0.6	14
454	Clinical characteristics of elderly depressive patients with low metaiodobenzylguanidine uptake. <i>Psychogeriatrics</i> , 2019, 19, 566-573.	0.6	2
455	The Neuropathological and Clinical Diagnostic Criteria of Chronic Traumatic Encephalopathy: A Critical Examination in Relation to Other Neurodegenerative Diseases. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 591-608.	1.2	7
456	Myocardial metaiodobenzylguanidine tomoscintigraphy for the diagnosis of Lewy body disease in patients with high clinical suspicion and non-diagnostic ioflupane single-photon emission computed tomography. <i>Psychogeriatrics</i> , 2019, 19, 624-625.	0.6	0
457	Clinical Effects of Frontal Behavioral Impairment: Cortical Thickness and Cognitive Decline in Individuals with Subjective Cognitive Decline and Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 213-225.	1.2	0
459	CSF1R mutation presenting as dementia with Lewy bodies. <i>Neurocase</i> , 2019, 25, 17-20.	0.2	9

#	ARTICLE	IF	CITATIONS
460	Review: Clinical, neuropathological and genetic features of Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 635-654.	1.8	26
461	Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1652-1660.	3.3	11
462	Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline. <i>Journal of the Neurological Sciences</i> , 2019, 400, 188-193.	0.3	4
463	Symptom Clusters of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Their Comparative Risks of Dementia: A Cohort Study of 8530 Older Persons. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1054.e1-1054.e9.	1.2	40
464	Parkinson's Disease Dementia and Lewy Body Disease. <i>Seminars in Neurology</i> , 2019, 39, 274-282.	0.5	40
465	An Overview of Primary Dementias as Clinicopathological Entities. <i>Seminars in Neurology</i> , 2019, 39, 153-166.	0.5	13
466	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and $\alpha$ -synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 97-105.	1.1	22
468	Dysfunctional brain dynamics and their origin in Lewy body dementia. <i>Brain</i> , 2019, 142, 1767-1782.	3.7	94
469	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. <i>Sleep</i> , 2019, 42, .	0.6	30
470	Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. <i>Neurology</i> , 2019, 92, e2015-e2026.	1.5	28
471	Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but "failure to fit" is highly dependent on staging system applied. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 124-131.	1.1	21
472	A case of treatable dementia with Lewy bodies remarkably improved by immunotherapy. <i>Journal of Neuroimmunology</i> , 2019, 330, 35-37.	1.1	9
473	Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment. <i>European Journal of Neurology</i> , 2019, 26, 1098-1104.	1.7	20
474	Fact-finding survey on diagnostic procedures and therapeutic interventions for parkinsonism accompanying dementia with Lewy bodies. <i>Psychogeriatrics</i> , 2019, 19, 345-354.	0.6	2
475	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. <i>Brain</i> , 2019, 142, 744-759.	3.7	636
476	SHIFT IN HOSPITALIZATIONS FOR ALZHEIMER'S DISEASE TO RELATED DEMENTIAS IN FRANCE BETWEEN 2007 AND 2017. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-4.	1.5	3
477	Metabolic patterns across core features in dementia with lewy bodies. <i>Annals of Neurology</i> , 2019, 85, 715-725.	2.8	47
478	Diffuse Lewy body disease. <i>Journal of the Neurological Sciences</i> , 2019, 399, 144-150.	0.3	6

#	ARTICLE	IF	CITATIONS
479	Management of delirium in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 905-912.	1.4	28
480	HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson's Disease and Dementia with Lewy Bodies. <i>Journal of Parkinson's Disease</i> , 2019, 9, 97-107.	1.5	17
481	Is the regional cerebral blood flow always decreased in the occipital lobe of patients with dementia with Lewy bodies? A SPECT easy $\alpha$ -score imaging system perfusion study. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 112-118.	0.2	1
482	Dementia with Lewy bodies presenting as frontotemporal dementia phenotype. <i>Psychogeriatrics</i> , 2019, 19, 505-509.	0.6	4
483	Excessive Daytime Sleepiness in Major Dementia Syndromes. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 261-264.	0.9	14
484	Pathological Changes to the Subcortical Visual System and its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. <i>Neuroscience Bulletin</i> , 2019, 35, 295-300.	1.5	15
485	Abnormal $\alpha$ -synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility. <i>European Journal of Neurology</i> , 2019, 26, 1245-1251.	1.7	38
486	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. <i>Current Alzheimer Research</i> , 2019, 16, 91-101.	0.7	23
487	Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 995-1005.	1.2	16
488	Circadian rhythms of cardiovascular autonomic function: Physiology and clinical implications in neurodegenerative diseases. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2019, 217, 91-101.	1.4	29
489	Dissecting $\alpha$ -synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis. <i>Laboratory Investigation</i> , 2019, 99, 982-992.	1.7	15
490	Tactile hallucinations in dementia with Lewy bodies. <i>Psychogeriatrics</i> , 2019, 19, 435-439.	0.6	5
491	High rates of undiagnosed vascular cognitive impairment among American Indian veterans. <i>GeroScience</i> , 2019, 41, 69-76.	2.1	8
492	Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data. <i>Communications Biology</i> , 2019, 2, 77.	2.0	50
493	Movement Disorders with Dementia in Older Adults. <i>Clinical Handbooks in Neuropsychology</i> , 2019, , 543-575.	0.1	0
494	Neuropathological and genetic characteristics of a post-mortem series of cases with dementia with Lewy bodies clinically suspected of Creutzfeldt-Jakob's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 162-168.	1.1	11
495	Survival among the older adults with clinical signs of Lewy body dementia in 40 Swedish nursing homes: a 6-year follow-up study. <i>BMJ Open</i> , 2019, 9, e028010.	0.8	1
496	Long-Term Partnerships in Lewy Body Dementias. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
497	Definitions, epidemiology and natural history. , 2019, , .		0
498	Diagnostic positif et Â©tiologique des dÃ©mences frontotemporales. Pratique Neurologique - FMC, 2019, 10, 101-111.	0.1	0
499	Acute treatment of psychotic symptoms in a newly diagnosed Lewy body dementia patient with an accelerated titration schedule of rivastigmine and de-escalation of antipsychotics. BMJ Case Reports, 2019, 12, e230193.	0.2	3
500	The Pharmacology of Visual Hallucinations in Synucleinopathies. Frontiers in Pharmacology, 2019, 10, 1379.	1.6	36
501	Clinical Reasoning: A 58-year-old man with hand tremor and episodes of neck pain. Neurology, 2019, 93, 557-561.	1.5	1
502	Sleep talking and primary progressive aphasia: case study and autopsy findings in a patient with logopenic primary progressive aphasia and dementia with Lewy bodies. BMJ Case Reports, 2019, 12, e228938.	0.2	4
503	Survival and Progression in Synucleinopathy Phenotypes With Parkinsonism. Mayo Clinic Proceedings, 2019, 94, 1825-1831.	1.4	4
504	Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimerâ€™s Disease and Inconclusive First Biomarker. Journal of Alzheimer's Disease, 2019, 72, 1193-1207.	1.2	5
505	Cognitive training for people with mild to moderate dementia. The Cochrane Library, 2019, 3, CD013069.	1.5	143
506	Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimerâ€™s disease and neocortical Lewy body disease. Scientific Reports, 2019, 9, 17222.	1.6	12
507	Gray Matter Changes in Parkinsonâ€™s and Alzheimerâ€™s Disease and Relation to Cognition. Current Neurology and Neuroscience Reports, 2019, 19, 85.	2.0	36
508	Autonomic dysfunction: Diagnosis and management. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 123-137.	1.0	23
509	Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 139-148.	1.0	85
510	Cognitive rehabilitation for people with mild to moderate dementia. The Cochrane Library, 0, , .	1.5	15
511	Alzheimerâ€™s disease tau is a prominent pathology in LRRK2 Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2019, 7, 183.	2.4	101
512	Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimerâ€™s and Lewy Body Diseases. Journal of Alzheimer's Disease, 2019, 70, 877-887.	1.2	0
515	Delusional parasitosis in dementia with Lewy bodies: a case report. Annals of General Psychiatry, 2019, 18, 29.	1.2	13
516	Schizoaffective disorder comorbid with type 2 diabetes mellitus accompanied by frontotemporal atrophy and impaired cognition. Medicine (United States), 2019, 98, e15292.	0.4	0

#	ARTICLE	IF	CITATIONS
517	Dysfunctional Dynamics of Intra- and Inter-network Connectivity in Dementia With Lewy Bodies. <i>Frontiers in Neurology</i> , 2019, 10, 1265.	1.1	11
518	Recognizing and treating atypical Parkinson disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019, 167, 301-320.	1.0	10
519	Classification of atypical parkinsonism per pathology versus phenotype. <i>International Review of Neurobiology</i> , 2019, 149, 37-47.	0.9	10
520	Parkinsonism in genetic and sporadic Alzheimer's disease. <i>International Review of Neurobiology</i> , 2019, 149, 237-247.	0.9	2
521	A comparison of visual and semiquantitative analysis methods for planar cardiac 123I-MIBG scintigraphy in dementia with Lewy bodies. <i>Nuclear Medicine Communications</i> , 2019, 40, 734-743.	0.5	11
522	Pay attention to the basal ganglia: a volumetric study in early dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 108.	3.0	17
523	Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE $\epsilon$ <sub>4</sub> /TOMM40 long poly $\alpha$ T repeat allele variants. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 814-824.	1.8	14
524	Self-Injurious Behavior in a Patient With Dementia. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 6-11.	0.5	1
525	Neuropsychological Assessment of Dementia. , 2019, , 416-430.		2
526	Distinguishing Dementia With Lewy Bodies From Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 279-281.	0.6	2
527	Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other $\alpha$ -Synucleinopathies. <i>Frontiers in Neurology</i> , 2019, 10, 1204.	1.1	13
528	Clinical Use of Integrated Positron Emission Tomography-Magnetic Resonance Imaging for Dementia Patients. <i>Topics in Magnetic Resonance Imaging</i> , 2019, 28, 299-310.	0.7	9
529	Association of Longitudinal $\beta$ -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	2.8	22
530	Uniformity of cardiac 123I-MIBG uptake on SPECT images in older adults with normal cognition and patients with dementia. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2151-2163.	1.4	7
531	Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. <i>Neurobiology of Aging</i> , 2019, 73, 9-20.	1.5	26
532	How do we establish cardiac sympathetic nervous system imaging with 123I-mIBG in clinical practice? Perspectives and lessons from Japan and the US. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 1434-1451.	1.4	15
533	What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 93-100.	1.1	29
534	Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 73, 74-81.	1.5	16

#	ARTICLE	IF	CITATIONS
535	Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 447-467.	1.2	73
536	Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. <i>Neurobiology of Aging</i> , 2019, 76, 9-17.	1.5	23
537	Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. <i>Brain Pathology</i> , 2019, 29, 544-557.	2.1	33
538	Polysomnographic data in Dementia with Lewy Bodies: correlation with clinical symptoms and comparison with other $\alpha$ -synucleinopathies. <i>Sleep Medicine</i> , 2019, 55, 62-68.	0.8	20
539	Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar?. <i>NeuroImage: Clinical</i> , 2019, 21, 101628.	1.4	22
540	Dementia with Lewy bodies " from scientific knowledge to clinical insights. <i>Nature Reviews Neurology</i> , 2019, 15, 103-112.	4.9	49
541	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. <i>Movement Disorders</i> , 2019, 34, 9-21.	2.2	73
542	The democratic aspect of machine learning: Limitations and opportunities for Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 164-166.	2.2	8
543	Structural and Functional Magnetic Resonance Imaging of Dementia With Lewy Bodies. <i>International Review of Neurobiology</i> , 2019, 144, 95-141.	0.9	8
544	Molecular Imaging of Dementia With Lewy Bodies. <i>International Review of Neurobiology</i> , 2019, 144, 59-93.	0.9	10
545	Management of visual hallucinations in dementia and Parkinson's disease. <i>International Psychogeriatrics</i> , 2019, 31, 815-836.	0.6	10
546	Vascular dementia encoding in the French nationwide discharge summary database (PMSI): Variability over the 2007-2017 period. <i>Annales De Cardiologie Et D'Angiologie</i> , 2019, 68, 150-154.	0.3	4
547	Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies. <i>Clinica Chimica Acta</i> , 2019, 490, 222-228.	0.5	13
548	Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2019, 49, 2342-2353.	2.7	49
550	Loss of Swallow Tail Sign on Susceptibility-Weighted Imaging in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 61-65.	1.2	15
551	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2019, 15, 400-409.	0.4	60
552	Increased Serum Levels of $\alpha$ -Synuclein in Patients With Major Depressive Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 280-286.	0.6	18
553	Mass synaptometry: High-dimensional multi parametric assay for single synapses. <i>Journal of Neuroscience Methods</i> , 2019, 312, 73-83.	1.3	26

#	ARTICLE	IF	CITATIONS
554	EEG Resting-State Networks in Dementia with Lewy Bodies Associated with Clinical Symptoms. <i>Neuropsychobiology</i> , 2019, 77, 206-218.	0.9	16
555	Brains for Dementia Research: The Importance of Cohorts in Brain Banking. <i>Neuroscience Bulletin</i> , 2019, 35, 289-294.	1.5	6
556	Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies. <i>Ageing Research Reviews</i> , 2019, 50, 72-80.	5.0	70
557	Neuroimagen en demencia. Correlación clínico-radiológica. <i>Radiologia</i> , 2019, 61, 66-81.	0.3	1
558	Head Position During Sleep: Potential Implications for Patients with Neurodegenerative Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 631-638.	1.2	17
559	Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1117-1131.	3.3	18
560	<sup>18</sup> F-CAV-1 uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 344-352.	2.2	26
561	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. <i>JAMA Neurology</i> , 2019, 76, 470.	4.5	205
562	Evolution of Dementia Related to the Use of Alcohol in the French Nationwide Discharge Summary Database Between 2007 and 2017. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 188-192.	0.9	3
563	ICD-10-CM Diagnosis Coding for Neuropsychological Assessment. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 721-730.	0.3	7
564	Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. <i>Acta Neuropathologica</i> , 2019, 137, 71-88.	3.9	29
565	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	1.5	13
566	Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 233-242.	1.3	167
567	Quantitative components of the semantic verbal fluency test in cognitively healthy controls, mild cognitive impairment, and dementia subtypes. <i>Applied Neuropsychology Adult</i> , 2019, 26, 533-542.	0.7	12
568	The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. <i>Sleep Medicine Reviews</i> , 2019, 43, 37-46.	3.8	191
569	Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. <i>Acta Neuropathologica</i> , 2019, 137, 27-46.	3.9	87
570	Parkinson's Disease. <i>Medical Clinics of North America</i> , 2019, 103, 337-350.	1.1	269
571	Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 82-92.	1.1	22

#	ARTICLE	IF	CITATIONS
572	REM Sleep Behavior Disorder Associated with Dementia with Lewy Bodies. , 2019, , 67-76.		2
573	Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling. <i>Neurobiology of Aging</i> , 2019, 73, 123-134.	1.5	48
574	Cause of Death and End-of-Life Experiences in Individuals with Dementia with Lewy Bodies. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 67-73.	1.3	28
575	Available and future treatments for atypical parkinsonism. A systematic review. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 159-174.	1.9	22
576	Progress in the treatment of Parkinson-Plus syndromes. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 101-110.	1.1	6
577	Imaging Tau, Neuroinflammation, and $\alpha^2$ in Dementia With Lewy Bodies: A Deep-Phenotyping Case Report. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 77-80.	0.8	3
578	Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. <i>Psychological Medicine</i> , 2019, 49, 396-402.	2.7	51
579	The Neuropsychological Profile and Phenomenology of Late Onset Psychosis: A Cross-sectional Study on the Differential Diagnosis of Very-Late-Onset Schizophrenia-Like Psychosis, Dementia with Lewy Bodies and Alzheimer's Type Dementia with Psychosis. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 183-199.	0.3	38
580	Sex differences in the severity of neuropsychiatric symptoms and their relationship with clinico-demographic and psychosocial factors in patients with amnesic mild cognitive impairment and mild Alzheimer's disease. <i>Aging and Mental Health</i> , 2020, 24, 431-438.	1.5	8
581	Feeling of presence in dementia with Lewy bodies is related to reduced left frontoparietal metabolism. <i>Brain Imaging and Behavior</i> , 2020, 14, 1199-1207.	1.1	7
582	The effectiveness of electroconvulsive therapy for psychiatric symptoms and cognitive fluctuations similar to dementia with Lewy bodies: a case report. <i>Psychogeriatrics</i> , 2020, 20, 229-231.	0.6	4
583	Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 240-254.	1.8	21
584	Bright light therapy improved sleep disturbances in a patient with dementia with Lewy bodies. <i>Psychogeriatrics</i> , 2020, 20, 124-125.	0.6	4
585	Koro Delusion in Mild Cognitive Impairment Due to Alzheimer's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 204-206.	0.9	6
586	International Federation of Clinical Neurophysiology (IFCN) EEG research workgroup: Recommendations on frequency and topographic analysis of resting state EEG rhythms. Part 1: Applications in clinical research studies. <i>Clinical Neurophysiology</i> , 2020, 131, 285-307.	0.7	164
587	Factors That Influence Habitual Activity in Mild Cognitive Impairment and Dementia. <i>Gerontology</i> , 2020, 66, 197-208.	1.4	16
588	Therapeutic approaches to cholinergic deficiency in Lewy body diseases. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 41-53.	1.4	6
589	Diagnostic imaging of dementia with Lewy bodies, frontotemporal lobar degeneration, and normal pressure hydrocephalus. <i>Japanese Journal of Radiology</i> , 2020, 38, 64-76.	1.0	11



#	ARTICLE	IF	CITATIONS
590	Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. <i>Brain</i> , 2020, 143, 31-46.	3.7	53
591	Effects of curcumin on mitochondria in neurodegenerative diseases. <i>BioFactors</i> , 2020, 46, 5-20.	2.6	100
592	Relationship of substantia nigra hyperechogenicity to risk of Lewy body disease in idiopathic REM sleep behavior disorder patients: a longitudinal study. <i>Sleep Medicine</i> , 2020, 68, 31-34.	0.8	10
593	Falls in Synucleinopathies. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 30-43.	0.3	7
594	Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1984-1997.	3.3	17
595	CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 109-110.	0.9	8
596	Remote neuropsychological assessment of elderly Japanese population using the Alzheimer's Disease Assessment Scale: A validation study. <i>Journal of Telemedicine and Telecare</i> , 2020, 26, 482-487.	1.4	18
597	Vocal Fold "Paralysis": An Early Sign in Multiple System Atrophy. <i>Journal of Voice</i> , 2020, 34, 940-944.	0.6	4
598	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 75-86.	0.6	38
599	New evidence on the management of Lewy body dementia. <i>Lancet Neurology</i> , The, 2020, 19, 157-169.	4.9	167
600	Brain and Art. , 2020, , .		0
601	Cerebrospinal fluid levels of alpha-synuclein, amyloid $\beta^2$ , tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings. <i>Neuroscience Letters</i> , 2020, 715, 134564.	1.0	8
602	Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. <i>Movement Disorders</i> , 2020, 35, 5-19.	2.2	60
603	DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 177-182.	1.0	11
604	Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. <i>European Journal of Neurology</i> , 2020, 27, 475-483.	1.7	20
605	Evaluating the Sustained Attention Response Task to Quantify Cognitive Fluctuations in Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 333-339.	1.2	7
606	Assessing the role of nocturnal core body temperature dysregulation as a biomarker of neurodegeneration. <i>Journal of Sleep Research</i> , 2020, 29, e12939.	1.7	19
607	Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. <i>European Journal of Neurology</i> , 2020, 27, 644-652.	1.7	30

#	ARTICLE	IF	CITATIONS
608	Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. <i>Journal of Neurology</i> , 2020, 267, 380-389.	1.8	17
609	Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases. <i>Neuropathology</i> , 2020, 40, 30-39.	0.7	43
611	High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases. <i>Journal of Neural Transmission</i> , 2020, 127, 311-322.	1.4	13
612	Changes in gray matter volume and functional connectivity in dementia with Lewy bodies compared to Alzheimer's disease and normal aging: implications for fluctuations. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 9.	3.0	22
613	Greater Variability in Cognitive Decline in Lewy Body Dementia Compared to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1321-1330.	1.2	9
614	Caregiver-Reported Barriers to Quality End-of-Life Care in Dementia With Lewy Bodies: A Qualitative Analysis. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 728-737.	0.8	16
615	Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease. <i>Biological Psychiatry</i> , 2020, 87, 857-865.	0.7	29
616	Differentiating dementia disease subtypes with gait analysis: feasibility of wearable sensors?. <i>Gait and Posture</i> , 2020, 76, 372-376.	0.6	68
617	Diagnosis and Differential Diagnosis of Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 13-24.	1.0	15
618	Longitudinal study of striatal aromatic l-amino acid decarboxylase activity in patients with idiopathic rapid eye movement sleep behavior disorder. <i>Sleep Medicine</i> , 2020, 68, 50-56.	0.8	8
619	Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e73.	1.8	6
620	Metabolic Network Topology of Alzheimer's Disease and Dementia with Lewy Bodies Generated Using Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 197-207.	1.2	10
621	Cognitive Issues in the Older Adult. , 2020, , 425-452.		7
622	Amyloid Imaging and Longitudinal Clinical Progression in Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 573-577.	0.6	14
623	Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An 123I-FP-CIT SPECT study. <i>NeuroImage: Clinical</i> , 2020, 25, 102062.	1.4	17
624	Systematic review of genetic association studies in people with Lewy body dementia. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 436-448.	1.3	17
625	A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116645.	0.3	15
626	Genetic Creutzfeldt-Jakob disease mimicking dementia with Lewy bodies: Clinical and radiological findings. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116604.	0.3	7

#	ARTICLE	IF	CITATIONS
627	Evolving concepts on bradykinesia. <i>Brain</i> , 2020, 143, 727-750.	3.7	120
628	Characterization of novel conformation-selective $\alpha$ -synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104712.	2.1	31
629	A Comparative Study of Pathological Outcomes in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age and Brains for Dementia Research Cohorts. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 619-632.	1.2	6
630	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	2.2	42
631	Visual Hallucinations and Impaired Conscious Visual Perception in Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 377-385.	1.2	6
632	Human subiculo-fornico-mamillary system in Alzheimer's disease: Tau seeding by the pillar of the fornix. <i>Acta Neuropathologica</i> , 2020, 139, 443-461.	3.9	10
633	Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 91-97.	1.1	28
634	The Neuropsychological Profile of Mild Cognitive Impairment in Lewy Body Dementias. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 210-225.	1.2	15
635	Weighted network measures reveal differences between dementia types: An EEG study. <i>Human Brain Mapping</i> , 2020, 41, 1573-1590.	1.9	25
636	A Validation Study of the Remotely Administered Montreal Cognitive Assessment Tool in the Elderly Japanese Population. <i>Telemedicine Journal and E-Health</i> , 2020, 26, 920-928.	1.6	32
637	Family History is Associated with Phenotype in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 269-275.	1.2	2
638	What is happening with not recommended drugs for dementia in Argentina? Prescription patterns and direct costs analysis. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 270-275.	1.3	2
639	Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns. <i>Neurobiology of Aging</i> , 2020, 87, 11-17.	1.5	15
640	Thought visualization occurring in a patient of dementia with Lewy bodies. <i>Asian Journal of Psychiatry</i> , 2020, 48, 101882.	0.9	1
641	Anxiety symptoms are quantitatively and qualitatively different in dementia with Lewy bodies than in Alzheimer's disease in the years preceding clinical diagnosis. <i>Psychogeriatrics</i> , 2020, 20, 242-246.	0.6	11
642	Tau-positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020, 16, 561-571.	0.4	113
643	Cortical hypoperfusion in patients with idiopathic rapid eye movement sleep behavior disorder detected with arterial spin-labeled perfusion MRI. <i>Neurological Sciences</i> , 2020, 41, 809-815.	0.9	7
644	$\beta$ -Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e282-e291.	1.5	65

#	ARTICLE	IF	CITATIONS
645	Dementia With Lewy Bodies. <i>Alzheimer Disease and Associated Disorders</i> , 2020, 34, 178-182.	0.6	5
646	Neural Correlates of Cognitive Performance in Alzheimer's Disease- and Lewy Bodies-Related Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 873-885.	1.2	4
647	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1143-1156.	1.2	39
648	Prevalence of dementia in people with intellectual disabilities: Cross-sectional study. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 414-422.	1.3	22
649	Differences in cognitive profiles between Lewy body and Parkinson's disease dementia. <i>Journal of Neural Transmission</i> , 2020, 127, 323-330.	1.4	18
650	Posterior cortical atrophy initially presenting as dementia with Lewy bodies. <i>Neurological Sciences</i> , 2020, 41, 1607-1609.	0.9	1
651	Visual hallucinations in psychiatric, neurologic, and ophthalmologic disease. <i>Current Opinion in Ophthalmology</i> , 2020, 31, 475-482.	1.3	6
652	Efficacy of Olfactory and Pareidolia Tests Compared With That of Indicative Biomarkers in Diagnosis of Dementia With Lewy Bodies. <i>Frontiers in Neurology</i> , 2020, 11, 540291.	1.1	4
653	Research priorities of caregivers and individuals with dementia with Lewy bodies: An interview study. <i>PLoS ONE</i> , 2020, 15, e0239279.	1.1	12
654	Serum TNF- $\alpha$ and neurodegeneration in isolated REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 1-7.	1.1	7
655	Familial dementia with Lewy bodies with VPS13C mutations. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 31-33.	1.1	3
656	Comparison of 123I-MIBG scintigraphy and phosphorylated $\tau$ -synuclein skin deposits in synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 48-53.	1.1	22
657	Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351. <i>Clinical Nuclear Medicine</i> , 2020, 45, 841-847.	0.7	16
658	Past, present and future EEG in the clinical workup of dementias. <i>Psychiatry Research - Neuroimaging</i> , 2020, 306, 111182.	0.9	11
659	Sex differences in movement disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2020, 175, 275-282.	1.0	7
660	Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2020, 95, e3081-e3092.	1.5	32
661	The complex relationship between genotype, pathology and phenotype in familial dementia. <i>Neurobiology of Disease</i> , 2020, 145, 105082.	2.1	6
662	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	4.9	254

#	ARTICLE	IF	CITATIONS
663	The Influence of the COVID-19 Outbreak on the Lifestyle of Older Patients With Dementia or Mild Cognitive Impairment Who Live Alone. <i>Frontiers in Psychiatry</i> , 2020, 11, 570580.	1.3	10
664	Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7481.	1.8	16
665	Multimodal inÂvivo and postmortem assessments of tau in Lewy body disorders. <i>Neurobiology of Aging</i> , 2020, 96, 137-147.	1.5	14
666	Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 120.	3.0	17
667	Neural correlates of naming errors across different neurodegenerative diseases. <i>Neurology</i> , 2020, 95, e2816-e2830.	1.5	19
668	Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102453.	1.4	11
669	Early Disruption of Cortical Sleep-Related Oscillations in a Mouse Model of Dementia With Lewy Bodies (DLB) Expressing Human Mutant (A30P) Alpha-Synuclein. <i>Frontiers in Neuroscience</i> , 2020, 14, 579867.	1.4	9
670	FDG-PET Imaging of Dementia and Neurodegenerative Disease. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 562-571.	0.7	6
671	Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. <i>Clinical Neurophysiology</i> , 2020, 131, 2716-2731.	0.7	11
672	Novel monoclonal antibodies targeting the RRM2 domain of human TDP-43 protein. <i>Neuroscience Letters</i> , 2020, 738, 135353.	1.0	3
673	Structural imaging in dementia with Lewy bodies: the potential of multivariate data analysis. <i>Psychiatry Research - Neuroimaging</i> , 2020, 306, 111180.	0.9	5
675	A toxic subset of soluble Î±-synuclein species in dementia with Lewy body. <i>Brain Communications</i> , 2020, 2, fcaa016.	1.5	0
676	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. <i>Neurocase</i> , 2020, 26, 259-263.	0.2	6
677	Restâ€Activity Pattern Alterations in Idiopathic REM Sleep Behavior Disorder. <i>Annals of Neurology</i> , 2020, 88, 817-829.	2.8	19
678	Effect of biological treatments on psychotic symptoms in lewy body disease: A systematic review and metaâ€analysis of randomized controlled trials. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 1083-1096.	1.3	1
679	Seizure occurrence and related mortality in dementia with Lewy bodies. <i>Epilepsy and Behavior</i> , 2020, 111, 107311.	0.9	7
681	Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 103.	2.4	10
682	Case Report: The Role of Neuropsychological Assessment and Imaging Biomarkers in the Early Diagnosis of Lewy Body Dementia in a Patient With Major Depression and Prolonged Alcohol and Benzodiazepine Dependence. <i>Frontiers in Psychiatry</i> , 2020, 11, 684.	1.3	2

#	ARTICLE	IF	CITATIONS
683	Bradykinesia in Alzheimer's disease and its neurophysiological substrates. <i>Clinical Neurophysiology</i> , 2020, 131, 850-858.	0.7	36
684	The combined effect of amyloid- $\beta^2$ and tau biomarkers on brain atrophy in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2020, 27, 102333.	1.4	22
685	Extrastriatal 123I-FP-CIT SPECT impairment in degenerative parkinsonisms. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 38-43.	1.1	10
686	Neuroinflammation is associated with infiltration of T cells in Lewy body disease and $\beta$ -synuclein transgenic models. <i>Journal of Neuroinflammation</i> , 2020, 17, 214.	3.1	48
687	Approach to Cognitive Impairment in Parkinson's Disease. <i>Neurotherapeutics</i> , 2020, 17, 1495-1510.	2.1	29
688	Alpha Power and Functional Connectivity in Cognitive Decline: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1047-1088.	1.2	29
689	The Role of Glial Mitochondria in $\beta$ -Synuclein Toxicity. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 548283.	1.8	13
690	Characterization of EEG Data Revealing Relationships With Cognitive and Motor Symptoms in Parkinson's Disease: A Systematic Review. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 587396.	1.7	34
691	Very-late-onset psychotic symptoms: psychosis or dementia? A phenomenological approach. A systematic review. <i>Psychologie &amp; Neuropsychiatrie Du Vieillissement</i> , 2020, 18, 77-86.	0.2	1
692	Clinical impact of dual-tracer FDOPA and FDG PET/CT for the evaluation of patients with parkinsonian syndromes. <i>Medicine (United States)</i> , 2020, 99, e23060.	0.4	8
693	Behavioral and Psychological Effects of Coronavirus Disease-19 Quarantine in Patients With Dementia. <i>Frontiers in Psychiatry</i> , 2020, 11, 578015.	1.3	157
694	A/T(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies. <i>Diagnostics</i> , 2020, 10, 1015.	1.3	16
696	Physical Therapy for Gait, Balance, and Cognition in Individuals with Cognitive Impairment: A Retrospective Analysis. <i>Rehabilitation Research and Practice</i> , 2020, 2020, 1-12.	0.5	3
697	Defining and predicting transdiagnostic categories of neurodegenerative disease. <i>Nature Biomedical Engineering</i> , 2020, 4, 787-800.	11.6	22
698	Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 92.	3.0	18
699	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	1.9	33
700	Differential changes in visual and auditory event-related oscillations in dementia with Lewy bodies. <i>Clinical Neurophysiology</i> , 2020, 131, 2357-2366.	0.7	9
701	Direct Medical Costs of Dementia With Lewy Bodies by Disease Complexity. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1696-1704.e5.	1.2	8

#	ARTICLE	IF	CITATIONS
702	A Systematic Review and Comparison of Neurocognitive Features of Late-Life Attention-Deficit/Hyperactivity Disorder and Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 466-481.	1.2	2
703	Dream enactment behavior: review for the clinician. <i>Journal of Clinical Sleep Medicine</i> , 2020, 16, 1949-1969.	1.4	16
704	Cognitive Impairment Evaluation and Management. <i>Medical Clinics of North America</i> , 2020, 104, 807-825.	1.1	35
705	Cerebrospinal Fluid Biomarkers in Parkinson's Disease: A Critical Overview of the Literature and Meta-Analyses. <i>Brain Sciences</i> , 2020, 10, 466.	1.1	26
706	Does amnesia specifically predict Alzheimer's pathology? A neuropathological study. <i>Neurobiology of Aging</i> , 2020, 95, 123-130.	1.5	15
707	Hypersensitivity to atypical antipsychotics in dementia with Lewy bodies: is it common or rare?. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 44-45.	1.1	1
708	Late-Onset OCD as a Potential Harbinger of Dementia With Lewy Bodies: A Report of Two Cases. <i>Frontiers in Psychiatry</i> , 2020, 11, 554.	1.3	5
709	Tremor in Vascular Cognitive Impairment Raises the Possibility of Mixed Pathology With Lewy Body Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 781.	1.4	0
710	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1182-1195.	0.4	119
711	Hippocampal sclerosis, TDP43, and the duration of the symptoms of dementia of AD patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1546-1556.	1.7	15
712	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2020, 140, 449-461.	3.9	7
713	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. <i>Translational Psychiatry</i> , 2020, 10, 267.	2.4	30
714	Clinical Presentation of Chronic Traumatic Encephalopathy. <i>Seminars in Neurology</i> , 2020, 40, 370-383.	0.5	12
715	Characteristics of initial symptoms and symptoms at diagnosis in probable dementia with Lewy body disease: incidence of symptoms and gender differences. <i>Psychogeriatrics</i> , 2020, 20, 737-745.	0.6	31
716	The challenges of COVID-19 for people with dementia with Lewy bodies and family caregivers. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 1431-1436.	1.3	20
717	Specific occupational profiles as proxies of cognitive reserve induce neuroprotection in dementia with Lewy bodies. <i>Brain Imaging and Behavior</i> , 2020, 15, 1427-1437.	1.1	5
718	Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2257-2263.	1.3	21
719	Resting state activity and connectivity of the nucleus basalis of Meynert and globus pallidus in Lewy body dementia and Parkinson's disease dementia. <i>NeuroImage</i> , 2020, 221, 117184.	2.1	15

#	ARTICLE	IF	CITATIONS
720	Plasma immune markers in an idiopathic REM sleep behavior disorder cohort. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 145-150.	1.1	22
721	Mild cognitive impairment in Huntington's disease?. <i>Journal of the Neurological Sciences</i> , 2020, 413, 116779.	0.3	1
722	Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET. <i>NeuroImage</i> , 2020, 221, 117193.	2.1	9
723	Basic Fibroblast Growth Factor 2-Induced Proteome Changes Endorse Lewy Body Pathology in Hippocampal Neurons. <i>IScience</i> , 2020, 23, 101349.	1.9	4
724	A novel <i>SNCA</i> E83Q mutation in a case of dementia with Lewy bodies and atypical frontotemporal lobar degeneration. <i>Neuropathology</i> , 2020, 40, 620-626.	0.7	27
725	Multiplicity of $\alpha$ -Synuclein Aggregated Species and Their Possible Roles in Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8043.	1.8	33
726	Neuropsychological presentation of colpocephaly and porencephaly with symptom onset in adulthood. <i>Neurocase</i> , 2020, 26, 353-359.	0.2	2
727	Association of <i>ABI3</i> and <i>PLCG2</i> missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. <i>Acta Neuropathologica Communications</i> , 2020, 8, 172.	2.4	8
728	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2342-2355.	1.7	20
729	Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 135.	3.0	22
730	Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 137.	3.0	32
731	Orthostatic hypotension preceding dementia with Lewy bodies by over 15 years: a clinicopathologic case report. <i>Clinical Autonomic Research</i> , 2020, 30, 575-577.	1.4	3
732	Neuroimaging in dementias. , 2020, , 187-197.		0
733	Diffusion imaging in dementia with Lewy bodies: Associations with amyloid burden, atrophy, vascular factors and clinical features. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 109-115.	1.1	10
734	cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12083.	1.2	9
735	Nasal chemosensory tests: biomarker between dementia with Lewy bodies and Parkinson disease dementia. <i>Rhinology</i> , 2020, 58, 0-0.	0.7	5
736	Mild cognitive impairment with Lewy bodies: neuropsychiatric supportive symptoms and cognitive profile. <i>Psychological Medicine</i> , 2022, 52, 1147-1155.	2.7	26
737	Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer's disease neuropathology. <i>Scientific Reports</i> , 2020, 10, 14579.	1.6	29



#	ARTICLE	IF	CITATIONS
738	The Contribution of Vascular Pathology Toward Cognitive Impairment in Older Individuals with Intermediate Braak Stage Tau Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1005-1015.	1.2	5
739	Visuo-Perceptual and Decision-Making Contributions to Visual Hallucinations in Mild Cognitive Impairment in Lewy Body Disease: Insights from a Drift Diffusion Analysis. <i>Brain Sciences</i> , 2020, 10, 540.	1.1	4
740	Proteomic Characterization of the Olfactory Molecular Imbalance in Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6371.	1.8	6
743	Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 184-193.	1.1	21
744	Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19. <i>Frontiers in Psychiatry</i> , 2020, 11, 579934.	1.3	44
745	Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1219-1226.	0.9	17
746	What Can Person-Centred Care in Dementia Learn from the Recovery Movement?. , 2020, , 202-212.		0
747	Epidemiology and Mental Health in Old Age. , 2020, , 5-23.		0
749	Young-Onset Dementias. , 2020, , 38-49.		0
750	Rare and Unusual Dementias. , 2020, , 50-77.		0
751	Mania in Late Life. , 2020, , 78-91.		0
752	Alcohol Misuse in Older People. , 2020, , 92-104.		0
753	Drug Misuse in Older People. , 2020, , 105-115.		0
754	Mental Health in Parkinson's Disease. , 2020, , 116-128.		0
755	The Home Assessment in Old Age Psychiatry. , 2020, , 129-138.		0
756	Driving in Dementia. , 2020, , 139-148.		0
757	Mini-Mental State Examination for the Detection and Prediction of Dementia in People with and without Mild Cognitive Impairment. , 2020, , 149-160.		0
758	Biomarkers and the Diagnosis of Preclinical Alzheimer's Disease. , 2020, , 161-172.		0

#	ARTICLE	IF	CITATIONS
759	To Scan or Not to Scan. , 2020, , 173-190.		0
760	Supporting Self-Management in Early Dementia. , 2020, , 191-201.		0
761	Psychosocial Interventions in Dementia. , 2020, , 213-222.		0
762	Palliative Care in Dementia. , 2020, , 223-242.		0
763	Review of Treatment for Late-Life Depression. , 2020, , 243-253.		0
764	Reducing the Healthcare Burden of Delirium. , 2020, , 254-265.		0
765	Controlling the Confusion. , 2020, , 266-278.		0
766	Residence Capacity. , 2020, , 305-316.		0
769	Comparisons of cardiovascular dysautonomia and cognitive impairment between de novo Parkinsonâ€™s disease and de novo dementia with Lewy bodies. BMC Neurology, 2020, 20, 350.	0.8	19
771	Mental Health Laws from All UK Jurisdictions. , 2020, , 279-292.		0
772	Deprivation of Liberty. , 2020, , 293-304.		0
773	Understanding the Person with Dementia. , 2020, , 317-327.		0
774	Alpha-synuclein Levels in the Differential Diagnosis of Lewy Bodies Dementia and Other Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2020, 34, 220-224.	0.6	15
775	Regional gray matter-dedicated SUVR with 3D-MRI detects positive amyloid deposits in equivocal amyloid PET images. Annals of Nuclear Medicine, 2020, 34, 856-863.	1.2	3
776	Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia. Alzheimer's Research and Therapy, 2020, 12, 107.	3.0	47
777	Neuropsychiatric profiles in mild cognitive impairment with Lewy bodies. Aging and Mental Health, 2021, 25, 2011-2017.	1.5	11
778	Autonomic Dysfunction in the Synucleinopathies. Seminars in Neurology, 2020, 40, 492-501.	0.5	17
779	Hippocampal subfield pathologic burden in Lewy body diseases <i>vs</i>. Alzheimerâ€™s disease. Neuropathology and Applied Neurobiology, 2020, 46, 707-721.	1.8	21

#	ARTICLE	IF	CITATIONS
780	Assessment of genetic risk for improved clinical-neuropathological correlations. <i>Acta Neuropathologica Communications</i> , 2020, 8, 160.	2.4	4
781	Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1143-1155.	1.2	13
782	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. <i>Biomolecules</i> , 2020, 10, 1177.	1.8	14
783	A Preliminary Trial in the Efficacy of Yokukansankachimpinango on REM Sleep Behavior Disorder in Dementia With Lewy Bodies. <i>Frontiers in Nutrition</i> , 2020, 7, 119.	1.6	5
784	Dementia-related psychosis and the potential role for pimavanserin. <i>CNS Spectrums</i> , 2022, 27, 7-15.	0.7	8
785	The Role of EEG in the Diagnosis, Prognosis and Clinical Correlations of Dementia with Lewy Bodies—A Systematic Review. <i>Diagnostics</i> , 2020, 10, 616.	1.3	24
786	Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy. <i>Npj Parkinson's Disease</i> , 2020, 6, 39.	2.5	8
787	Proton pump inhibitors and the risk of Alzheimer's disease and non-Alzheimer's dementias. <i>Scientific Reports</i> , 2020, 10, 21046.	1.6	21
788	Differentiating Oneiric Stupor in Agrypnia Excitata From Dreaming Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 565694.	1.1	7
789	The Rise of Dementia With Lewy Bodies: Nursing Interventions and Implications. <i>Journal of Neuroscience Nursing</i> , 2020, 52, 311-315.	0.7	0
790	The Cognitive Profile of Mild Cognitive Impairment Due to Dementia With Lewy Bodies—An Updated Review. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 597579.	1.7	6
791	Identification of Circular RNA hsa_Circ_0003391 in Peripheral Blood Is Potentially Associated With Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 601965.	1.7	31
792	Resting Heart Rate Variability Is Associated With Subsequent Orthostatic Hypotension: Comparison Between Healthy Older People and Patients With Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2020, 11, 567984.	1.1	7
793	Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT. <i>Frontiers in Neurology</i> , 2020, 11, 568438.	1.1	8
794	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. <i>NeuroImage: Clinical</i> , 2020, 28, 102504.	1.4	14
795	The positive and negative appraisals of caregiving (PANAC) scale: A new measure to examine the caregiving experience in Alzheimer's disease and related dementias. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12104.	1.8	6
796	Trajectories and risk factors of dementia progression: a memory clinic cohort followed up to 3 years from diagnosis. <i>International Psychogeriatrics</i> , 2021, 33, 779-789.	0.6	9
797	Interaction of neuropsychiatric symptoms with APOE $\epsilon$ 4 and conversion to dementia in MCI patients in a Memory Clinic. <i>Scientific Reports</i> , 2020, 10, 20058.	1.6	13

#	ARTICLE	IF	CITATIONS
798	<sup>18</sup> F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. <i>Brain</i> , 2020, 143, 3477-3494.	3.7	100
799	Genetic Analysis of Chinese Patients with Early-Onset Dementia Using Next-Generation Sequencing. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 1831-1839.	1.3	7
800	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020, 11, 572976.	1.1	65
801	Does a Positive Amyloid Scan Always Mean Alzheimer Disease?. , 2020, , 99-102.		0
802	Study design and baseline characteristics of a population-based prospective cohort study of dementia in Japan: the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). <i>Environmental Health and Preventive Medicine</i> , 2020, 25, 64.	1.4	47
803	Neuropathological features of cognitive decline in Lewy body dementia. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 356-361.	0.2	0
804	Dementia with Lewy bodies and Parkinson disease dementia. <i>Neurology</i> , 2020, 94, 858-859.	1.5	4
805	Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e2076-e2087.	1.5	42
806	Reduced dopamine transporter binding predicts early transition to Lewy body disease in Japanese patients with idiopathic rapid eye movement sleep behavior disorder. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116821.	0.3	13
807	Thalamic pulvinar metabolism, sleep disturbances, and hallucinations in dementia with Lewy bodies: Positron emission tomography and actigraphy study. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 934-943.	1.3	7
808	A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid $\beta$ -amyloid <sub>42</sub> , total-tau, phospho-tau and $\alpha$ -synuclein in the differential diagnosis of neurodegenerative dementia. <i>Journal of Neurology</i> , 2020, 267, 2567-2581.	1.8	6
809	Neuropathological findings in multiple system atrophy with cognitive impairment. <i>Journal of Neural Transmission</i> , 2020, 127, 1031-1039.	1.4	13
810	Prospective predictors of decline <i>in</i> stability in mild cognitive impairment with Lewy bodies or Alzheimer's disease. <i>Psychological Medicine</i> , 2021, 51, 2590-2598.	2.7	7
811	Low dopamine transporter binding in the nucleus accumbens in geriatric patients with severe depression. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 424-430.	1.0	18
812	Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 473-490.	1.2	19
813	Evaluating <sup>2</sup> -[ <sup>18</sup> F]FDG-PET in differential diagnosis of dementia using a data-driven decision model. <i>NeuroImage: Clinical</i> , 2020, 27, 102267.	1.4	9
814	Fibrillar form of $\alpha$ -synuclein-specific scFv antibody inhibits $\alpha$ -synuclein seeds induced aggregation and toxicity. <i>Scientific Reports</i> , 2020, 10, 8137.	1.6	9
815	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1885-1912.	3.3	134

#	ARTICLE	IF	CITATIONS
816	Functional neuroimaging evidence supporting the dual syndrome hypothesis of cognitive impairment in Lewy body disease. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 378-384.	0.2	1
817	Ethnic disparities in the uptake of anti-dementia medication in young and late-onset dementia. <i>International Psychogeriatrics</i> , 2023, 35, 381-390.	0.6	12
818	Anti-Cholinergic Derangement of Cortical Metabolism on 18F-FDG PET in a Patient with Frontotemporal Lobar Degeneration Dementia: A Case of the TREDEM Registry. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1107-1117.	1.2	1
819	Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116886.	0.3	13
820	The utility of simple questions to evaluate cognitive impairment. <i>PLoS ONE</i> , 2020, 15, e0233225.	1.1	0
821	Freezing of Speech Single Questionnaire as a Screening Tool for Cognitive Dysfunction in Patients With Dementia With Lewy Bodies. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 65.	1.7	7
822	CSF p-tau/A $\beta$ 242 ratio and brain FDG-PET may reliably detect MCI $\rightarrow$ imminent $\rightarrow$ converters to AD. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3152-3164.	3.3	26
823	What to make of equivocal amyloid imaging results. <i>Neurocase</i> , 2020, 26, 137-146.	0.2	2
824	Insulin resistance and Parkinson's disease. , 2020, , 293-347.		0
825	Lewy Body Degenerations as Neuropsychiatric Disorders. <i>Psychiatric Clinics of North America</i> , 2020, 43, 361-381.	0.7	3
826	Examining the Relationship between a Verbal Incidental Learning Measure from the WAIS-IV and Neuroimaging Biomarkers for Alzheimer's Pathology. <i>Developmental Neuropsychology</i> , 2020, 45, 95-109.	1.0	5
827	Changes in Regional Cerebral Perfusion Over Time in Idiopathic $\langle$ REM $\rangle$ Sleep Behavior Disorder. <i>Movement Disorders</i> , 2020, 35, 1475-1481.	2.2	14
828	Interrupting the trajectory of frailty in dementia with Lewy bodies with anabolic exercise, dietary intervention and deprescribing of hazardous medications. <i>BMJ Case Reports</i> , 2020, 13, e231336.	0.2	4
829	ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, e46-e58.	1.5	97
830	Delirium disorder. <i>Neurology</i> , 2020, 95, 173-178.	1.5	38
831	Sleep Disturbances in Patients with Autoimmune Encephalitis. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 28.	2.0	18
832	Appropriate assessment method of 123I-MIBG myocardial scintigraphy for the diagnosis of Lewy body diseases and idiopathic REM sleep behavior disorder. <i>Journal of Neurology</i> , 2020, 267, 3248-3257.	1.8	5
833	Impact of Cognitive Frailty on Activities of Daily Living, Cognitive Function, and Conversion to Dementia Among Memory Clinic Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 895-903.	1.2	7

#	ARTICLE	IF	CITATIONS
834	Treatment Options for Dementia with Lewy Bodies: A Network Meta-Analysis of Randomised Control Trials. <i>Neurology and Therapy</i> , 2020, 9, 521-534.	1.4	5
835	Reproducibility of EEG functional connectivity in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 68.	3.0	73
836	Logopenic aphasia due to Lewy body disease dramatically improved with donepezil. <i>ENeurologicalSci</i> , 2020, 19, 100241.	0.5	8
837	Evidence-based Positron Emission Tomography. , 2020, , .		3
838	Cognitive tests aid in clinical differentiation of Alzheimer's disease versus Alzheimer's disease with Lewy body disease: Evidence from a pathological study. <i>Alzheimer's and Dementia</i> , 2020, 16, 1173-1181.	0.4	13
839	<scp>Alpha</scp>Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies. <i>Annals of Neurology</i> , 2020, 88, 503-512.	2.8	78
840	Altered awareness of motor symptoms in Parkinson's disease and Dementia with Lewy Bodies: A systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 972-981.	1.3	7
841	Prospective longitudinal evaluation of cytokines in mild cognitive impairment due to <scp>AD</scp> and Lewy body disease. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 1250-1259.	1.3	14
842	Predicting phenoconversion in pure autonomic failure. <i>Neurology</i> , 2020, 95, e889-e897.	1.5	36
843	Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network Hubs. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 370-375.	0.9	20
844	Levodopa-induced dyskinesia in dementia with Lewy bodies and Parkinson disease with dementia. <i>Neurology: Clinical Practice</i> , 2020, 10, 156-161.	0.8	4
845	Animal-Assisted and Pet-Robot Interventions for Ameliorating Behavioral and Psychological Symptoms of Dementia: A Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2020, 8, 150.	1.4	27
846	Progressive Parkinsonism Three Years after Shunt Surgery in a Patient with Idiopathic Normal Pressure Hydrocephalus. <i>Internal Medicine</i> , 2020, 59, 2183-2186.	0.3	3
847	Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. <i>Scientific Reports</i> , 2020, 10, 9161.	1.6	55
848	Salience Network Atrophy Links Neuron Type-Specific Pathobiology to Loss of Empathy in Frontotemporal Dementia. <i>Cerebral Cortex</i> , 2020, 30, 5387-5399.	1.6	37
849	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <i>Molecular Neurodegeneration</i> , 2020, 15, 36.	4.4	46
851	Clinical diagnosis of Lewy body dementia. <i>BJPsych Open</i> , 2020, 6, e61.	0.3	33
852	Subtypes of dementia with Lewy bodies are associated with $\alpha$ -synuclein and tau distribution. <i>Neurology</i> , 2020, 95, e155-e165.	1.5	47

#	ARTICLE	IF	CITATIONS
853	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. <i>Acta Neuropathologica</i> , 2020, 139, 1001-1024.	3.9	46
854	A case of oral cenesthopathy in which dementia with Lewy bodies developed during treatment. <i>Psychogeriatrics</i> , 2020, 20, 766-768.	0.6	6
855	Systematic review of gene expression studies in people with Lewy body dementia. <i>Acta Neuropsychiatrica</i> , 2020, 32, 281-292.	1.0	12
856	Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm. <i>NeuroImage: Clinical</i> , 2020, 26, 102243.	1.4	25
857	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. <i>NeuroImage: Clinical</i> , 2020, 26, 102248.	1.4	24
858	Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 465-473.	0.9	17
859	The Oral Health Status of Chinese Elderly People with and without Dementia: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1913.	1.2	19
860	Cognitive deficit, and neuropathological correlates, in the oldest-old. <i>Revue Neurologique</i> , 2020, 176, 670-676.	0.6	7
862	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. <i>Clinica Chimica Acta</i> , 2020, 506, 55-66.	0.5	2
863	Epidemiology of neurological diseases in older adults. <i>Revue Neurologique</i> , 2020, 176, 642-648.	0.6	45
864	Education Moderates the Association of Probable REM Sleep Behavior Disorder With Cognitive and Motor Impairments in Community-Dwelling Older People. <i>Frontiers in Neurology</i> , 2020, 11, 109.	1.1	3
867	Confirmation of <sup>123</sup> I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1628-1635.	2.8	18
868	Clinical and striatal dopamine transporter predictors of $\beta^2$ -amyloid in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e1344-e1352.	1.5	17
869	Spatial metabolic profiles to discriminate dementia with Lewy bodies from Alzheimer disease. <i>Journal of Neurology</i> , 2020, 267, 1960-1969.	1.8	16
870	Contribution of Alzheimer's disease neuropathologic change to the cognitive dysfunction in human brains with Lewy body-related pathology. <i>Neurobiology of Aging</i> , 2020, 91, 56-65.	1.5	8
871	Primary Progressive Aphasia as a Prodromal State of Dementia With Lewy Bodies: A Case Report. <i>Frontiers in Neurology</i> , 2020, 11, 49.	1.1	11
872	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020, 95, e953-e961.	1.5	50
873	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between $\alpha$ -synucleinopathies. <i>Journal of Neurology</i> , 2020, 267, 3444-3456.	1.8	17

#	ARTICLE	IF	CITATIONS
874	Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. <i>JAMA Neurology</i> , 2020, 77, 1299.	4.5	109
875	Pregabalin as a Treatment for Anxiety in Patients With Dementia With Lewy Bodies. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 297-299.	0.7	5
876	The insula, a grey matter of tastes: a volumetric MRI study in dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 79.	3.0	8
877	Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4718.	1.8	15
878	Dysautonomia in Alzheimer's Disease. <i>Medicina (Lithuania)</i> , 2020, 56, 337.	0.8	11
879	Prevalence of triple/dual disease (Alzheimer's disease, Lewy body disease, and white matter disease). <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 171-176.	0.2	7
880	Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e662-e670.	1.5	28
881	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	1.5	17
882	Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 88.	2.4	52
883	Mutation Analysis of the Genes Associated with Parkinson's Disease in a Finnish Cohort of Early-Onset Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 955-965.	1.2	0
884	Positron emission computed tomography/single photon emission computed tomography in Parkinson disease. <i>Chinese Medical Journal</i> , 2020, 133, 1448-1455.	0.9	6
885	Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 82.	3.0	41
886	Use of skin advanced glycation end product levels measured using a simple noninvasive method as a biological marker for the diagnosis of neuropsychiatric diseases. <i>International Journal of Methods in Psychiatric Research</i> , 2020, 29, e1824.	1.1	5
887	Cognitive function has a stronger correlation with perceived age than with chronological age. <i>Geriatrics and Gerontology International</i> , 2020, 20, 779-784.	0.7	12
888	APOE4 exacerbates $\alpha$ -synuclein pathology and related toxicity independent of amyloid. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	90
889	Correlation of microglial activation with white matter changes in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2020, 25, 102200.	1.4	17
890	Numerous ballooned neurons in a 94-year-old man with dementia with Lewy bodies. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116722.	0.3	1
891	New use of psychotropic medication after hospitalization among people with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 640-649.	1.3	5



#	ARTICLE	IF	CITATIONS
892	The utility of heart-to-mediastinum ratio using a planar image created from IQ-SPECT with Iodine-123 meta-iodobenzylguanidine. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2569-2577.	1.4	11
893	Sleep and Cognitive Impairments in Neurodegenerative Diseases. <i>Neuroscience and Behavioral Physiology</i> , 2020, 50, 275-282.	0.2	1
894	Genetic architecture of neurodegenerative dementias. <i>Neuropharmacology</i> , 2020, 168, 108014.	2.0	5
895	Common neurodegenerative disorders in the perioperative setting: Recommendations for screening from the Society for Perioperative Assessment and Quality Improvement (SPAQI). <i>Perioperative Care and Operating Room Management</i> , 2020, 20, 100092.	0.2	4
896	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	1.5	42
897	Cardiac sympathetic denervation and synucleinopathy in Alzheimer's disease with brain Lewy body disease. <i>Brain Communications</i> , 2020, 2, fcaa004.	1.5	7
898	An Informant-Based Simple Questionnaire for Visuospatial Dysfunction Assessment in Dementia. <i>Frontiers in Neuroscience</i> , 2020, 14, 44.	1.4	12
899	Differentiating between dementia, delirium and depression in older people. <i>Nursing Standard (Royal Tj ETQq1 1 0.784314 rgBT /Over</i>	0.1	1
900	Dopaminergic Depletion, $\beta$ -Amyloid Burden, and Cognition in Lewy Body Disease. <i>Annals of Neurology</i> , 2020, 87, 739-750.	2.8	27
901	Generation and Characterization of Novel Monoclonal Antibodies Targeting $\beta$ 2-microglobulin across Human Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 407-418.	0.9	8
902	When does cerebral $\beta$ -amyloid deposition begin in Lewy body dementia?. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 362-371.	0.2	2
903	PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan. <i>Japanese Journal of Radiology</i> , 2020, 38, 343-357.	1.0	10
904	Fabry Disease With Concomitant Lewy Body Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 378-392.	0.9	16
905	Analysis of risk factors for depression in Alzheimer's disease patients. <i>International Journal of Neuroscience</i> , 2020, 130, 1136-1141.	0.8	8
906	Risk factors for earlier dementia onset in autopsy-confirmed Alzheimer's disease, mixed Alzheimer's with Lewy bodies, and pure Lewy body disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 524-530.	0.4	13
907	The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1647-1659.	1.2	4
908	How can we best care for people with dementia with Lewy bodies pharmacologically?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 513-515.	0.9	1
909	Cardiac <sup>123</sup> I-MIBG planar heart to mediastinum ratios depend on patient size; phantom studies suggest SPECT-CT could improve quantification. <i>Biomedical Physics and Engineering Express</i> , 2020, 6, 015011.	0.6	0

#	ARTICLE	IF	CITATIONS
910	Mirror neurons and their relationship with neurodegenerative disorders. <i>Journal of Neuroscience Research</i> , 2020, 98, 1070-1094.	1.3	21
911	Mechanisms of alpha-synuclein toxicity: An update and outlook. <i>Progress in Brain Research</i> , 2020, 252, 91-129.	0.9	49
912	Synucleinopathies: Where we are and where we need to go. <i>Journal of Neurochemistry</i> , 2020, 153, 433-454.	2.1	62
913	Fineâ€Mapping of <i>SNCA</i> in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. <i>Annals of Neurology</i> , 2020, 87, 584-598.	2.8	39
914	Frontal-executive dysfunction affects dementia conversion in patients with amnesic mild cognitive impairment. <i>Scientific Reports</i> , 2020, 10, 772.	1.6	27
915	Cognitive impairment in Parkinson's disease is multifactorial: A neuropsychological study. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 500-508.	1.0	11
916	Case series of dementia with Lewy bodies: consensus criteria in practice. <i>Australasian Psychiatry</i> , 2020, 28, 80-83.	0.4	1
917	Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias. <i>Annals of Neurology</i> , 2020, 87, 394-404.	2.8	65
918	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1444-1453.	1.8	4
919	Microbleeds in dementia with Lewy bodies. <i>Journal of Neurology</i> , 2020, 267, 1491-1498.	1.8	8
920	<i>APOE</i> genotype regulates pathology and disease progression in synucleinopathy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	102
921	Imaging biomarkers in neurodegeneration: current and future practices. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 49.	3.0	96
922	Validation of machine learning models to detect amyloid pathologies across institutions. <i>Acta Neuropathologica Communications</i> , 2020, 8, 59.	2.4	20
923	Brain volumes and dual-task performance correlates among individuals with cognitive impairment: a retrospective analysis. <i>Journal of Neural Transmission</i> , 2020, 127, 1057-1071.	1.4	7
924	Serum neuronal exosomes predict and differentiate Parkinsonâ€™s disease from atypical parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 720-729.	0.9	148
925	<p>The Effect of Type 2 Diabetes Mellitus on Neuropsychological Symptoms in Chinese Early Alzheimerâ€™s Disease Population</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 829-836.	1.0	6
926	Myocardial Sympathetic Innervation Imaging with MIBG in Dementia with Lewy Bodies. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2164-2166.	1.4	1
927	Role of [18F]-FDG PET in patients with atypical parkinsonism associated with dementia. <i>Clinical and Translational Imaging</i> , 2020, 8, 107-122.	1.1	3

#	ARTICLE	IF	CITATIONS
928	Cognitive Impairment and Dementia in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 365-377.	1.0	43
929	Neuropsychiatric feature profiles of patients with Lewy body dementia. <i>Clinical Neurology and Neurosurgery</i> , 2020, 194, 105832.	0.6	22
930	Colombian consortium for the study of Lewy body dementia COL-DLB. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116807.	0.3	2
931	Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease. <i>Brain Pathology</i> , 2020, 30, 766-778.	2.1	19
932	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 512-519.	0.9	75
933	Role of Alterations in Protein Kinase p38 $\beta$ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and $\alpha$ -Synuclein Transgenic Models. <i>Frontiers in Neuroscience</i> , 2020, 14, 286.	1.4	15
934	The Different Relationship between Homocysteine and Uric Acid Levels with Respect to the MTHFR C677T Polymorphism According to Gender in Patients with Cognitive Impairment. <i>Nutrients</i> , 2020, 12, 1147.	1.7	10
935	Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. <i>Acta Neuropathologica</i> , 2020, 140, 49-62.	3.9	218
936	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. <i>Brain Stimulation</i> , 2020, 13, 1031-1039.	0.7	39
937	Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. <i>PLoS ONE</i> , 2020, 15, e0231720.	1.1	27
938	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	4.9	121
939	Clinical and pathological features affecting cardiac sympathetic denervation in autopsy-confirmed dementia with Lewy bodies. <i>European Journal of Neurology</i> , 2020, 27, 1155-1163.	1.7	1
940	Presence phenomena in parkinsonian disorders: Phenomenology and neuropsychological correlates. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 785-793.	1.3	7
941	The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12020.	1.8	18
942	Differences in correlations of depression and anhedonia with cardiovascular sympathetic functions during a head-up tilt test in drug-naïve Parkinson's disease patients. <i>Neurological Sciences</i> , 2020, 41, 2825-2830.	0.9	4
943	DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB. <i>Neurobiology of Aging</i> , 2020, 93, 143.e5-143.e7.	1.5	3
944	Analysis of $\alpha$ -synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa010.	1.5	21
945	Prevalence and Clinical Implications of the Mirror and TV Signs in Advanced Alzheimer's Disease and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2020, 10, 56-62.	0.6	8

#	ARTICLE	IF	CITATIONS
946	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 44.	3.0	23
947	EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 46.	3.0	41
948	Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer's and non-Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 35.	3.0	43
949	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.5	365
950	Electroencephalogram in dementia with Lewy bodies: a systematic review. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 1197-1208.	1.4	14
951	The identified clinical features of Parkinson's disease in homo-, heterozygous and digenic variants of PINK1. <i>Neurobiology of Aging</i> , 2021, 97, 146.e1-146.e13.	1.5	14
952	Association between cerebrospinal fluid Orexin A level and severity of rapid eye movement sleep behaviour disorder in dementia with Lewy bodies. <i>Psychogeriatrics</i> , 2021, 21, 128-130.	0.6	5
953	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. <i>Movement Disorders</i> , 2021, 36, 632-641.	2.2	3
954	Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt $\alpha$ -Synucleinopathies. <i>Annals of Neurology</i> , 2021, 89, 293-303.	2.8	12
955	Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. <i>Acta Neuropathologica</i> , 2021, 141, 25-37.	3.9	43
956	Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 612-622.	3.3	16
957	Cognitive Decline in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease: A Prospective Cohort Study. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 272-284.	0.6	15
958	RAB39B is redistributed in dementia with Lewy bodies and is sequestered within $\alpha^2$ plaques and Lewy bodies. <i>Brain Pathology</i> , 2021, 31, 120-132.	2.1	11
959	Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson's disease dementia. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 143-156.	1.8	19
960	The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 375-383.	0.6	36
961	Delirium in the acute hospital setting: the role of psychiatry. <i>BJ Psych Advances</i> , 2021, 27, 49-59.	0.5	4
962	Analysis of the LRP10 gene in patients with Parkinson's disease and dementia with Lewy bodies from Southern Italy. <i>Neurological Sciences</i> , 2021, 42, 305-308.	0.9	5
963	Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 325-337.	0.9	2

#	ARTICLE	IF	CITATIONS
964	Cricopharyngeal bar on videofluoroscopy: high specificity for inclusion body myositis. <i>Journal of Neurology</i> , 2021, 268, 1016-1024.	1.8	9
965	The development of new method to differentiate between Dementia with Lewy bodies and Alzheimer's disease by cerebral perfusion SPECT-comparison to CIscore. <i>Japanese Journal of Radiology</i> , 2021, 39, 198-205.	1.0	4
966	Dementia with Lewy bodies in first-generation immigrants in a European memory clinic. <i>Acta Neurologica Belgica</i> , 2021, 121, 219-223.	0.5	6
967	A 10 year retrospective cohort study of inpatients with younger-onset dementia. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 294-301.	1.3	15
968	Mild cognitive impairment with Lewy bodies: blood perfusion with arterial spin labelling. <i>Journal of Neurology</i> , 2021, 268, 1284-1294.	1.8	11
969	Parkinsonian gait in elderly people: Significance of the threshold value of two and more falls per year. <i>Revue Neurologique</i> , 2021, 177, 385-393.	0.6	3
970	Heart rate response to orthostatic challenge in patients with dementia with Lewy bodies and Alzheimer's disease. <i>Psychogeriatrics</i> , 2021, 21, 62-70.	0.6	3
971	Magnetic resonance imaging abnormalities as a marker of multiple system atrophy in isolated rapid eye movement sleep behavior disorder. <i>Sleep</i> , 2021, 44, .	0.6	9
972	Four-Year Follow-up of [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography-Based Parkinson's Disease-Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression. <i>Movement Disorders</i> , 2021, 36, 230-235.	2.2	31
973	Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia. <i>European Journal of Neurology</i> , 2021, 28, 1142-1152.	1.7	11
974	Heidenhain variant of Creutzfeldt-Jakob disease resembles dementia with Lewy bodies. <i>Psychogeriatrics</i> , 2021, 21, 121-124.	0.6	1
975	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.4	81
976	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. <i>Annals of Neurology</i> , 2021, 89, 520-533.	2.8	21
977	The revised Addenbrooke's Cognitive Examination can facilitate differentiation of dementia with Lewy bodies from Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 831-838.	1.3	3
978	Rapid eye movement sleep behavior disorder: A proof-of-concept neuroprotection study for prodromal synucleinopathies. <i>European Journal of Neurology</i> , 2021, 28, 1210-1217.	1.7	9
979	A Prodromal Brain-Clinical Pattern of Cognition in Synucleinopathies. <i>Annals of Neurology</i> , 2021, 89, 341-357.	2.8	28
980	Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 895-904.	2.2	31
981	Suicide and Lewy body dementia: Report of a Lewy body dementia association working group. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 373-382.	1.3	9

#	ARTICLE	IF	CITATIONS
982	Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography. <i>Neurobiology of Aging</i> , 2021, 101, 172-180.	1.5	14
983	Next-Generation RNA-Sequencing of Serum Small Extracellular Vesicles Discovers Potential Diagnostic Biomarkers for Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 573-584.	0.6	13
984	Atypical parkinsonian syndromes in a North African tertiary referral center. <i>Brain and Behavior</i> , 2021, 11, e01924.	1.0	5
985	Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer's disease pathology at death. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 713-721.	1.3	10
986	Mild Cognitive Impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021, 50, 72-80.	0.7	80
987	Cognitive Impairment in Older Adults and Therapeutic Strategies. <i>Pharmacological Reviews</i> , 2021, 73, 152-162.	7.1	24
988	Clinical relevance of brain atrophy subtypes categorization in memory clinics. <i>Alzheimer's and Dementia</i> , 2021, 17, 641-652.	0.4	14
989	Neurogeriatric approach to delirium/dementia in a multi-faculty university hospital. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 68-72.	0.2	3
990	Alzheimer's Disease Neuropathological Comorbidities are Common in the Younger-Old. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 389-400.	1.2	44
991	Hypomethylation of SNCA in Idiopathic REM Sleep Behavior Disorder Associated With Phenoconversion. <i>Movement Disorders</i> , 2021, 36, 955-962.	2.2	4
992	Systematic review and meta-analysis of human transcriptomics reveals neuroinflammation, deficient energy metabolism, and proteostasis failure across neurodegeneration. <i>Neurobiology of Disease</i> , 2021, 149, 105225.	2.1	54
993	Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. <i>Brain</i> , 2021, 144, 278-287.	3.7	68
994	Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 627-637.	1.2	5
995	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 99, 11-18.	1.5	11
996	Did inspector Kurt Wallander develop dementia with Lewy bodies?. <i>Sleep Medicine</i> , 2021, 78, 36-37.	0.8	0
997	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021, 146, 111223.	1.2	4
998	Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 958-968.	0.6	17
999	Cognitively oriented treatments in dementia. , 2021, , 15-34.		1

#	ARTICLE	IF	CITATIONS
1000	Association between cortical microinfarcts and total small vessel disease burden in cerebral amyloid angiopathy on 3T magnetic resonance imaging. <i>European Journal of Neurology</i> , 2021, 28, 794-799.	1.7	6
1001	Neurological examination: what do psychiatrists need to know?. <i>BJ Psych Advances</i> , 2021, 27, 313-319.	0.5	0
1002	Altered awareness of cognitive and neuropsychiatric symptoms in Parkinson's disease and Dementia with Lewy Bodies: A systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 15-30.	1.3	13
1003	Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster-Randomized Trial. <i>Movement Disorders</i> , 2021, 36, 143-151.	2.2	5
1004	Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy. <i>Alzheimer's and Dementia</i> , 2021, 17, 81-88.	0.4	27
1005	Difficulties and associated coping methods regarding visual hallucinations caused by dementia with Lewy bodies. <i>Dementia</i> , 2021, 20, 291-307.	1.0	2
1006	Visual versus semiquantitative analysis of 18F-fluorodeoxyglucose-positron emission tomography brain images in patients with dementia. <i>World Journal of Nuclear Medicine</i> , 2021, 20, 82-89.	0.3	2
1007	Justification for Integrated Care of Dementia and Presbycusis: Focused on National Dementia Policy. <i>Audiology and Speech Research</i> , 2021, 17, 112-119.	0.1	2
1008	Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 819-832.	1.2	6
1010	Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2021, 179, 189-205.	1.0	12
1011	Different Morphology of Neuritic Plaques in the Archicortex of Alzheimer's Disease with Comorbid Synucleinopathy: A Pilot Study. <i>Current Alzheimer Research</i> , 2021, 17, 948-958.	0.7	3
1012	Functional connectivity of the nucleus basalis of Meynert in Lewy body dementia and Alzheimer's disease. <i>International Psychogeriatrics</i> , 2021, 33, 89-94.	0.6	12
1013	Degenerative Diseases of the CNS. , 2021, , 353-389.		0
1014	Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders. , 2021, , 249-295.e17.		0
1015	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. <i>Brain</i> , 2022, 145, 1079-1097.	3.7	30
1016	Risk of dementia in APOE $\epsilon$ 4 carriers is mitigated by a polygenic risk score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12229.	1.2	16
1017	Psychological assessment of neurocognitive disorders. , 2021, , 251-262.		1
1019	The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. <i>Brain Communications</i> , 2021, 3, fcab180.	1.5	17

#	ARTICLE	IF	CITATIONS
1020	Ethnic Differences in Attending a Tertiary Dementia Clinic in Israel. <i>Frontiers in Neurology</i> , 2020, 11, 578068.	1.1	1
1021	The Cognitive & Leisure Activity Scale (CLAS): A new measure to quantify cognitive activities in older adults with and without cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12134.	1.8	11
1022	Evaluating a novel behavioral paradigm for visual hallucinations in Dementia with Lewy bodies. <i>Aging Brain</i> , 2021, 1, 100011.	0.7	2
1023	An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DELB). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12171.	1.8	9
1024	A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1833-1841.	3.3	15
1025	Diagnosis and Management of Seizures in Neurodegenerative Diseases. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	0.7	12
1026	Psychosis Management in Lewy Body Dementia: A Comprehensive Clinical Approach. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 255-261.	1.2	8
1027	Lewy bodies in the olfactory system and the hypothalamus. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2021, 182, 235-244.	1.0	2
1028	V180I genetic Creutzfeldt-Jakob disease with cardiac sympathetic nerve denervation masquerading as Parkinson's disease. <i>Medicine (United States)</i> , 2021, 100, e24294.	0.4	4
1029	Predictors of caregiver burden in aged caregivers of demented older patients. <i>BMC Geriatrics</i> , 2021, 21, 59.	1.1	50
1030	Clinico-pathological comparison of patients with autopsy-confirmed Alzheimer's disease, dementia with Lewy bodies, and mixed pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12189.	1.2	9
1031	Mood and emotional disorders associated with parkinsonism, Huntington disease, and other movement disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2021, 183, 175-196.	1.0	4
1032	Mechanisms and Physiologic Effects of REM Sleep and Its Disruption. <i>The Journal of Japan Society for Clinical Anesthesia</i> , 2021, 41, 116-120.	0.0	0
1033	Aducanumab: Appropriate Use Recommendations. <i>Journal of prevention of Alzheimer's disease</i> , The, 2021, 8, 1-13.	1.5	115
1034	Feasibility of pharmacokinetic parametric PET images in scaled subprofile modelling using principal component analysis. <i>NeuroImage: Clinical</i> , 2021, 30, 102625.	1.4	4
1035	<i>Klinik der Demenzen.</i> , 2021, , 59-92.		0
1036	Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. <i>Acta Neuropathologica</i> , 2021, 141, 511-526.	3.9	31
1037	Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer's disease. <i>Brain</i> , 2022, 145, 1773-1784.	3.7	28



#	ARTICLE	IF	CITATIONS
1038	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , 2021, 31, 102754.	1.4	27
1039	Prevalence and Associated Factors of Visual Hallucinations in Patients with Vascular Cognitive Impairment. <i>Behavioural Neurology</i> , 2021, 2021, 1-7.	1.1	0
1041	Posterior Cortical Atrophy phenotype in a GBA N370S mutation carrier: a case report. <i>BMC Neurology</i> , 2021, 21, 17.	0.8	3
1042	Hypothalamic $\alpha$ -synuclein and its relation to autonomic symptoms and neuroendocrine abnormalities in Parkinson disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 223-233.	1.0	2
1043	Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2486-2499.	3.3	21
1044	Data linkages in epidemiology. , 2021, , 95-117.		0
1045	Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 725.	1.8	7
1046	[18F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases. <i>Brain Communications</i> , 2021, 3, fcab177.	1.5	2
1047	PET and SPECT Imaging of Neurodegenerative Diseases. , 2021, , 1309-1334.		0
1048	Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12235.	1.2	6
1049	Benzodiazepines and antidepressants: Effects on cognitive and functional decline in Alzheimer's disease and Lewy body dementia. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 917-925.	1.3	21
1050	Routine magnetoencephalography in memory clinic patients: A machine learning approach. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12227.	1.2	9
1051	Parkinsonian Dementias. , 2021, , 91-117.		0
1052	Dementia and Systemic Disease. , 2021, , 1099-1110.		1
1053	Management of Sleep Disorders in Patients with Dementia. , 2021, , 229-250.		0
1054	Management of Patients with Dementia: An Introduction. , 2021, , 1-18.		1
1055	An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. <i>World Psychiatry</i> , 2021, 20, 34-51.	4.8	100
1056	Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2834-2845.	3.3	22

#	ARTICLE	IF	CITATIONS
1057	R869C mutation in molecular motor KIF17 gene is involved in dementia with Lewy bodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12143.	1.2	1
1058	Impaired sensory evidence accumulation and network function in Lewy body dementia. <i>Brain Communications</i> , 2021, 3, fcab089.	1.5	8
1059	Premotor and fronto-striatal mechanisms associated with presence hallucinations in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2021, 32, 102791.	1.4	2
1060	The hippocampal region is necessary for text comprehension and memorization: a combined VBM/DTI study in neuropsychological patients. <i>Brain Imaging and Behavior</i> , 2021, 15, 2367-2376.	1.1	1
1061	Cingulate Island Sign in Single Photon Emission Computed Tomography: Clinical Biomarker Correlations in Lewy Body Disease and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1003-1008.	1.2	2
1062	Comprehensive Evaluation of the Functional Activities Questionnaire (FAQ) and Its Reliability and Validity. <i>Assessment</i> , 2022, 29, 748-763.	1.9	27
1063	Setting Up a Cognitive Training Service for Egyptian Older Adults. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1673-1682.	1.2	2
1064	Hippocampal network hyperexcitability in young transgenic mice expressing human mutant alpha-synuclein. <i>Neurobiology of Disease</i> , 2021, 149, 105226.	2.1	10
1065	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEVELOP design and baseline results. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 53.	3.0	21
1066	Heterogeneity in $\alpha$ -synuclein fibril activity correlates to disease phenotypes in Lewy body dementia. <i>Acta Neuropathologica</i> , 2021, 141, 547-564.	3.9	23
1067	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European DLB consortium project. <i>Alzheimer's and Dementia</i> , 2021, 17, 1277-1286.	0.4	5
1068	<sup>123</sup> I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease: a new quantitative analysis of autopsy confirmed cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 662-667.	0.9	13
1069	APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 631145.	1.1	30
1070	A Novel Machine Learning Algorithm Predicts Dementia With Lewy Bodies Versus Parkinson's Disease Dementia Based on Clinical and Neuropsychological Scores. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 317-320.	1.2	8
1071	Anosognosia for memory in dementia with Lewy bodies compared with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1059-1064.	1.3	4
1072	Visual evoked potential abnormalities in dementia with Lewy bodies. <i>Neurophysiologie Clinique</i> , 2021, 51, 425-431.	1.0	6
1073	Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1317-1328.	0.4	79
1074	Early diagnosis of prodromal dementia with Lewy bodies using clinical history of probable REM sleep behaviour disorder and cardiac <sup>123</sup> I-MIBG scintigraphy in memory clinics. <i>Psychogeriatrics</i> , 2021, 21, 288-295.	0.6	7

#	ARTICLE	IF	CITATIONS
1075	Introduction of an assessment toolkit associated with increased rate of DLB diagnosis. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 50.	3.0	3
1076	Neuropsychiatric symptoms and comorbidity: Associations with dementia progression rate in a memory clinic cohort. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 960-969.	1.3	9
1077	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 25.	2.4	23
1078	Effect of Alzheimer's Disease and Lewy Body Disease on Metabolic Changes. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1471-1487.	1.2	2
1079	Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 313-324.	0.9	5
1080	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. <i>Brain Pathology</i> , 2021, 31, e12942.	2.1	9
1081	Cerebrospinal Fluid Hypocretin and Nightmares in Dementia Syndromes. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2021, 11, 19-25.	0.6	6
1082	Sex differences for phenotype in pathologically defined dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 745-750.	0.9	23
1083	PICALM mRNA Expression in the Blood of Patients with Neurodegenerative Diseases and Geriatric Depression. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1055-1062.	1.2	14
1084	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
1085	The Effect of Baseline Patient and Caregiver Mindfulness on Dementia Outcomes. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1345-1367.	1.2	9
1086	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. <i>Frontiers in Neuroscience</i> , 2021, 15, 647783.	1.4	17
1087	Correlation of Frontal Atrophy and CSF Tau Levels With Neuropsychiatric Symptoms in Patients With Cognitive Impairment: A Memory Clinic Experience. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 595758.	1.7	10
1088	Balance Impairments as Differential Markers of Dementia Disease Subtype. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 639337.	2.0	6
1089	Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences. <i>Cells</i> , 2021, 10, 656.	1.8	25
1090	Detection of $\alpha$ -synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2021, 20, 203-212.	4.9	174
1091	Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer's disease. <i>PLoS ONE</i> , 2021, 16, e0248413.	1.1	5
1093	Genetic testing in dementia—a medical genetics perspective. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1158-1170.	1.3	9

#	ARTICLE	IF	CITATIONS
1095	Challenges in Predicting Cognitive Decline in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 1-8.	0.7	6
1096	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. <i>Neurology</i> , 2021, 96, 848-863.	1.5	149
1097	Collaborative Neuropathology Network Characterizing Outcomes of TBI (CONNECT-TBI). <i>Acta Neuropathologica Communications</i> , 2021, 9, 32.	2.4	13
1098	Î±-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 885-893.	1.2	9
1099	Comparison of the Caregiving Experience of Grief, Burden, and Quality of Life in Dementia with Lewy Bodies, Alzheimer's Disease, and Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 421-432.	1.2	13
1100	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021, 298, 517-530.	3.6	27
1101	Detection of Wandering Behaviors Using a Body-Worn Inertial Sensor in Patients With Cognitive Impairment: A Feasibility Study. <i>Frontiers in Neurology</i> , 2021, 12, 529661.	1.1	12
1102	Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innostest. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 604119.	1.7	17
1103	Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Brain Communications</i> , 2021, 3, fcab045.	1.5	37
1104	First symptom guides diagnosis and prognosis in neurodegenerative diseases—a retrospective study of autopsy proven cases. <i>European Journal of Neurology</i> , 2021, 28, 1801-1811.	1.7	11
1105	Odor Identification Testing Can Assist in the Clinical Distinction Between Psychiatric Disorders and Neurological/Neurodegenerative Disorders. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 244-249.	0.6	1
1106	Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 1121-1133.	0.4	40
1107	Widespread Decreases in Cerebral Copper Are Common to Parkinson's Disease Dementia and Alzheimer's Disease Dementia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 641222.	1.7	21
1109	Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 82-90.	1.1	2
1110	Feasibility of unattended home sleep apnea testing in a cognitively impaired clinic population. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 435-444.	1.4	5
1111	Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder-Related Metabolic Pattern Expression. <i>Movement Disorders</i> , 2021, 36, 1889-1898.	2.2	18
1112	Neuropsychiatric symptoms in early stage of Alzheimer's and non-Alzheimer's dementia, and the risk of progression to severe dementia. <i>Age and Ageing</i> , 2021, 50, 1709-1718.	0.7	16
1113	Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. <i>Brain</i> , 2021, 144, 2186-2198.	3.7	100

#	ARTICLE	IF	CITATIONS
1114	Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond. <i>Cmaj</i> , 2021, 193, E371-E377.	0.9	28
1116	Locus Coeruleus Malfunction Is Linked to Psychopathology in Prodromal Dementia With Lewy Bodies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 641101.	1.7	16
1117	Neuroimaging in dementia. <i>Wiener Medizinische Wochenschrift</i> , 2021, 171, 274-281.	0.5	5
1118	â€œSemantic variant primary progressive aphasiaâ€ due to comorbidity of Lewy body disease and a previous cerebral venous infarction in the left anterior temporal lobe: A case report. <i>ENeurologicalSci</i> , 2021, 22, 100318.	0.5	4
1119	Prevalence of the core clinical features and the other neuropsychiatric symptoms in dementia with Lewy bodies. <i>Psychogeriatrics</i> , 2021, 21, 443-445.	0.6	1
1120	Elevated cerebral blood flow in patients with pure autonomic failure. <i>Clinical Autonomic Research</i> , 2021, 31, 405-414.	1.4	3
1121	Evolution of Capgras syndrome in neurodegenerative disease: the multiplication phenomenon. <i>Neurocase</i> , 2021, 27, 160-164.	0.2	1
1122	The fate of patients with REM sleep behavior disorder and mild cognitive impairment. <i>Sleep Medicine</i> , 2021, 79, 205-210.	0.8	19
1123	The Logic and Pitfalls of Parkinson's Disease as â€œBrainâ€ Firstâ€ Versus â€œBodyâ€ Firstâ€ Subtypes. <i>Movement Disorders</i> , 2021, 36, 594-598.	2.2	28
1124	A New Rise of Non-Human Primate Models of Synucleinopathies. <i>Biomedicines</i> , 2021, 9, 272.	1.4	8
1125	Neural cell-surface and intracellular autoantibodies in patients with cognitive impairment from a memory clinic cohort. <i>Journal of Neural Transmission</i> , 2021, 128, 357-369.	1.4	13
1127	Laboratoryâ€ Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the <scp>MoDiMSA Study Group</scp>. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 322-340.	0.8	7
1128	Bringing psychiatrists into the picture: Automated measurement of regional MRI brain volume in patients with suspected dementia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 799-808.	1.3	1
1129	Functional Brain Connectivity Patterns Associated with Visual Hallucinations in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 311-320.	1.2	2
1130	Consideration of different scoring approaches for a verbal incidental learning measure from the WAIS-IV using hippocampal volumes. <i>Applied Neuropsychology Adult</i> , 2021, , 1-11.	0.7	0
1131	The predictive value of normal EEGs in dementia due to Alzheimerâ€™s disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1038-1048.	1.7	3
1133	Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBDâ€MOD). <i>Alzheimer's and Dementia</i> , 2021, 17, 1675-1686.	0.4	19
1134	Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimerâ€™s Disease or Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1603-1612.	1.2	2

#	ARTICLE	IF	CITATIONS
1135	Distinctive regional asymmetry in dopaminergic and serotonergic dysfunction in degenerative Parkinsonisms. <i>Journal of the Neurological Sciences</i> , 2021, 423, 117363.	0.3	5
1136	The Impact of the COVID-19 Pandemic on the Cognition of People with Dementia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4285.	1.2	29
1137	Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases. <i>Journal of Neural Transmission</i> , 2021, 128, 687-699.	1.4	13
1138	In Vivo Diagnosis of Synucleinopathies. <i>Neurology</i> , 2021, 96, e2513-e2524.	1.5	63
1139	Anosognosia in dementia with Lewy bodies: a systematic review. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 334-342.	0.3	2
1140	Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology. <i>Neurotherapeutics</i> , 2021, 18, 728-752.	2.1	30
1141	Visual text hallucinations in a patient with posterior cortical atrophy attributable to <sup>1</sup>Alzheimer's disease and <sup>1</sup>Lewy body disease. <i>Psychogeriatrics</i> , 2021, 21, 683-685.	0.6	0
1143	Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 86.	3.0	19
1144	LeSCoD: a new clinical scale for the detection of Lewy body disease in neurocognitive disorders. <i>Journal of Neurology</i> , 2021, 268, 3886-3896.	1.8	0
1145	Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer's Disease Pathology <sup>1</sup> . <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1243-1256.	1.2	20
1146	Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions. <i>Frontiers in Neurology</i> , 2021, 12, 644317.	1.1	51
1147	Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease. <i>Neurology</i> , 2021, 96, e2685-e2693.	1.5	15
1148	Reduced Synaptic Density in Patients with Lewy Body Dementia: An [ <sup>11</sup> C]UCB $\tau$ PET Imaging Study. <i>Movement Disorders</i> , 2021, 36, 2057-2065.	2.2	39
1149	Prodromal Parkinson disease subtypes â€” key to understanding heterogeneity. <i>Nature Reviews Neurology</i> , 2021, 17, 349-361.	4.9	171
1150	Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy. <i>Brain</i> , 2021, 144, 1138-1151.	3.7	24
1151	Generalized Rhythmic Delta Activity Frontally Predominant Differentiates Dementia With Lewy Bodies From Alzheimer's Disease and Parkinson's Disease Dementia: A Conventional Electroencephalography Visual Analysis. <i>Clinical EEG and Neuroscience</i> , 2021, , 155005942199714.	0.9	0
1152	The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1221-1229.	1.2	12
1153	Dopamine transporter SPECT imaging in Parkinson's disease and parkinsonian disorders. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 400-410.	0.4	11

#	ARTICLE	IF	CITATIONS
1154	Functional connectivity in mild cognitive impairment with Lewy bodies. <i>Journal of Neurology</i> , 2021, 268, 4707-4720.	1.8	10
1156	LRP10 interacts with SORL1 in the intracellular vesicle trafficking pathway in non-neuronal brain cells and localises to Lewy bodies in Parkinson's disease and dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2021, 142, 117-137.	3.9	15
1157	Face pareidolia is associated with right striatal dysfunction in drug-naïve patients with Parkinson's disease. <i>Neurological Sciences</i> , 2021, 42, 5327-5334.	0.9	6
1158	The role of APOE in cognitive trajectories and motor decline in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 7819.	1.6	14
1159	A comparison of the prevalence of Fear of Falling between older patients with Lewy body dementia, Alzheimer's disease, and without dementia. <i>Experimental Gerontology</i> , 2021, 146, 111248.	1.2	9
1160	Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3960.	1.8	0
1161	Utility of the pareidolia test in mild cognitive impairment with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1407-1414.	1.3	4
1162	Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies. <i>Neurology</i> , 2021, 96, e2801-e2811.	1.5	25
1163	Sick Sinus Syndrome Mimicking Autonomic Dysfunction of Dementia With Lewy Bodies. <i>Cureus</i> , 2021, 13, e14667.	0.2	1
1164	Etiology of Dementia in Thai Patients. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2021, 11, 64-70.	0.6	4
1165	Agitation and apathy increase risk of dementia in psychiatric inpatients with late-onset psychiatric symptoms. <i>BMC Psychiatry</i> , 2021, 21, 214.	1.1	6
1166	Structural connectivity networks in Alzheimer's disease and Lewy body disease. <i>Brain and Behavior</i> , 2021, 11, e02112.	1.0	4
1167	Neuropsychiatric Symptoms in Patients with Dementia Associated with Increased Psychological Distress in Caregivers During the COVID-19 Pandemic. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1705-1712.	1.2	42
1168	Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist. <i>American Journal of Neuroradiology</i> , 2021, 42, 998-1007.	1.2	13
1169	Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure. <i>Annals of Neurology</i> , 2021, 89, 1212-1220.	2.8	51
1170	Insights into Lewy body disease from rare neurometabolic disorders. <i>Journal of Neural Transmission</i> , 2021, 128, 1567-1575.	1.4	7
1171	Protocol for an observational cohort study identifying factors predicting accurately end of life in dementia with Lewy bodies and promoting quality end-of-life experiences: the PACE-DLB study. <i>BMJ Open</i> , 2021, 11, e047554.	0.8	2
1172	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	18.1	784

#	ARTICLE	IF	CITATIONS
1173	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 659898.	1.7	9
1174	Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer's Disease and Other Types of Dementing Disorders. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 230-240.	2.5	44
1175	Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 231-244.	1.2	19
1176	Subjective experience of time in dementia with Lewy bodies during COVID-19 lockdown. <i>Current Psychology</i> , 2023, 42, 4653-4662.	1.7	5
1177	Different patterns of $\beta$ -amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism. <i>Neurobiology of Aging</i> , 2021, 101, 199-206.	1.5	2
1179	Prevalence of depression, anxiety, and apathy symptoms across dementia stages: A systematic review and meta-analysis. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1330-1344.	1.3	89
1180	Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population. <i>EBioMedicine</i> , 2021, 67, 103361.	2.7	23
1181	Consistent skin $\alpha$ -synuclein positivity in REM sleep behavior disorder – A two center two-to-four-year follow-up study. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 108-113.	1.1	16
1182	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	1.0	13
1183	Hippocampal and insula volume in mild cognitive impairment with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 27-33.	1.1	10
1184	Clinical Care and Unmet Needs of Individuals With Dementia With Lewy Bodies and Caregivers. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 327-334.	0.6	7
1185	The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1811-1817.	2.0	3
1186	Visual hallucinations. <i>Practical Neurology</i> , 2021, 21, 327-332.	0.5	5
1187	Living with Dementia in Aotearoa (LiDiA): a cross-sectional feasibility study protocol for a multiethnic dementia prevalence study in Aotearoa/New Zealand. <i>BMJ Open</i> , 2021, 11, e046143.	0.8	2
1188	Anosognosia in Early- and Late-Onset Dementia and Its Association With Neuropsychiatric Symptoms. <i>Frontiers in Psychiatry</i> , 2021, 12, 658934.	1.3	6
1189	Robust $\alpha$ -synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 80.	2.4	11
1190	Prevalence of isolated RBD in the city of Catania, Italy: a population-based study. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 2241-2248.	1.4	11
1191	Of Criteria and Men – Diagnosing Atypical Parkinsonism: Towards an Algorithmic Approach. <i>Brain Sciences</i> , 2021, 11, 695.	1.1	2



#	ARTICLE	IF	CITATIONS
1192	An autopsy case of corticobasal syndrome with pure diffuse Lewy Body Disease. <i>Neurocase</i> , 2021, 27, 231-237.	0.2	4
1193	Blood DNA Methylation Levels in the WNT5A Gene Promoter Region: A Potential Biomarker for Agitation in Subjects with Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1601-1611.	1.2	3
1194	Assessing Dementia Prevalence in the Wisconsin Longitudinal Study: Cohort Profile, Protocol, and Preliminary Findings. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 751-768.	1.2	3
1195	Neuropsychological profile associated with an alpha-synuclein gene (<i>SNCA</i>) duplication. <i>Clinical Neuropsychologist</i> , 2022, 36, 1787-1798.	1.5	8
1196	Update on neuroimaging in non-Alzheimer's disease dementia: a focus on the Lewy body disease spectrum. <i>Current Opinion in Neurology</i> , 2021, 34, 532-538.	1.8	6
1197	40 Years Anniversary of Cardiac 123I-mIBG Imaging: State of the Heart. <i>Current Cardiovascular Imaging Reports</i> , 2021, 14, 1.	0.4	1
1198	Old age genetically confirmed frontotemporal lobar degeneration with TDP $\beta$ 43 has limbic predominant TDP $\beta$ 43 deposition. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1050-1059.	1.8	10
1199	Dementia Incidence, Burden and Cost of Care: A Filipino Community-Based Study. <i>Frontiers in Public Health</i> , 2021, 9, 628700.	1.3	12
1200	Risk factors for mild behavioral impairment in non-demented geriatrics: a population-based survey in Taiwan. <i>International Psychogeriatrics</i> , 2021, , 1-9.	0.6	1
1201	Late life psychotic features in prodromal Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 67-73.	1.1	5
1202	Interrater agreement in dementia diagnosis: A systematic review and meta-analysis. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1127-1147.	1.3	9
1203	Sex is a defining feature of neuroimaging phenotypes in major brain disorders. <i>Human Brain Mapping</i> , 2022, 43, 500-542.	1.9	25
1204	Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased $\alpha$ -synuclein, tau, amyloid $\beta$ 2 or vascular pathology. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1080-1091.	1.8	14
1205	Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder. <i>Npj Parkinson's Disease</i> , 2021, 7, 40.	2.5	9
1206	Developments of a population-based prospective cohort study for dementia (the Nakajima study) and an educational program for dementia experts (the NINPRO). <i>Neurology and Clinical Neuroscience</i> , 0, , .	0.2	0
1207	IRM encéphalique: quelle place dans le bilan des maladies neurologiques à expression cognitive?. <i>Pratique Neurologique - FMC</i> , 2021, 12, 158-164.	0.1	0
1208	<sup>123</sup> I-Metaiodobenzylguanidine Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 717-724.	0.8	3
1209	Nelotanserin as symptomatic treatment for rapid eye movement sleep behavior disorder: a double-blind randomized study using video analysis in patients with dementia with Lewy bodies or Parkinson's disease dementia. <i>Sleep Medicine</i> , 2021, 81, 180-187.	0.8	22

#	ARTICLE	IF	CITATIONS
1210	Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up. <i>Scientific Reports</i> , 2021, 11, 10837.	1.6	9
1211	Psychosocial support for people with dementia with Lewy bodies. <i>Nursing and Residential Care</i> , 2021, 23, 1-8.	0.1	1
1212	Molecular and Anatomical Imaging of Dementia With Lewy Bodies and Frontotemporal Lobar Degeneration. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 264-274.	2.5	7
1213	Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?. <i>Frontiers in Neurology</i> , 2021, 12, 629442.	1.1	22
1214	Multi-domain prognostic models used in middle aged adults without known cognitive impairment for predicting subsequent dementia. <i>The Cochrane Library</i> , 0, , .	1.5	2
1215	White matter abnormalities of right hemisphere attention networks contribute to visual hallucinations in dementia with Lewy bodies. <i>Cortex</i> , 2021, 139, 86-98.	1.1	9
1216	Case Report: De Clerambault's Syndrome in Dementia With Lewy Bodies. <i>Frontiers in Psychiatry</i> , 2021, 12, 665868.	1.3	3
1217	Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1295-1309.	1.2	15
1219	Poly (ADP-ribose) Interacts With Phosphorylated $\alpha$ -Synuclein in Post Mortem PD Samples. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 704041.	1.7	14
1220	Simple Quantitative Indices for the Differentiation of Advanced-Stage Alzheimer's Disease and Other Limbic Tauopathies. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1093-1102.	1.2	4
1221	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , The, 2021, 20, 484-496.	4.9	396
1222	Assessing Nigrostriatal Dopaminergic Pathways via 123I-FP-CIT SPECT in Dementia With Lewy Bodies in a Psychiatric Patient Cohort. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 672956.	1.7	6
1224	The feasibility and acceptability of a psychosocial intervention to support people with dementia with Lewy bodies and family care partners. <i>Dementia</i> , 2021, , 147130122110285.	1.0	2
1225	Association of Lewy Bodies With Age-Related Clinical Characteristics in Black and White Decedents. <i>Neurology</i> , 2021, 97, e825-e835.	1.5	4
1226	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , 2021, 97, e523-e534.	1.5	4
1227	Association Between Homocysteine and Vitamin Levels in Demented Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1781-1792.	1.2	8
1228	Diagnosis of Dementia with Lewy Bodies: Fluctuations, Biomarkers, and beyond. , 0, , .		2
1229	Rapid Eye Movement Sleep Behavior Disorder-like Symptoms Due to Arousal Responses Associated with Severe Obstructive Sleep Apnea-hypopnea. <i>Internal Medicine</i> , 2021, 60, 1775-1778.	0.3	0

#	ARTICLE	IF	CITATIONS
1230	Biomarkers for neurodegenerative diseases. <i>Nature Medicine</i> , 2021, 27, 954-963.	15.2	399
1232	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	3.7	26
1233	Survey of the End-of-life Care Preferences of Patients with Mild Dementia and Differences from Hopes of Familial Caregivers Regarding End-of-life Care for Patients. <i>An Official Journal of the Japan Primary Care Association</i> , 2021, 44, 45-52.	0.1	0
1234	Catatonia as the Initial Manifestation of Dementia with Lewy Bodies. <i>American Journal of Case Reports</i> , 2021, 22, e932018.	0.3	4
1235	Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 527-534.	1.2	19
1237	The Cerebellum Is a Common Key for Visuospatial Execution and Attention in Parkinson's Disease. <i>Diagnostics</i> , 2021, 11, 1042.	1.3	4
1238	Exploring the experiences of living with Lewy body dementia: An integrative review. <i>Journal of Advanced Nursing</i> , 2021, 77, 4632-4645.	1.5	8
1239	Lewy Body Dementias: A Coin with Two Sides?. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2021, 11, 94.	1.0	8
1240	Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 690293.	1.7	32
1241	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. <i>Neurology</i> , 2021, 97, e814-e824.	1.5	14
1242	Exploring the Connection between Porphyromonas gingivalis and Neurodegenerative Diseases: A Pilot Quantitative Study on the Bacterium Abundance in Oral Cavity and the Amount of Antibodies in Serum. <i>Biomolecules</i> , 2021, 11, 845.	1.8	14
1243	Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 75-81.	1.1	11
1245	Assessing the Views of Professionals, Patients, and Care Partners Concerning the Use of Computer Tools in Memory Clinics: International Survey Study. <i>JMIR Formative Research</i> , 2021, 5, e31053.	0.7	6
1246	Use of Charlson Comorbidity Index and Nomogram to Predict Mortality in Elderly Patients with Late-Life Schizophrenia. <i>Healthcare (Switzerland)</i> , 2021, 9, 783.	1.0	2
1247	Update on Major Neurocognitive Disorders. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 271-281.	0.4	1
1248	Diagnostic Value of the CSF $\alpha$ -Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. <i>Neurology</i> , 2021, 97, e930-e940.	1.5	51
1249	G protein-coupled receptor kinases are associated with Alzheimer's disease pathology. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 942-957.	1.8	12
1250	Plasma amyloid- $\beta$ oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 133.	3.0	19

#	ARTICLE	IF	CITATIONS
1251	A glutaminy cyclase-catalyzed Î±-synuclein modification identified in human synucleinopathies. <i>Acta Neuropathologica</i> , 2021, 142, 399-421.	3.9	13
1252	Comparing Stop Signal Reaction Times in Alzheimer's and Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-10.	0.3	3
1254	Improving the diagnosis and management of Lewy body dementia: the DIAMOND-Lewy research programme including pilot cluster RCT. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-120.	0.4	8
1256	Systematic video-analysis of motor events during REM sleep in idiopathic REM sleep behavior disorder, follow-up and DAT-SPECT. <i>Sleep Medicine</i> , 2021, 83, 132-144.	0.8	9
1257	Four Common Late-Life Cognitive Trajectories Patterns Associate with Replicable Underlying Neuropathologies. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 647-659.	1.2	11
1258	Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases. <i>Acta Neuropathologica</i> , 2021, 142, 449-474.	3.9	27
1259	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.1	391
1260	The Impact of the COVID-19 Pandemic on Alzheimer's Disease and Other Dementias. <i>Frontiers in Psychiatry</i> , 2021, 12, 703481.	1.3	15
1261	Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 314-328.	0.6	9
1262	Lower urinary tract dysfunction in Parkinsonian syndromes. <i>Neurological Sciences</i> , 2021, 42, 4045-4054.	0.9	6
1264	The Impact of the COVID-19 Pandemic and Lockdown on Mild Cognitive Impairment, Alzheimer's Disease and Dementia With Lewy Bodies in China: A 1-Year Follow-Up Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 711658.	1.3	24
1265	Locus Coeruleus Pathology Indicates a Continuum of Lewy Body Dementia. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1641-1650.	1.5	11
1266	Current Nosology of Neural Autoantibody-Associated Dementia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 711195.	1.7	10
1267	Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. <i>Scientific Reports</i> , 2021, 11, 14394.	1.6	7
1268	Suspecting dementia: canaries, chameleons and zebras. <i>Practical Neurology</i> , 2021, 21, 300-312.	0.5	13
1269	Multidisciplinary pharmacotherapy collaboration for home-based older adults with dementia: a study focusing on physicians, pharmacists, and nursing professionals. <i>Psychogeriatrics</i> , 2021, 21, 749-762.	0.6	0
1270	Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. <i>Journal of Neurochemistry</i> , 2021, 158, 1394-1411.	2.1	42
1271	Symptoms and Treatment Needs of People with Dementia-Related Psychosis: A Mixed-Methods Study of the Patient Experience. <i>Clinical Gerontologist</i> , 2021, , 1-15.	1.2	2

#	ARTICLE	IF	CITATIONS
1272	Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes. <i>Radiology</i> , 2021, 300, 260-278.	3.6	55
1273	Knowledge domain and emerging trends in visual hallucination research: A scientometric analysis. <i>World Journal of Psychiatry</i> , 2021, 11, 491-506.	1.3	0
1274	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 949-967.	1.4	4
1275	Lewy body-associated proteins: victims, instigators, or innocent bystanders? The case of AIMP2 and alpha-synuclein. <i>Neurobiology of Disease</i> , 2021, 156, 105417.	2.1	4
1276	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 269-279.	1.2	10
1277	Pre-Loss Grief in Caregivers of Older Adults with Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1847-1859.	1.2	6
1278	Parkinson's Disease—An Introduction. <i>Series in Bioengineering</i> , 2022, , 1-24.	0.3	2
1279	Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 913-919.	1.2	27
1280	Neurophysiological evaluation of visual function in iRBD: potential role in stratifying RBD conversion risk. <i>Sleep Medicine</i> , 2021, 84, 26-31.	0.8	0
1281	Experiences of people with dementia and their caregivers during the COVID-19 pandemic in India: A mixed-methods study. <i>Dementia</i> , 2022, 21, 214-235.	1.0	15
1282	Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months. <i>Neurology</i> , 2021, 97, e1031-e1040.	1.5	11
1283	A Modified CAIDE Risk Score as a Screening Tool for Cognitive Impairment in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1755-1768.	1.2	11
1284	Artificial Intelligence for Alzheimer's Disease: Promise or Challenge?. <i>Diagnostics</i> , 2021, 11, 1473.	1.3	38
1285	Altered Spatiotemporal Dynamics of the Resting Brain in Mild Cognitive Impairment with Lewy Bodies. <i>Movement Disorders</i> , 2021, 36, 2435-2440.	2.2	5
1286	123I-Ioflupane SPECT and 18F-FDG PET Combined Use in the Characterization of Movement and Cognitive Associated Disorders in Neurodegenerative Diseases. <i>Current Alzheimer Research</i> , 2021, 18, 196-207.	0.7	2
1287	Overview of the Complex Figure Test and Its Clinical Application in Neuropsychiatric Disorders, Including Copying and Recall. <i>Frontiers in Neurology</i> , 2021, 12, 680474.	1.1	26
1288	Disease-, region- and cell type specific diversity of $\beta$ -synuclein carboxy terminal truncations in synucleinopathies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 146.	2.4	10
1289	Characteristics of Early-Onset Dementia in Chiba Prefecture, Japan: A Multicenter Survey. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 283-288.	0.7	1

#	ARTICLE	IF	CITATIONS
1290	Serum tyrosine is associated with better cognition in Lewy body dementia. <i>Brain Research</i> , 2021, 1765, 147481.	1.1	9
1291	Day-to-day reciprocal associations between depressive symptoms, cognitive performance and sleep and the single-subject design. <i>International Psychogeriatrics</i> , 2021, , 1-7.	0.6	2
1292	Autoimmune Encephalitis Resembling Dementia Syndromes. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	22
1293	5-HT1A Partial Agonist Tandosiprone for Behavioral and Psychological Symptoms in Oldest-old Patients with Dementia at a Special Elderly Nursing Home. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 514-520.	0.9	2
1294	Informal caregiver experiences at the end-of-life of individuals living with dementia with Lewy bodies: An interview study. <i>Dementia</i> , 2022, 21, 287-303.	1.0	2
1295	Gastric Electrical Dysarrhythmia in Probable Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2021, 12, 687215.	1.1	3
1296	Motor Dysfunction Questionnaire and Dopamine Transporter Imaging Composite Scale Improve Differentiating Dementia With Lewy Bodies From Alzheimer's Disease With Motor Dysfunction. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 709215.	1.7	3
1297	An Update on Neurodegenerative Disease for Eye Care Providers. <i>Advances in Ophthalmology and Optometry</i> , 2021, 6, 13-38.	0.3	0
1298	Face Masks Protect From Infection but May Impair Social Cognition in Older Adults and People With Dementia. <i>Frontiers in Psychology</i> , 2021, 12, 640548.	1.1	11
1299	Neurodegenerative movement disorders: An epigenetics perspective and promise for the future. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 897-909.	1.8	16
1300	The <i>APOE</i> $\epsilon$ 4 variant and hippocampal atrophy in Alzheimer's disease and Lewy body dementia: a systematic review of magnetic resonance imaging studies and therapeutic relevance. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 851-870.	1.4	7
1301	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 136.	3.0	30
1302	The functional brain favours segregated modular connectivity at old age unless affected by neurodegeneration. <i>Communications Biology</i> , 2021, 4, 973.	2.0	8
1303	Psychotic Features Among Patients in the Prodromal Stage of Dementia with Lewy Bodies During Longitudinal Observation. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1917-1927.	1.2	14
1304	Diagnosi clinicolaboratoristica della malattia di Alzheimer. <i>EMC - Neurologia</i> , 2021, 21, 1-15.	0.0	0
1305	Outcome Measures for Dementia With Lewy Body Clinical Trials. <i>Alzheimer Disease and Associated Disorders</i> , 2021, Publish Ahead of Print, .	0.6	9
1306	AHA update. <i>Nursing</i> , 2021, 51, 24-30.	0.2	1
1307	Cognitive Decline in Parkinson's Disease: A Subgroup of Extreme Decliners Revealed by a Data-Driven Analysis of Longitudinal Progression. <i>Frontiers in Psychology</i> , 2021, 12, 729755.	1.1	4

#	ARTICLE	IF	CITATIONS
1308	Distinct brain dysfunctions underlying visuo-constructive deficit in DLB and AD. <i>Brain Imaging and Behavior</i> , 2021, , 1.	1.1	3
1309	Implication of Small Vessel Disease MRI Markers in Alzheimer's Disease and Lewy Body Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 545-556.	1.2	3
1310	Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy. <i>Movement Disorders</i> , 2022, 37, 52-61.	2.2	7
1311	Internal Jugular Vein Velocity and Spontaneous Echo Contrast Correlate with Alzheimer's Disease and Cognitive Function. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1-10.	1.2	2
1312	Structural and Functional Insights into $\alpha$ -Synuclein Fibril Polymorphism. <i>Biomolecules</i> , 2021, 11, 1419.	1.8	39
1313	Using Optical Coherence Tomography to Screen for Cognitive Impairment and Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 723-736.	1.2	9
1314	Measuring anxiety in Lewy Body Disease – which scale to choose?. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2021, 5, 100110.	0.5	0
1315	A multiparametric MRI study of structural brain damage in dementia with lewy bodies: A comparison with Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 154-161.	1.1	3
1316	Seizure prevalence in neurodegenerative diseases – a study of autopsy proven cases. <i>European Journal of Neurology</i> , 2022, 29, 12-18.	1.7	6
1317	Shift of musical hallucinations to visual hallucinations after correction of the hearing deficit in a patient with Lewy body dementia: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 449.	0.4	2
1319	Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 717930.	1.7	10
1320	Can Medial Temporal Impairment Be an Imaging Red Flag for Neurodegeneration in Disproportionately Enlarged Subarachnoid Space Hydrocephalus?. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1199-1209.	1.2	2
1321	Brain energy metabolism and neurodegeneration: hints from CSF lactate levels in dementias. <i>Neurobiology of Aging</i> , 2021, 105, 333-339.	1.5	14
1322	Ophthalmic manifestations of dementing disorders. <i>Current Opinion in Ophthalmology</i> , 2021, 32, 515-520.	1.3	5
1323	The Frontal Behavioral Battery: A Measure of Frontal Lobe Symptoms in Brain Aging and Neurodegenerative Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 721-739.	1.2	0
1324	Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 741-751.	1.2	2
1325	Changes of Metabolic Connectivity in Dementia with Lewy Bodies with Visual Hallucinations: A <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Study. <i>Brain Connectivity</i> , 2021, 11, 518-528.	0.8	5
1327	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , The, 2021, 20, 739-752.	4.9	220

#	ARTICLE	IF	CITATIONS
1328	Niemann-Pick Type C 1 (NPC1) and NPC2 Gene Variability in Demented Patients with Evidence of Brain Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1313-1323.	1.2	5
1329	Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 757-766.	1.2	1
1330	Comorbid alpha synucleinopathies in idiopathic normal pressure hydrocephalus. <i>Journal of Neurology</i> , 2022, 269, 2022-2029.	1.8	7
1331	Transferrin Biosynthesized in the Brain Is a Novel Biomarker for Alzheimer's Disease. <i>Metabolites</i> , 2021, 11, 616.	1.3	16
1332	Collusion of $\beta$ -Synuclein and $A\beta$ aggravating co-morbidities in a novel prion-type mouse model. <i>Molecular Neurodegeneration</i> , 2021, 16, 63.	4.4	12
1333	Operational Determination of Subjective Cognitive Decline, Mild Cognitive Impairment, and Dementia Using Sum of Boxes of the Clinical Dementia Rating Scale. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 705782.	1.7	9
1334	Alpha-synuclein pathology of olfactory bulbs/peduncles in the Vantaa85+ cohort exhibit two divergent patterns: a population-based study. <i>Acta Neuropathologica</i> , 2021, 142, 777-780.	3.9	8
1335	Preliminary Validation of the Learning Ratio for the HVLTR and BVMT-R in Older Adults. <i>Cognitive and Behavioral Neurology</i> , 2021, 34, 170-181.	0.5	10
1337	Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. <i>Acta Neuropathologica</i> , 2021, 142, 961-984.	3.9	31
1339	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	1.5	18
1340	Late-Onset Oligosymptomatic Myotonic Dystrophy Type 1 Mimicking Prodromal Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 982-983.	0.6	0
1341	Neuropsychological basis of impaired gesture imitations in patients with Alzheimer's disease and dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	4
1342	Tau and MAPT genetics in tauopathies and synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 142-154.	1.1	26
1343	Development of $\beta$ -Synuclein Real-Time Quaking-Induced Conversion as a Diagnostic Method for $\beta$ -Synucleinopathies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 703984.	1.7	12
1344	Role of Inflammation in Lewy Body Dementia. , 2021, , 190-212.		0
1345	Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimer's Disease. <i>Biomedicines</i> , 2021, 9, 1272.	1.4	8
1346	Alzheimer's patients detection using support vector machine (SVM) with quantitative analysis. <i>Neuroscience Informatics</i> , 2021, 1, 100012.	2.8	19
1347	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 367-382.	2.9	21



#	ARTICLE	IF	CITATIONS
1348	Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. <i>Clinical Neurophysiology</i> , 2021, 132, 2568-2607.	0.7	85
1349	Apolipoprotein E4, amyloid, and cognition in Alzheimer's and Lewy body disease. <i>Neurobiology of Aging</i> , 2021, 106, 45-54.	1.5	9
1350	Human amyloid beta and $\alpha$ -synuclein co-expression in neurons impair behavior and recapitulate features for Lewy body dementia in <i>Caenorhabditis elegans</i> . <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166203.	1.8	14
1351	Frontal lobe dysfunction is associated with reduced DAT-SPECT accumulation in Lewy body disease. <i>Journal of the Neurological Sciences</i> , 2021, 430, 119998.	0.3	3
1352	Neuropsychiatric Manifestations Across Neurological Conditions. , 2022, , 167-175.		0
1353	Neurodegenerative Motor Conditions. , 2022, , 106-114.		0
1354	Validation of a New Screening Tool for Dementia: The Simple Observation Checklist for Activities of		

#	ARTICLE	IF	CITATIONS
1366	Quantification of the Trans-Synaptic Partners Neuroligin-Neurexin in CSF of Neurodegenerative Diseases by Parallel Reaction Monitoring Mass Spectrometry. SSRN Electronic Journal, 0, , .	0.4	0
1368	Identification of Heterogeneous Subtypes of Mild Cognitive Impairment Using Cluster Analyses Based on PET Imaging of Tau and Astrogliosis. Frontiers in Aging Neuroscience, 2020, 12, 615467.	1.7	10
1369	The prevalence and co-incidence of geriatric syndromes in older patients with early-stage Alzheimer's disease and dementia with Lewy bodies. Aging Clinical and Experimental Research, 2021, 33, 2599-2603.	1.4	22
1370	Dopamine transporter imaging predicts clinically-defined $\alpha$ -synucleinopathy in REM sleep behavior disorder. Annals of Clinical and Translational Neurology, 2021, 8, 201-212.	1.7	37
1371	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. Movement Disorders, 2020, 35, 859-867.	2.2	33
1372	Genetic Variations and Neuropathologic Features of Patients with $\alpha$ -PRKN Mutations. Movement Disorders, 2021, 36, 1634-1643.	2.2	7
1374	Falls in Parkinson's Disease and Lewy Body Dementia. , 2020, , 191-210.		1
1375	Epidemiology and Falls Risk Factors in Cognitively Impaired Older Adults. , 2020, , 35-48.		1
1376	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
1377	Neuropsychological Aspects: Cognition in RBD. , 2019, , 491-507.		2
1378	Relationship Between Tau, $A\beta$ Amyloid and $\alpha$ -Synuclein Pathologies. Advances in Experimental Medicine and Biology, 2019, 1184, 169-176.	0.8	7
1379	ACR Appropriateness Criteria® Dementia. Journal of the American College of Radiology, 2020, 17, S100-S112.	0.9	11
1380	Overview of sleep disturbances and their management in Parkinson plus disorders. Journal of the Neurological Sciences, 2020, 415, 116891.	0.3	5
1381	Genetic architecture of common non-Alzheimer's disease dementias. Neurobiology of Disease, 2020, 142, 104946.	2.1	27
1382	Local cortical overexpression of human wild-type alpha-synuclein leads to increased dendritic spine density in mouse. Neuroscience Letters, 2020, 733, 135051.	1.0	6
1383	Anterior EEG slowing in dementia with Lewy bodies: a multicenter European cohort study. Neurobiology of Aging, 2020, 93, 55-60.	1.5	14
1384	Topography of cortical thinning in the Lewy body diseases. NeuroImage: Clinical, 2020, 26, 102196.	1.4	15
1385	Utility of quantitative EEG in early Lewy body disease. Parkinsonism and Related Disorders, 2020, 75, 70-75.	1.1	27

#	ARTICLE	IF	CITATIONS
1386	Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 55-62.	1.1	28
1387	Sex-related differences in the relationship between $\beta^2$ -amyloid and cognitive trajectories in older adults.. <i>Neuropsychology</i> , 2020, 34, 835-850.	1.0	9
1388	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. <i>Nature Communications</i> , 2020, 11, 619.	5.8	67
1389	Cortical connectivity of the nucleus basalis of Meynert in Parkinson's disease and Lewy body dementias. <i>Brain</i> , 2021, 144, 781-788.	3.7	24
1390	Astroglial tau pathology alone preferentially concentrates at sulcal depths in chronic traumatic encephalopathy neuropathologic change. <i>Brain Communications</i> , 2020, 2, fcaa210.	1.5	19
1391	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 296-304.	0.9	35
1392	West Nile Virus Neuroinvasive Disease Accelerating Probable Dementia With Lewy Bodies. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 269-270.	0.6	2
1393	Biomarker Use for Dementia With Lewy Body Diagnosis. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 55-61.	0.6	8
1398	Active case finding of dementia in ambulatory care settings: a comparison of three strategies. <i>European Journal of Neurology</i> , 2020, 27, 1867-1878.	1.7	5
1399	A direct comparison of the 2005 and 2017 criteria for dementia with Lewy bodies. <i>Psychogeriatrics</i> , 2020, 20, 785-786.	0.6	1
1400	Successful management of persistent distressing neuropsychiatric symptoms by clozapine in a patient suffering from dementia with Lewy bodies. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224710.	0.2	3
1402	Impact of the cerebrospinal fluid-mask algorithm on the diagnostic performance of 123I-Ioflupane SPECT: an investigation of parkinsonian syndromes. <i>EJNMMI Research</i> , 2019, 9, 85.	1.1	3
1403	123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies. <i>European Radiology Experimental</i> , 2020, 4, 27.	1.7	2
1404	11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 25.	0.6	18
1405	Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. <i>British Journal of Psychiatry</i> , 2021, 218, 276-282.	1.7	18
1406	Lewy Body Dementias. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 128-146.	0.4	16
1407	Synucleinopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 72-92.	0.4	13
1408	Cohort Study in Parkinsonism. <i>Neurology: Clinical Practice</i> , 2021, 11, e407-e413.	0.8	9

#	ARTICLE	IF	CITATIONS
1409	Nucleus basalis of meynert stimulation for lewy body dementia: A phase I randomized clinical trial. <i>Neurology</i> , 2021, 96, 10.1212/WNL.00000000000011227.	1.5	22
1410	Cognitive Profile and Markers of Alzheimer Diseaseâ€“Type Pathology in Patients With Lewy Body Dementias. <i>Neurology</i> , 2021, 96, e1855-e1864.	1.5	28
1411	Using a patient-reported outcome to improve detection of cognitive impairment and dementia: The patient version of the Quick Dementia Rating System (QDRS). <i>PLoS ONE</i> , 2020, 15, e0240422.	1.1	13
1412	The Quick Physical Activity Rating (QPAR) scale: A brief assessment of physical activity in older adults with and without cognitive impairment. <i>PLoS ONE</i> , 2020, 15, e0241641.	1.1	17
1413	The Number Symbol Coding Task: A brief measure of executive function to detect dementia and cognitive impairment. <i>PLoS ONE</i> , 2020, 15, e0242233.	1.1	28
1414	Olfaction and Colour Vision: What Can They Tell Us about Parkinsonâ€™s Disease?. <i>Prague Medical Report</i> , 2018, 119, 85-96.	0.4	9
1415	Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions. <i>Journal of Movement Disorders</i> , 2020, 13, 1-10.	0.7	48
1416	The continuum between neurodegeneration, brain plasticity, and movement: a critical appraisal. <i>Reviews in the Neurosciences</i> , 2020, 31, 723-742.	1.4	30
1418	The Differential Diagnosis of Parkinsonâ€™s Disease. , 0, , 109-128.		20
1419	Ekbom Syndrome associated with Lewy Body Dementia: A case report. <i>Dementia E Neuropsychologia</i> , 2020, 14, 83-87.	0.3	5
1421	Present Status of Medical Radiation and Nuclear Cardiology Usage in Japan. <i>Annals of Nuclear Cardiology</i> , 2018, 4, 142-148.	0.0	4
1422	How Do We Establish Cardiac Sympathetic Nervous System Imaging with $^{123}\text{I}$ -MIBG in Clinical Practice? Perspectives and Lessons from Japan and the US. <i>Annals of Nuclear Cardiology</i> , 2019, 5, 5-20.	0.0	5
1423	The CSF p-tau181/ $\text{A}\beta_{42}$ Ratio Offers a Good Accuracy â€œIn Vivoâ€œ in the Differential Diagnosis of Alzheimerâ€™s Dementia. <i>Current Alzheimer Research</i> , 2019, 16, 587-595.	0.7	17
1424	Genetic Variants and Oxidative Stress in Alzheimerâ€™s Disease. <i>Current Alzheimer Research</i> , 2020, 17, 208-223.	0.7	23
1425	Protective Effects of Polydatin Against Dementia-Related Disorders. <i>Current Neuropharmacology</i> , 2020, 19, 127-135.	1.4	11
1426	Intrinsic Alertness Is Impaired in Patients with Nigrostriatal Degeneration: A Prospective Study with Reference to $^{123}\text{I}$ FP-CIT SPECT and $^{18}\text{F}$ FDG PET. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1721-1729.	1.2	2
1427	Gray Matter Atrophy Associated with Extrapyramidal Signs in the Lewy Body Variant of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 1043-1049.	1.2	2
1428	Alzheimer's Disease-Related Lesions. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S173-S179.	1.2	4

#	ARTICLE	IF	CITATIONS
1429	Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes. Deutsches A&#x0308;rzteblatt International, 2019, 116, 747-754.	0.6	27
1430	Coping with Dementia in the Middle of the COVID-19 Pandemic. Journal of Korean Medical Science, 2020, 35, e383.	1.1	40
1431	Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. Cells, 2021, 10, 38.	1.8	16
1432	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. Cells, 2020, 9, 1252.	1.8	8
1433	Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in		

#	ARTICLE	IF	CITATIONS
1448	PCA-LBD in Gaucher disease type 1: a case description. <i>Neurological Sciences</i> , 2022, 43, 715-718.	0.9	0
1449	Convolutional neural network-based automatic heart segmentation and quantitation in 123I-metaiodobenzylguanidine SPECT imaging. <i>EJNMMI Research</i> , 2021, 11, 105.	1.1	4
1450	Sleep Disturbances and Phenoconversion in Patients with REM Sleep Behavior Disorder. <i>Journal of Clinical Medicine</i> , 2021, 10, 4709.	1.0	2
1451	CD4 <sup>+</sup> T cells contribute to neurodegeneration in Lewy body dementia. <i>Science</i> , 2021, 374, 868-874.	6.0	92
1452	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. <i>Pharmacological Reviews</i> , 2021, 73, 1204-1268.	7.1	11
1453	Dementia subtype prediction models constructed by penalized regression methods for multiclass classification using serum microRNA expression data. <i>Scientific Reports</i> , 2021, 11, 20947.	1.6	5
1454	Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 163.	3.0	12
1455	Evolving Causes of Rapidly Progressive Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 315-320.	0.6	4
1456	Neurofilament light chain and $\alpha$ -synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. <i>Npj Parkinson's Disease</i> , 2021, 7, 93.	2.5	45
1457	Parkinsonism and dementia. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120015.	0.3	8
1459	Olfactory impairment in mild cognitive impairment with Lewy bodies and Alzheimer's disease. <i>International Psychogeriatrics</i> , 2022, 34, 585-592.	0.6	10
1460	Lewy pathology of the submandibular gland in Lewy body disease: A report of autopsy cases. <i>Neuropathology</i> , 2021, 41, 476-483.	0.7	6
1461	Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1263-1274.	3.3	12
1462	Functional neurological disorder and somatic symptom disorder in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120017.	0.3	10
1463	How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 53-58.	1.1	6
1465	Critères diagnostiques. , 2011, , 111-117.		0
1466	Démences Confusion mentale aiguë. , 2012, , 450-472.		0
1468	Dementia and Social Neuroscience: Historical and Cultural Perspectives. , 2017, , 243-253.		0

#	ARTICLE	IF	CITATIONS
1469	Navigating Uncharted Waters: A Nursing Perspective on Lewy Body Dementia. Australasian Journal of Neuroscience, 2018, 28, 5-12.	0.2	0
1470	National Clinical Guidelines. , 2017, , .		2
1471	Pareidolias in idiopathic RBDâ€”an author response letter to the Editorial â€œWhat the â€”man in the moonâ€™ can tell us about the future of our brainsâ€• Annals of Translational Medicine, 2017, 5, 438-438.	0.7	0
1474	Alzheimer's Disease âˆ†. , 2018, , .		0
1475	Research Progress of Radionuclide Imaging in Rapid-Eye Movement Sleep Behavior Disorder (RBD). International Journal of Psychiatry and Neurology, 2018, 07, 53-59.	0.1	0
1476	Investigation. , 2018, , 207-240.		0
1478	èªŸŸç—†ç—¾æ,£è”ç™,ã,-ã,ãf%ãf ©ã,ãf³2017. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 544-549.		0
1479	Sindrome confusionale. EMC - Neurologia, 2018, 18, 1-11.	0.0	0
1480	Classification and Diagnosis of Dementia. The Japanese Journal of Rehabilitation Medicine, 2018, 55, 637-642.	0.0	0
1481	Imagerie molÃ©culaire de demain : quels biomarqueurs et pour quelle maladie ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1523-1527.	0.0	0
1483	Diagnostic Dilemmas. , 2019, , 473-532.		0
1484	Dementia with Lewy bodies. V M Bekhterev Review of Psychiatry and Medical Psychology, 2018, , 11-21.	0.1	4
1487	Organische (und symptomatische) psychische StÃ¶rungen. , 2019, , 187-246.e3.		1
1489	Analysis for Alzheimer's Disease and Dementia with Lewy Bodies Using Average Frequency and Cross-correlation of EEG Data. Transactions of the Society of Instrument and Control Engineers, 2019, 55, 536-544.	0.1	0
1490	Dementia with Lewy Bodies. , 2019, , 239-254.		0
1491	Methods (1): Participants and Test Methods. , 2019, , 21-49.		0
1492	Neurodegenerative Diseases: Lewy Body Dementia. , 2019, , 933-944.		0
1494	Results (2): Estimates of Diagnostic Accuracy. , 2019, , 109-148.		0

#	ARTICLE	IF	CITATIONS
1497	Tiapríde for the Treatment of REM Sleep Behaviour Disorder in Dementia with Lewy Bodies: A Case Series. <i>The Open Neurology Journal</i> , 2019, 13, 63-66.	0.4	0
1499	SÃntomas mnÃ©sicos. <i>EMC - Tratado De Medicina</i> , 2019, 23, 1-4.	0.0	0
1504	Neurodegenerative Diseases and Changes in Artistic Expression. , 2020, , 27-39.		1
1505	Apport de la clinique du psychotraumatisme dans le soin du patient Ã© confus. <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2019, 19, 308-314.	0.1	0
1506	Demenz: Was ist das, welche Formen gibt es, wie wird sie entdeckt und behandelt?. , 2020, , 5-18.		0
1510	On the misalignment between research and clinical practice in psychology: An example from the Alzheimerâ€™s and dementia field.. <i>Canadian Psychology</i> , 2020, 61, 127-139.	1.4	0
1511	Neurological conditions in charaka indriya sthana - an explorative study. <i>International Journal of Complementary &amp; Alternative Medicine</i> , 2020, 13, 107-119.	0.1	4
1516	for Cognitive Impairment and Dementia in Parkinsonâ€™s. <i>NeuroMethods</i> , 2021, , 193-225.	0.2	0
1517	Clinical Reasoning: A 65-Year-Old Man Presented with Parkinsonism and Motor Fluctuation. <i>Journal of the Korean Neurological Association</i> , 2020, 38, 243-251.	0.0	0
1518	Cardiac and Blood Pressure Safety of Transdermal Rivastigmine in Elderly Patients With Dementia With Lewy Bodies. <i>Alzheimer Disease and Associated Disorders</i> , 2020, 34, 339-343.	0.6	7
1520	Validation of the Korean Quick Dementia Rating System (K-QDRS). <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1645-1656.	1.2	2
1522	Association between CSF alpha-synuclein seeding activity and genetic status in Parkinsonâ€™s disease and dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 175.	2.4	49
1523	Impact of Behavioral and Psychological Symptoms on Caregiver Burden in Patients With Dementia With Lewy Bodies. <i>Frontiers in Psychiatry</i> , 2021, 12, 753864.	1.3	9
1524	Diffusion MRI: Applications in the Brain. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2020, 1, 605-636.	0.0	0
1525	Psychopharmacologic treatment. , 2020, , 315-399.		1
1526	SPECT and PET of the Brain. , 2020, , 211-231.		0
1528	Differential Changes in Arteriolar Cerebral Blood Volume between Parkinsonâ€™s Disease Patients with Normal and Impaired Cognition and Mild Cognitive Impairment (MCI) Patients without Movement Disorderâ€™ An Exploratory Study. <i>Tomography</i> , 2020, 6, 333-342.	0.8	7
1529	Dementia with Lewy Bodies with Pure Agraphia for Kanji (Japanese Morphograms). <i>Internal Medicine</i> , 2020, 59, 3217-3224.	0.3	0



#	ARTICLE	IF	CITATIONS
1530	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0
1531	Comorbidities and Geriatric Syndromes Related to Orthostatic Hypotension. , 2021, , 61-72.		0
1532	Neuroimaging Findings in Patients with Hallucinations: Evidence from Neurodegenerative and Psychiatric Conditions. , 2021, , 555-587.		1
1533	Orthostatic Hypotension in Neurodegenerative Diseases. , 2021, , 73-87.		0
1534	REM sleep behavior in Parkinson disease: Frequent, particularly with higher age. PLoS ONE, 2020, 15, e0243454.	1.1	14
1535	Differentiating Dementia with Lewy Bodies from Alzheimer's Disease Using the Fall Risk Evaluation Questionnaire. Internal Medicine, 2022, 61, 1687-1692.	0.3	4
1536	Phenomenology of Atypical Parkinsonism. , 2020, , 37-61.		0
1537	Clinical Assessment and Intervention With Persons Living With Dementia. , 2020, , .		0
1538	Concurrent Validity of the ABC Dementia Scale with Other Standard Scales: A New Comprehensive Instrument for Assessing Dementia in Japan. Dementia and Geriatric Cognitive Disorders, 2020, 49, 617-627.	0.7	0
1539	Neuropsychological Assessment in Later Life. , 2020, , .		0
1540	Concurrent Delusions of Ocular Parasitosis and Complex Visual Hallucinations from Charles Bonnet Syndrome Treated Successfully with Aripiprazole in an Elderly Male: A Case Report. , 2021, 25, 1-3.		3
1541	Utility of ALBA screening instrument. , 2020, , 411-427.		1
1542	Delusions in dementias. , 2020, , 647-664.		0
1543	Evidence-Based PET for Neurological Diseases. , 2020, , 125-136.		0
1544	Störungen der Basalganglienfunktion. , 2020, , 179-203.		0
1545	Alzheimer's disease and other dementias. , 2020, , C24.4.2-C24.4.2.P126.		1
1546	Treating Medical Comorbidities Associated with Dementia Among Latinos. , 2020, , 69-89.		0
1547	Alzheimer's disease and other neurocognitive disorders. , 2020, , 161-183.		0

#	ARTICLE	IF	CITATIONS
1549	Linking motor speech function and dementia. , 2020, , 665-676.		0
1550	CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12098.	1.8	5
1551	Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. Alzheimer Disease and Associated Disorders, 2020, 34, 357-359.	0.6	3
1552	Dementia and Memory Disorders in Abuse in the Elderly. , 2020, , 55-83.		0
1553	Synuclein in neurodegeneration. Advances in Clinical Chemistry, 2021, 103, 97-134.	1.8	10
1554	The Relationship between the Most Common Subtypes of Dementia and Orthostatic Hypotension in Older Adults. Dementia and Geriatric Cognitive Disorders, 2020, 49, 628-635.	0.7	8
1555	Dementia and bladder dysfunction: a focus on treatments with anticholinergics. , 2020, , 233-250.		0
1556	The Enigma of Lewy Body Dementia: a Case Report. Acta Clinica Croatica, 2020, 59, 771-776.	0.1	1
1558	Pharmacotherapy of non-Alzheimer's types of dementia. Neurologie Pro Praxi, 2020, 21, 41-45.	0.0	2
1559	La copia de pentÁgonos en el diagnÃ³stico de la demencia con cuerpos de Lewy prodrÃ³mica. Neurologia Argentina, 2020, 12, 85-89.	0.1	0
1560	Sloping Shoulders Sign: A Practical Radiological Sign for the Differentiation of Alzheimerâ€™s Disease and Argyrophilic Grain Disease. Journal of Alzheimer's Disease, 2021, 84, 1719-1727.	1.2	3
1561	The Resilience Index: A Quantifiable Measure of Brain Health and Risk of Cognitive Impairment and Dementia. Journal of Alzheimer's Disease, 2021, 84, 1729-1746.	1.2	11
1562	The Association Between Hyperhidrosis and Dementia: A Community-Based Research. Journal of Alzheimer's Disease, 2021, , 1-11.	1.2	0
1563	Ultrabrief Right Unilateral Electroconvulsive Therapy for the Treatment of the Neuropsychiatric Symptoms of Dementia with Lewy Bodies. Journal of ECT, 2022, 38, 39-44.	0.3	7
1564	Neuropathology of Alzheimer's Disease. Neurotherapeutics, 2022, 19, 173-185.	2.1	83
1565	Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiology of Disease, 2021, 161, 105557.	2.1	72
1566	The Elder Autopsy. , 2020, , 51-71.		1
1568	Chinese patients with Lewy body dementia had shorter survival and developed complications earlier than those with Alzheimerâ€™s disease. Singapore Medical Journal, 2020, 61, 551-558.	0.3	2

#	ARTICLE	IF	CITATIONS
1570	Neuroimaging Findings in Mild Cognitive Impairment. , 2021, , 367-425.		1
1572	SPECT/PET Findings in Dementia with Lewy Bodies. , 2021, , 515-561.		0
1575	Shape Profile of Corpus Callosum As a Signature to Phenotype Different Dementia. Journal of Neurosciences in Rural Practice, 2021, 12, 185-192.	0.3	3
1576	Alzheimer disease biomarker profiles in dementia with Lewy bodies. Neurology, 2020, 95, 1076-1077.	1.5	0
1577	Antidementia. , 2021, , 581-626.		1
1578	Evidence that the Kennedy and polyamine pathways are dysregulated in human brain in cases of dementia with Lewy bodies. Brain Research, 2020, 1743, 146897.	1.1	5
1579	A Model to Assess the Outcomes Associated With Dementia With Lewy Bodies. Alzheimer Disease and Associated Disorders, 2021, 35, 68-74.	0.6	2
1580	Dementia with Lewy bodies and Parkinsonâ€™s disease dementia-two independent disorders or one clinical entity within a clinical spectrum of synucleinopathies?. Current Problems of Psychiatry, 2020, 21, 161-166.	0.1	0
1581	Computational electroencephalography analysis for characterizing brain networks. Annals of Clinical Neurophysiology, 2020, 22, 82-91.	0.1	0
1582	Early perfusion and dopamine transporter imaging using F-FP-CIT PET/CT in patients with parkinsonism. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 360-372.	1.0	15
1584	Advances in dementia with Lewy bodies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110576.	1.5	14
1585	Generating diagnostic profiles of cognitive decline and dementia using magnetoencephalography. Neurobiology of Aging, 2022, 111, 82-94.	1.5	5
1586	Neurology Evaluation in Dementia and Neurodegenerative Disease. , 2022, , 227-245.		0
1587	A metabolite panel that differentiates Alzheimer's disease from other dementia types. Alzheimer's and Dementia, 2022, 18, 1345-1356.	0.4	20
1588	A Neurologist's Practical Approach to Cognitive Impairment. Seminars in Neurology, 2021, 41, 686-698.	0.5	0
1589	Autophagy in Î±-Synucleinopathiesâ€”An Overstrained System. Cells, 2021, 10, 3143.	1.8	12
1590	Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients. Neuropathology, 2021, 41, 450-456.	0.7	1
1591	Prediction of P-tau/AÎ²42 in the cerebrospinal fluid with blood microRNAs in Alzheimerâ€™s disease. BMC Medicine, 2021, 19, 264.	2.3	12

#	ARTICLE	IF	CITATIONS
1592	Alpha-Synuclein and Cognitive Decline in Parkinson Disease. <i>Life</i> , 2021, 11, 1239.	1.1	18
1593	Association of Neurofibrillary Tangle Distribution With Age at Onsetâ€‘Related Clinical Heterogeneity in Alzheimer Disease. <i>Neurology</i> , 2022, 98, .	1.5	9
1594	The role of noncoding RNAs in Parkinsonâ€™s disease: biomarkers and associations with pathogenic pathways. <i>Journal of Biomedical Science</i> , 2021, 28, 78.	2.6	45
1596	Autonomic symptoms are predictive of dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2022, 95, 1-4.	1.1	6
1597	Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. <i>Npj Parkinson's Disease</i> , 2021, 7, 107.	2.5	11
1598	The Feasibility of Differentiating Lewy Body Dementia and Alzheimerâ€™s Disease by Deep Learning Using ECD SPECT Images. <i>Diagnostics</i> , 2021, 11, 2091.	1.3	8
1599	Identification of a Qualitative Signature for the Diagnosis of Dementia With Lewy Bodies. <i>Frontiers in Genetics</i> , 2021, 12, 758103.	1.1	1
1600	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32.	4.5	38
1601	The temporal onset of the core features in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2022, 18, 591-601.	0.4	19
1602	Brain diseases and aspiration pneumonia in older person. <i>Neurology and Clinical Neuroscience</i> , 0, , .	0.2	1
1603	It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimerâ€™s and Lewy Body Disease Spectra. <i>Frontiers in Systems Neuroscience</i> , 2021, 15, 777706.	1.2	8
1604	Muscarinic Receptors Expression in the Peripheral Blood Cells Differentiate Dementia with Lewy Bodies from Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 323-330.	1.2	4
1605	Association of Superficial White Matter Alterations with Cerebrospinal Fluid Biomarkers and Cognitive Decline in Neurodegenerative Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 431-442.	1.2	2
1606	Orexin-A in Patients With Lewy Body Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021, 12, 765701.	1.5	2
1607	Minor hallucinations in isolated rapid eye movement sleep behavior disorder indicative of early phenoconversion: A preliminary study. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 348-359.	1.0	5
1608	Dementia in Southeast Asia: influence of onset-type, education, and cerebrovascular disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 195.	3.0	4
1609	Clinicopathological heterogeneity of Alzheimer's disease with pure Alzheimer's disease pathology: Cases associated with dementia with Lewy bodies, very earlyâ€‘onset dementia, and primary progressive aphasia. <i>Neuropathology</i> , 2021, , .	0.7	7
1610	Î±-Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox. <i>Cell and Bioscience</i> , 2021, 11, 196.	2.1	8

#	ARTICLE	IF	CITATIONS
1611	The role of cardiovascular autonomic failure in the differential diagnosis of $\alpha$ -synucleinopathies. <i>Neurological Sciences</i> , 2022, 43, 187-198.	0.9	5
1612	Evaluation of Bedside Tests of Attention and Arousal Assessing Delirium in Parkinson's Disease, Dementia, and Older Adults. <i>Journal of Parkinson's Disease</i> , 2022, 12, 655-665.	1.5	0
1613	Can Corticomuscular Coherence Differentiate between REM Sleep Behavior Disorder with or without Parkinsonism?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5585.	1.0	3
1614	Imaging Markers of Subcortical Vascular Dementia in Patients With Multiple-Lobar Cerebral Microbleeds. <i>Frontiers in Neurology</i> , 2021, 12, 747536.	1.1	2
1615	Very Early-Onset Alzheimer's Disease in the Third Decade of Life with de novo PSEN1 Mutations. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 65-71.	1.2	3
1616	Alzheimer's disease and sleep disorders: Insights into the possible disease connections and the potential therapeutic targets. <i>Asian Journal of Psychiatry</i> , 2022, 68, 102961.	0.9	10
1617	Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial. <i>Movement Disorders</i> , 2022, 37, 513-524.	2.2	21
1618	Lewy Body Dementias: Controversies and Drug Development. <i>Neurotherapeutics</i> , 2022, 19, 55-67.	2.1	5
1619	Frequency of dementia in Parkinson's disease: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120077.	0.3	19
1620	An older man with visual hallucinations, tremor, and gait dysfunction. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2021, 34, 62-64.	0.1	0
1622	Understanding Alzheimer's disease as a disorder of consciousness. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12203.	1.8	13
1623	Central Nervous System Imaging in Movement Disorders. , 2021, , .		0
1624	Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. <i>Zhurnal Nevrologii I Psikhiiatrii Imeni S S Korsakova</i> , 2021, 121, 6.	0.1	31
1626	Risk Factors for Phenoconversion in <scp>Rapid Eye Movement</scp> Sleep Behavior Disorder. <i>Annals of Neurology</i> , 2022, 91, 404-416.	2.8	27
1627	Increased expression of pathological markers in Parkinson's disease dementia post-mortem brains compared to dementia with Lewy bodies. <i>BMC Neuroscience</i> , 2022, 23, 3.	0.8	7
1628	Reorganization of rich clubs in functional brain networks of dementia with Lewy bodies and Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2022, 33, 102930.	1.4	3
1629	Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120088.	0.3	1
1630	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. <i>EBioMedicine</i> , 2022, 75, 103793.	2.7	4

#	ARTICLE	IF	CITATIONS
1631	GBA mutations, glucosylceramide and Parkinson's disease. <i>Current Opinion in Neurobiology</i> , 2022, 72, 148-154.	2.0	23
1632	Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials. <i>ENeurologicalSci</i> , 2022, 26, 100384.	0.5	0
1633	Depression and Dementia in Older Adults: A Neuropsychological Review. , 2021, 12, 1920.		20
1634	Neurogenic cardiovascular disorders in $\alpha$ -synucleinopathies: diagnostic and therapy issues. <i>Arterial Hypertension (Russian Federation)</i> , 2022, 27, 509-521.	0.1	0
1635	Use of transcranial sonography for the diagnosis of patients with Parkinson's disease and Lewy body dementia. <i>Neurologie Pro Praxi</i> , 2021, 22, 376-385.	0.0	0
1636	Quantifying test-retest reliability of repeated objective attentional measures in Lewy body dementia. <i>Journal of Neurology</i> , 2022, 269, 3605-3613.	1.8	1
1637	Neurophysiological Correlates of Motor and Cognitive Dysfunction in Prodromal and Overt Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 579-588.	1.2	5
1638	Correlation between noise pareidolia test scores for visual hallucinations and regional cerebral blood flow in dementia with Lewy bodies. <i>Annals of Nuclear Medicine</i> , 2022, 36, 384-392.	1.2	5
1639	60 Years of Achievements by KSNM in Neuroimaging Research. <i>Nuclear Medicine and Molecular Imaging</i> , 2022, 56, 3-16.	0.6	0
1640	Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?. <i>Frontiers in Psychiatry</i> , 2021, 12, 808724.	1.3	4
1641	The influence of cerebrovascular disease in dementia with Lewy bodies and Parkinson's disease dementia. <i>European Journal of Neurology</i> , 2022, 29, 1254-1265.	1.7	9
1643	Evolution of Prodromal Multiple System Atrophy from REM Sleep Behavior Disorder: A Descriptive Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 983-991.	1.5	3
1644	Brain TDP $\alpha$ 3 pathology in corticobasal degeneration: Topographical correlation with neuronal loss. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	8
1645	A Comparison of Caregiver Burden for Different Types of Dementia: An 18-Month Retrospective Cohort Study. <i>Frontiers in Psychology</i> , 2021, 12, 798315.	1.1	7
1646	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers. <i>Brain</i> , 2022, 145, 4056-4064.	3.7	19
1647	Serum progranulin is not associated with rs5848 polymorphism in Korean patients with neurodegenerative diseases. <i>PLoS ONE</i> , 2022, 17, e0261007.	1.1	0
1648	The Outcome of Patients with Amyloid-Negative Amnestic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 629-640.	1.2	2
1649	Event-related oscillations differentiate between cognitive, motor and visual impairments. <i>Journal of Neurology</i> , 2022, 269, 3529-3540.	1.8	7

#	ARTICLE	IF	CITATIONS
1650	Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology. <i>Journal of Neurology</i> , 2022, 269, 3636-3652.	1.8	8
1651	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. <i>Neurology</i> , 2022, 98, .	1.5	10
1652	Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool. <i>Journal of Neurochemistry</i> , 2023, 164, 346-363.	2.1	10
1653	Characteristics of Cortical Atrophy and White Matter Lesions Between Dementia With Lewy Bodies and Alzheimer's Disease: A Case-Control Study. <i>Frontiers in Neurology</i> , 2021, 12, 779344.	1.1	6
1654	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	1.1	12
1655	Brain Perfusion Single-Photon Emission Computed Tomography Using an Easy Z-Score Imaging System Predicts Progression to Neurodegenerative Dementia in Rapid Eye Movement Sleep Behavior Disorder. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 577-584.	0.7	1
1656	Diffuse Lewy body disease presenting as Parkinson's disease with progressive aphasia. <i>Neuropathology</i> , 2022, 42, 82-89.	0.7	4
1657	Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 651-658.	0.9	64
1658	Resilience in People with Lewy Body Disorders and Their Care Partners: Association with Mental Health, Relationship Satisfaction, and Care Burden. <i>Brain Sciences</i> , 2022, 12, 148.	1.1	5
1659	Lewy body disease or diseases with Lewy bodies?. <i>Npj Parkinson's Disease</i> , 2022, 8, 3.	2.5	26
1660	Cardiovascular Risk Factors and Phenoconversion to Neurodegenerative Synucleinopathies in Idiopathic REM Sleep Behavior Disorder. <i>Journal of Parkinson's Disease</i> , 2022, , 1-7.	1.5	1
1661	Therapeutics in the Pipeline Targeting $\alpha$ -Synuclein for Parkinson's Disease. <i>Pharmacological Reviews</i> , 2022, 74, 207-237.	7.1	39
1662	Mass Synaptometry: Applying Mass Cytometry to Single Synapse Analysis. <i>Methods in Molecular Biology</i> , 2022, 2417, 69-88.	0.4	4
1663	Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 9.	3.0	2
1664	NDUFA1 p.Gly32Arg variant in early-onset dementia. <i>Neurobiology of Aging</i> , 2022, 114, 113-116.	1.5	6
1665	Role of Apolipoprotein E in the Clinical Profile of Atypical Parkinsonian Syndromes. <i>Alzheimer Disease and Associated Disorders</i> , 2022, 36, 36-43.	0.6	3
1666	Predictors of Life Expectancy in Autopsy-Confirmed Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 271-281.	1.2	4
1667	Exosomal MicroRNA-Based Predictive Model for Preclinical Alzheimer's Disease: A Multicenter Study. <i>Biological Psychiatry</i> , 2022, 92, 44-53.	0.7	11

#	ARTICLE	IF	CITATIONS
1668	Impaired Sphingolipid Hydrolase Activities in Dementia with Lewy Bodies and Multiple System Atrophy. <i>Molecular Neurobiology</i> , 2022, 59, 2277-2287.	1.9	7
1669	Signature laminar distributions of pathology in frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2022, 143, 363-382.	3.9	12
1670	Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 2-15.	0.9	26
1671	Microstructural changes in prodromal dementia with Lewy bodies compared to normal ageing: Multiparametric quantitative MRI evidences. <i>European Journal of Neuroscience</i> , 2022, 55, 611-623.	1.2	1
1672	Infectious Agents as Potential Drivers of $\alpha$ -Synucleinopathies. <i>Movement Disorders</i> , 2022, 37, 464-477.	2.2	7
1673	ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 826213.	1.7	7
1674	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 14.	3.0	10
1675	The vascular risk factors and vascular neuropathology in subjects with autopsy-confirmed dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	4
1676	Systematic review of pharmacological interventions for people with Lewy body dementia. <i>Aging and Mental Health</i> , 2022, , 1-14.	1.5	10
1677	Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer's Disease Spectrum: Who Really Deserves an A+?. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1009-1020.	1.2	5
1678	An autopsy case of Alzheimer's disease with amygdala-predominant Lewy pathology presenting with frontotemporal dementia-like psychiatric symptoms. <i>Neuropathology</i> , 2022, , .	0.7	0
1679	The $A\beta_{1-42}/A\beta_{1-40}$ ratio in CSF is more strongly associated to tau markers and clinical progression than $A\beta_{1-42}$ alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	3.0	18
1680	Cognitive, Psychiatric, and Motor Symptoms-Based Algorithmic Approach to Differentiate Among Various Types of Dementia Syndromes. <i>Journal of Nervous and Mental Disease</i> , 2022, 210, 129-135.	0.5	2
1681	Striatal dopamine transporter degeneration in right-handed REM sleep behavior disorder patients progresses faster in the left hemisphere. <i>Parkinsonism and Related Disorders</i> , 2022, 95, 107-112.	1.1	3
1682	Narrow doorways alter brain connectivity and step patterns in isolated REM sleep behaviour disorder. <i>NeuroImage: Clinical</i> , 2022, 33, 102958.	1.4	3
1683	Caring for patients with cognitive dysfunction, fluctuations and dementia caused by Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 407-434.	0.9	5
1684	Validation of the National Alzheimer's Coordinating Center (NACC) Lewy Body Disease Module neuropsychological tests. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12279.	1.2	3
1685	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2022, 34, 102954.	1.4	3



#	ARTICLE	IF	CITATIONS
1686	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fca013.	1.5	15
1687	Consequences of variability in $\alpha$ -synuclein fibril structure on strain biology. <i>Acta Neuropathologica</i> , 2022, 143, 311-330.	3.9	15
1688	Plasma Cholesterol Levels as Potential Nutritional Biomarkers for Lewy Body Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 779-786.	1.2	2
1689	Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder. <i>Movement Disorders</i> , 2022, , .	2.2	1
1690	Neuropathological lesions and their contribution to dementia and cognitive impairment in a heterogeneous clinical population. <i>Alzheimer's and Dementia</i> , 2022, 18, 2403-2412.	0.4	4
1691	Blood mRNA Expression in Alzheimer's Disease and Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 964-975.	0.6	9
1692	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. <i>Movement Disorders</i> , 2022, 37, 669-683.	2.2	30
1693	<i>GIPC1</i> CCG Repeat Expansion Is Associated with Movement Disorders. <i>Annals of Neurology</i> , 2022, 91, 704-715.	2.8	18
1694	Fluid markers of synapse degeneration in synucleinopathies. <i>Journal of Neural Transmission</i> , 2022, 129, 187-206.	1.4	4
1695	Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimer's Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13633.	1.8	8
1697	Gamma camera imaging in movement disorders. , 2022, , .		0
1698	Aetiology and pathophysiology of neurodegenerative disorders. , 2022, , 1-16.		0
1699	Early Life Quality on Instrumental, Daily and Neuropsychological Activities of Lewy Body Disease about 70 Patients in the Geriatric Department at the Pitié-Salpêtrière Hospital of Paris, France. <i>Open Journal of Internal Medicine</i> , 2022, 12, 56-68.	0.1	0
1700	Sleep and dementia. , 2022, , .		0
1701	Using a Non-Wearable Actigraphy in Nursing Care for Dementia With Lewy Bodies. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2022, 37, 153331752210827.	0.9	3
1703	Impact of medical and neurological disorders on parasomnias. , 2022, , .		0
1704	Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases. <i>Theranostics</i> , 2022, 12, 3045-3056.	4.6	8
1705	Associations Between Regional Cerebral Blood Flow and Psychiatric Symptoms in Dementia With Lewy Bodies Without Parkinsonism. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2022, 37, 153331752210751.	0.9	2

#	ARTICLE	IF	CITATIONS
1706	Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence. <i>Acta Neuropathologica Communications</i> , 2022, 10, 21.	2.4	8
1708	Cognition, Behavior, and Caregiver Stress in Dementia during the COVID-19 Pandemic: An Indian Perspective. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 90-100.	0.7	2
1709	Correlates of Conversion from Mild Cognitive Impairment to Dementia with Lewy Bodies: Data from the National Alzheimer's Coordinating Center. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1643-1654.	1.2	6
1710	Influence of antidepressant use on 123I-MIBG heart and lung uptakes in the diagnosis of Lewy body disease. <i>Annals of Nuclear Medicine</i> , 2022, 36, 488-494.	1.2	3
1711	Unique Lewy pathology in myotonic dystrophy type 1. <i>Neuropathology</i> , 2022, 42, 104-116.	0.7	3
1712	Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 594-602.	1.3	2
1713	Brain Diseases and Fall-Related Surgery in Older Persons. <i>European Neurology</i> , 2022, , 1-5.	0.6	3
1714	Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia. <i>Npj Parkinson's Disease</i> , 2022, 8, 16.	2.5	4
1716	Patterns of Mixed Pathologies in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 595-607.	1.2	8
1717	Current Concepts of Mixed Pathologies in Neurodegenerative Diseases. <i>Canadian Journal of Neurological Sciences</i> , 2023, 50, 329-345.	0.3	22
1719	Case report: Late-onset mania as a presentation of underlying Lewy body disease. <i>Bipolar Disorders</i> , 2022, 24, 693-696.	1.1	3
1720	Cardiac Alpha-Synuclein Is Present in Alpha-Synucleinopathies. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1125-1131.	1.5	4
1721	Biomarkers Analysis and Clinical Manifestations in Comorbid Creutzfeldt-Jakob Disease: A Retrospective Study in 215 Autopsy Cases. <i>Biomedicines</i> , 2022, 10, 680.	1.4	2
1722	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1495.	5.8	11
1723	Large-scale network dysfunction in $\beta$ -Synucleinopathy: A meta-analysis of resting-state functional connectivity. <i>EBioMedicine</i> , 2022, 77, 103915.	2.7	14
1724	Prevalence of Behavioral and Psychological Symptoms in Patients With Cognitive Decline Before and During the COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2022, 13, 839683.	1.3	6
1725	Evaluation of Brain SPECT with 99mTc-TRODAT-1 in the Differential Diagnosis of Parkinsonism. <i>Parkinson's Disease</i> , 2022, 2022, 1-10.	0.6	1
1726	Progressing Towards Blood Based Diagnostic RNA Biomarkers for Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
1727	A prospective multicenter validation study of a machine learning algorithm classifier on quantitative electroencephalogram for differentiating between dementia with Lewy bodies and Alzheimer's dementia. PLoS ONE, 2022, 17, e0265484.	1.1	0
1728	Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies. Brain, 2022, 145, 4448-4458.	3.7	9
1729	Functional and structural brain network correlates of visual hallucinations in Lewy body dementia. Brain, 2022, 145, 2190-2205.	3.7	14
1730	Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study. Brain Communications, 2022, 4, fcac040.	1.5	8
1731	Autopsy Validation of the Diagnostic Accuracy of <sup>123</sup> I-Metaiodobenzylguanidine Myocardial Scintigraphy for Lewy Body Disease. Neurology, 2022, 98, .	1.5	10
1732	Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain, 2022, 145, 2769-2784.	3.7	15
1733	Cerebrospinal Fluid Total Tau Protein Correlates With Longitudinal, Progressing Cognitive Dysfunction in Anti-Neural Autoantibody-Associated Dementia and Alzheimer's Dementia: A Case-Control Study. Frontiers in Immunology, 2022, 13, 837376.	2.2	7
1734	Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid- $\beta^2$ and $\alpha$ -synuclein pathologies in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathologica Communications, 2022, 10, 36.	2.4	7
1735	Functional Cognitive Disorder Presents High Frequency and Distinct Clinical Profile in Patients With Low Education. Frontiers in Aging Neuroscience, 2022, 14, 789190.	1.7	1
1736	Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem). Neurological Sciences, 2022, 43, 4221-4229.	0.9	1
1737	The Added Value of Cerebrospinal Fluid Neurofilament Light Chain to Existing Diagnostic Methods and Biomarkers in a Mixed Memory Clinic Cohort of Consecutive Patients. Journal of Alzheimer's Disease Reports, 2022, 6, 121-127.	1.2	2
1738	Predictive Diagnostic Approach to Dementia and Dementia Subtypes Using Wireless and Mobile Electroencephalography: A Pilot Study. Bioelectricity, 2022, 4, 3-11.	0.6	1
1739	Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism. Movement Disorders, 2022, 37, 1245-1255.	2.2	8
1740	Skin Conditions and Movement Disorders: Hiding in Plain Sight. Movement Disorders Clinical Practice, 2022, 9, 566-583.	0.8	3
1741	Effect of comorbid Parkinson's disease and Parkinson's disease dementia on the course of idiopathic normal pressure hydrocephalus. Journal of Neurosurgery, 2022, , 1-8.	0.9	1
1742	Effect of GBA gene variants on clinical characteristics of dementia with Lewy bodies: a review and meta-analyses. Neurological Sciences, 2022, 43, 3541-3550.	0.9	4
1743	$\alpha$ -Synuclein Radiotracer Development and <i>In Vivo</i> Imaging: Recent Advancements and New Perspectives. Movement Disorders, 2022, 37, 936-948.	2.2	24
1744	Assessment of autonomic symptoms may assist with early identification of mild cognitive impairment with Lewy bodies. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	6

#	ARTICLE	IF	CITATIONS
1745	Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. Cellular and Molecular Life Sciences, 2022, 79, 174.	2.4	45
1746	Caffeine Consumption and Dementia: Are Lewy Bodies the Link?. Annals of Neurology, 2022, 91, 834-846.	2.8	4
1747	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
1749	Heterogeneity of Multiple System Atrophy: An Update. Biomedicines, 2022, 10, 599.	1.4	13
1750	Identifying subtle functional change in individuals with mild cognitive impairment: development and validation of the Healthy Brain Ageing " Functional Assessment Questionnaire. Aging, Neuropsychology, and Cognition, 2023, 30, 536-554.	0.7	3
1751	Manual and automated analysis of atrophy patterns in dementia with Lewy bodies on MRI. BMC Neurology, 2022, 22, 114.	0.8	4
1752	Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias. JAMA Psychiatry, 2022, 79, 359.	6.0	26
1753	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases. Neurobiology of Aging, 2022, 115, 88-108.	1.5	11
1754	The Wisconsin Alzheimer's Institute Dementia Diagnostic Clinic Network: A community of practice to improve dementia care. Journal of the American Geriatrics Society, 2022, 70, 2121-2133.	1.3	4
1755	"Occipital Pole" Sign on 18F-FDG PET for Dementia With Lewy Bodies and Posterior Cortical Atrophy. Clinical Nuclear Medicine, 2022, Publish Ahead of Print, .	0.7	1
1756	Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 87, 991-997.	1.2	10
1757	Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies. Neurology, 2022, 98, .	1.5	9
1758	Guidelines for diagnosis and treatment of depression in older adults: A report from the Japanese Society of mood disorders. Psychiatry and Clinical Neurosciences, 2022, 76, 222-234.	1.0	25
1759	In vivo vesicular acetylcholine transporter density in human peripheral organs: an [18F]FEOBV PET/CT study. EJNMMI Research, 2022, 12, 17.	1.1	6
1760	Factors associated with burden among male caregivers for people with dementia. Journal of the Chinese Medical Association, 2022, 85, 462-468.	0.6	2
1761	Sarcopenia is as common in older patients with dementia with Lewy bodies as it is in those with Alzheimer's disease. Geriatrics and Gerontology International, 2022, 22, 418-424.	0.7	11
1762	Blood pressure and heart rate responses to orthostatic challenge and Valsalva manoeuvre in mild cognitive impairment with Lewy bodies. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	4
1763	The Non-motor Symptoms, Disability Progression, and Survival Analysis of Atypical Parkinsonism: Case Series from Eastern India and Brief Review of Literature. Journal of Neurosciences in Rural Practice, 0, .	0.3	0

#	ARTICLE	IF	CITATIONS
1764	Effects of Alzheimer and Lewy Body Disease Pathologies on Brain Metabolism. <i>Annals of Neurology</i> , 2022, 91, 853-863.	2.8	7
1765	Mortality in nursing home residents stratified according to subtype of dementia: a longitudinal study over three years. <i>BMC Geriatrics</i> , 2022, 22, 282.	1.1	2
1766	The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 887-899.	1.2	1
1767	Lewy body dementia is associated with an increased risk of atrial fibrillation: A case-control study. <i>Journal of Clinical Neuroscience</i> , 2022, 99, 62-65.	0.8	2
1768	Synuclein-One study: skin biopsy detection of phosphorylated $\alpha$ -synuclein for diagnosis of synucleinopathies. <i>Biomarkers in Medicine</i> , 2022, 16, 499-509.	0.6	8
1769	Spatial covariance analysis of FDG-PET and HMPAO-SPECT for the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2022, 322, 111460.	0.9	4
1770	Inflammation in dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2022, 168, 105698.	2.1	26
1771	Utility of 18F FDG-PET in Parkinsonism in an African population. <i>ENeurologicalSci</i> , 2022, 27, 100399.	0.5	1
1772	Predictors of emergency department visit among people with dementia in Taiwan. <i>Archives of Gerontology and Geriatrics</i> , 2022, 101, 104701.	1.4	4
1773	Using the ATN system as a guide for the neuropsychological assessment of Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 926-943.	0.8	6
1774	A case report of late-onset schizophrenia differentiated from a dementing disorder. <i>Neurocase</i> , 2021, 27, 467-473.	0.2	1
1775	Praktická část zobrazovací metod u extrapyramidových onemocnění a demence. <i>Neurologie Pro Praxi</i> , 2021, 22, 351-351.	0.0	0
1776	A case of V180I genetic mutation Creutzfeldt Jakob disease (CJD) with delusional misidentification as an initial symptom. <i>Prion</i> , 2022, 16, 7-13.	0.9	5
1777	Neuroimaging alterations in dementia with Lewy bodies and neuroimaging differences between dementia with Lewy bodies and Alzheimer's disease: An activation likelihood estimation meta-analysis. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 183-205.	1.9	8
1779	Role of Electroconvulsive Therapy in Managing Major Depressive Episodes in Patients With Dementia With Lewy Bodies. <i>Journal of ECT</i> , 2022, 38, e21-e22.	0.3	1
1780	Impaired performances on the category cued memory test in mild Alzheimer's disease and dementia with Lewy bodies: A comparative validity study. <i>Applied Neuropsychology Adult</i> , 2021, , 1-6.	0.7	3
1781	Single-synapse analyses of Alzheimer's disease implicate pathologic tau, DJ1, CD47, and ApoE. <i>Science Advances</i> , 2021, 7, eabk0473.	4.7	14
1782	Therapeutic Application of rTMS in Atypical Parkinsonian Disorders. <i>Behavioural Neurology</i> , 2021, 2021, 1-12.	1.1	0

#	ARTICLE	IF	CITATIONS
1784	Neuropathology and molecular diagnosis of Synucleinopathies. <i>Molecular Neurodegeneration</i> , 2021, 16, 83.	4.4	101
1787	Subtypes and Treatment of Mild Cognitive Impairment. <i>Korean Journal of Clinical Geriatrics</i> , 2021, 22, 61-66.	0.3	0
1789	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. <i>Acta Neuropathologica</i> , 2022, 143, 15-31.	3.9	29
1790	Multimodality Anatomic and Molecular Imaging of Parkinson Disease and Atypical Parkinson Syndromes with MRI, Iodine 123 N-[11C]-Fluoropropyl-2-[125I]-Carbomethoxy-3-[125I]-4-Iodophenyl) Nortropane SPECT (Dopamine Transporter SPECT), Iodine 123 Metaiodobenzylguanidine Cardiac Scintigraphy, and [ <sup>18F</sup> ]FDG-PET. <i>Neurographics</i> , 2021, 11, 259-274.	0.0	0
1791	Dynamic planar scintigraphy for the rapid kinetic measurement of myocardial 123I-MIBG turnover can identify Lewy body disease. <i>EJNMMI Research</i> , 2021, 11, 122.	1.1	0
1792	Association of <sup>125</sup> I-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. <i>Neurology</i> , 2022, 98, .	1.5	10
1793	Elderly people with gait disorder in Lewy body diseases, white matter diseases, and their combination: A neuroimaging-assisted analysis. <i>Neurology and Clinical Neuroscience</i> , 2022, 10, 25-29.	0.2	2
1794	Anhedonia in Neurodegenerative Diseases. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 255-277.	0.8	6
1795	Exploring the Recent Trends in Management of Dementia and Frailty: Focus on Diagnosis and Treatment. <i>Current Medicinal Chemistry</i> , 2022, 29, 5289-5314.	1.2	7
1796	Determinants of long-term care service use by persons with dementia: A national dementia registry study conducted in Taiwan. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	3
1797	On cell loss in Parkinson's disease, and the citations that followed. <i>Npj Parkinson's Disease</i> , 2022, 8, 38.	2.5	0
1798	Remembering John Q Trojanowski, in his own words: A life dedicated to discovering building blocks and using them to build bridges of knowledge, collaboration, and discovery. <i>Npj Parkinson's Disease</i> , 2022, 8, 43.	2.5	1
1799	Epidemiology and economic burden of Lewy body dementia in the United States. <i>Current Medical Research and Opinion</i> , 2022, 38, 1177-1188.	0.9	9
1800	Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder. <i>Neurology</i> , 2022, 98, .	1.5	14
1801	High Correlation among Brain-Derived Major Protein Levels in Cerebrospinal Fluid: Implication for Amyloid-Beta and Tau Protein Changes in Alzheimer's Disease. <i>Metabolites</i> , 2022, 12, 355.	1.3	3
1802	How long does it take to diagnose young-onset dementia? A comparison with late-onset dementia. <i>Neurological Sciences</i> , 2022, 43, 4729-4734.	0.9	6
1803	Progressive cognitive impairment and familial spastic paraparesis due to PRESENILIN 1 mutation: anatomoclinical characterization. <i>Journal of Neurology</i> , 2022, , 1.	1.8	1
1804	Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview. <i>Current Pharmaceutical Design</i> , 2022, 28, .	0.9	4

#	ARTICLE	IF	CITATIONS
1805	Prodromal Dementia With Lewy Bodies and Recurrent Panic Attacks as the First Symptom: A Case Report. <i>Frontiers in Neurology</i> , 2022, 13, 839539.	1.1	6
1806	Clinicoradiological features in progressive supranuclear palsy comorbid with argyrophilic grains. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 484-488.	0.8	3
1808	RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of $\alpha$ -Synuclein. <i>Biomolecules</i> , 2022, 12, 576.	1.8	7
1809	MCC950 ameliorates the dementia symptom at the early age of line M83 mouse and reduces hippocampal $\alpha$ -synuclein accumulation. <i>Biochemical and Biophysical Research Communications</i> , 2022, 611, 23-30.	1.0	8
1810	A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias. <i>Clinical Interventions in Aging</i> , 2022, Volume 17, 467-477.	1.3	8
1847	A Longitudinal Study of Plasma $\tau$ 181 in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease. <i>Movement Disorders</i> , 2022, 37, 1495-1504.	2.2	11
1848	APOE4 exacerbates $\alpha$ -synuclein seeding activity and contributes to neurotoxicity in Alzheimer's disease with Lewy body pathology. <i>Acta Neuropathologica</i> , 2022, 143, 641-662.	3.9	24
1849	The clinical approach to the identification of higher-order visual dysfunction in neurodegenerative disease. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 229-242.	2.0	3
1850	Macroscopic findings of brain with dementia. <i>Neuropathology</i> , 2022, , .	0.7	3
1851	Clinical Perception and Treatment Options for Behavioral and Psychological Symptoms of Dementia (BPSD) in Italy. <i>Frontiers in Psychiatry</i> , 2022, 13, 843088.	1.3	3
1852	The management of dementia worldwide: A review on policy practices, clinical guidelines, end-of-life care, and challenge along with aging population. <i>BioScience Trends</i> , 2022, 16, 119-129.	1.1	7
1853	Lateralized <i>ante mortem</i> and <i>post mortem</i> pathology in a case of Lewy body disease with corticobasal syndrome. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12294.	1.8	2
1854	Translocator Protein (18 kDa) Polymorphism (rs6971) in the Korean Population. <i>Dementia and Neurocognitive Disorders</i> , 2022, 21, 71.	0.4	3
1855	Misdiagnosis of dementia with Lewy bodies due to venlafaxine. <i>Progress in Neurology and Psychiatry</i> , 2022, 26, 8-10.	0.4	2
1856	Behavioral and Psychological Symptoms of Dementia in Different Dementia Disorders: A Large-Scale Study of 10,000 Individuals. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1307-1318.	1.2	22
1857	Managing the Behavioral and Psychological Symptoms of Dementia. <i>Current Treatment Options in Neurology</i> , 2022, 24, 183-201.	0.7	4
1858	Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies. <i>Medicina (Lithuania)</i> , 2022, 58, 612.	0.8	1
1859	Adverse Events of Physiotherapy Interventions in Parkinsonian Patients. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 744-750.	0.8	3

#	ARTICLE	IF	CITATIONS
1860	Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism. <i>Npj Parkinson's Disease</i> , 2022, 8, 53.	2.5	3
1861	Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. <i>Translational Neurodegeneration</i> , 2022, 11, 24.	3.6	6
1862	Neuropathological associations of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) differ between the oldest-old and younger-old. <i>Acta Neuropathologica</i> , 2022, 144, 45-57.	3.9	10
1863	Cognitive and affective disturbances in patients with Parkinson's disease: Perspectives for classifying of motor/neuropsychiatric subtypes. <i>Neuroscience Letters</i> , 2022, 781, 136675.	1.0	12
1864	Ultrastructural and biochemical classification of pathogenic tau, $\hat{\pm}$ -synuclein and TDP-43. <i>Acta Neuropathologica</i> , 2022, 143, 613-640.	3.9	22
1865	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	5.3	52
1866	Delusions, Hallucinations, and Cognitive Decline in Middle Age: A Case of Dementia, GIGYF2 Gene Mutation, and 22q11 Duplication. <i>Indian Journal of Psychological Medicine</i> , 0, , 025371762210848.	0.6	2
1867	Biomarker A+T $\hat{\alpha}$ <sup>2</sup> : is this Alzheimer's disease or not? A combined CSF and pathology study. <i>Brain</i> , 2023, 146, 1166-1174.	3.7	12
1868	Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology. <i>Movement Disorders</i> , 2022, 37, 1505-1515.	2.2	12
1869	EEG Abnormalities During Delirium as a Prodromal Feature of Dementia with Lewy Bodies: A Case Report. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 223-228.	1.2	1
1870	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. <i>EBioMedicine</i> , 2022, 80, 104021.	2.7	26
1871	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	28
1872	Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects. <i>Revue Neurologique</i> , 2022, 178, 472-483.	0.6	2
1873	Autonomic dysfunction in older individuals: The contributions of multiple brain diseases and diabetes. <i>Neurology and Clinical Neuroscience</i> , 2022, 10, 198-209.	0.2	1
1874	Cognitive profile in idiopathic autonomic failure: relation with white matter hyperintensities and neurofilament levels. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 864-876.	1.7	4
1875	Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse A $\hat{\beta}$ <sup>2</sup> plaque pathology when injected into newborn mouse hosts.. <i>Free Neuropathology</i> , 2022, 3, .	2.4	2
1879	Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	1
1880	Baseline Cerebrospinal Fluid $\hat{\pm}$ -Synuclein in Parkinson's Disease Is Associated with Disease Progression and Cognitive Decline. <i>Diagnostics</i> , 2022, 12, 1259.	1.3	0



#	ARTICLE	IF	CITATIONS
1881	The promise of amplification assays for accurate early detection of $\alpha$ -synucleinopathies: A review. <i>Experimental Gerontology</i> , 2022, 165, 111842.	1.2	6
1882	Cardiac 123I-mIBG Imaging in Heart Failure. <i>Pharmaceuticals</i> , 2022, 15, 656.	1.7	5
1883	Prosodic characteristics of prepausal words produced by patients with neurodegenerative disease. , O, , .		1
1884	Synuclein Motor Dysfunction Composite Scale for the Discrimination of Dementia With Lewy Bodies From Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	1
1885	Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5842.	1.8	8
1886	Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update. <i>Drugs and Aging</i> , 2022, 39, 505-522.	1.3	10
1887	Factors Associated with Behavioral and Psychological Symptoms&nbsp;Of&nbsp;Dementia During Covid-19factors Associated with Behavioral and Psychological Symptoms&nbsp;Of&nbsp;Dementia During COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1888	One Autopsy Proved Neocortical Lewy Body Disease Without the Involvement of the Olfactory Bulb and Brainstem. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	0
1889	Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	6
1890	Sleep disturbance in elderly patients with dementia at home and the factors associated with its identification: An observational study. <i>Japanese Journal of Geriatrics</i> , 2022, 59, 200-208.	0.0	0
1891	Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression. <i>Brain</i> , 2022, 145, 3162-3178.	3.7	13
1893	An adaptive measure of visuospatial impairment in Dementia with Lewy Bodies. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	2
1894	Fractal dimension of the brain in neurodegenerative disease and dementia: A systematic review. <i>Ageing Research Reviews</i> , 2022, 79, 101651.	5.0	20
1895	Clinical Manifestations of Early-Onset Dementia With Lewy Bodies Compared With Late-Onset Dementia With Lewy Bodies and Early-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 702.	4.5	4
1896	Basal Forebrain Impairment: Understanding the Mnemonic Function of the Septal Region Translates in Therapeutic Advances. <i>Frontiers in Neural Circuits</i> , 0, 16, .	1.4	4
1897	Imaging Neuroinflammation in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 45S-52S.	2.8	22
1898	Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?. <i>Parkinsonism and Related Disorders</i> , 2022, 100, 24-32.	1.1	17
1899	Imaging of Synaptic Density in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 60S-67S.	2.8	29

#	ARTICLE	IF	CITATIONS
1900	<sup>18</sup> F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies. Journal of Nuclear Medicine, 2022, 63, 2S-12S.	2.8	27
1901	Differential diagnosis of patients with atypical Parkinsonian syndrome using 18F-FDG and 18F-FP CIT PET: A report of five cases. Radiology Case Reports, 2022, 17, 2765-2770.	0.2	1
1902	Troubles cognitifs et psycho-comportementaux dans la maladie de Parkinson idiopathique et les syndromes parkinsoniens atypiques. , 2022, , 277-290.		0
1904	Maladie d'Alzheimer et affections apparentées. , 2022, , 133-141.		0
1905	Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimer's disease topography. NeuroImage: Clinical, 2022, 35, 103080.	1.4	13
1906	Maladies apparentées à la maladie de Parkinson idiopathique. , 2022, , 253-265.		0
1907	Neurocognitive Disorders. , 2022, , .		0
1908	Which Test Is the Best to Assess Visuo-Cognitive Impairment in Patients with Parkinson's Disease with Mild Cognitive Impairment and Dementia? A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1749-1782.	1.5	3
1909	Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 6922.	1.8	2
1910	Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 6371.	1.8	10
1911	The Value of Neuroimaging in Dementia Diagnosis. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 800-821.	0.4	2
1912	Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia. Journal of Parkinson's Disease, 2022, , 1-14.	1.5	4
1913	A novel diagnostic approach for patients with adult-onset dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1039-1048.	0.9	3
1914	Incremental diagnostic value of 18F-Fluorometamol PET in differential diagnoses of Alzheimer's Disease-related neurodegenerative diseases from an unselected memory clinic cohort. Scientific Reports, 2022, 12, .	1.6	3
1915	Cognitive profile in mild cognitive impairment with Lewy bodies. Singapore Medical Journal, 2023, 64, 487-492.	0.3	3
1917	Vascular Lesions and Brain Atrophy in Alzheimer's, Vascular and Mixed Dementia: An Optimized 3T MRI Protocol Reveals Distinctive Radiological Profiles. Current Alzheimer Research, 2022, 19, 449-457.	0.7	3
1918	±-Synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders. Acta Neuropathologica, 2022, 144, 167-185.	3.9	12
1919	Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2022, 12, 1921-1935.	1.5	7

#	ARTICLE	IF	CITATIONS
1920	<sc>TDP</sc>â€43 Pathology Exacerbates Cognitive Decline in Primary <sc>Ageâ€Related</sc> Tauopathy. <i>Annals of Neurology</i> , 2022, 92, 425-438.	2.8	12
1922	Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest Old. <i>Neurology</i> , 2022, 99, .	1.5	22
1923	Rapidly Progressive Dementia. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 901-936.	0.4	8
1924	Cognitive Syndromes Associated With Movement Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 726-749.	0.4	0
1925	Neuropathology of Dementia Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 834-851.	0.4	11
1926	Old age amyotrophic lateral sclerosis and limbic TDPâ€43 pathology. <i>Brain Pathology</i> , 2022, 32, .	2.1	6
1927	Elevated Plasma Orexin-A Levels in Prodromal Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1037-1048.	1.2	5
1928	Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease. <i>Molecular Neurobiology</i> , 2022, 59, 1-9.	1.9	4
1929	Protocol for Rhapsody: a longitudinal observational study examining the feasibility of speech phenotyping for remote assessment of neurodegenerative and psychiatric disorders. <i>BMJ Open</i> , 2022, 12, e061193.	0.8	5
1930	Establishing In-House Cutoffs of CSF Alzheimerâ€™s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6891.	1.8	13
1931	Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 119-128.	1.1	10
1932	Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis. <i>Brain Communications</i> , 2022, 4, .	1.5	7
1933	Pinpointing novel risk loci for Lewy body dementia and the shared genetic etiology with Alzheimerâ€™s disease and Parkinsonâ€™s disease: a large-scale multi-trait association analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	10
1934	Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. <i>Brain Communications</i> , 2022, 4, .	1.5	11
1935	Striatal Dopaminergic Depletion Pattern Reflects Pathological Brain Perfusion Changes in Lewy Body Diseases. <i>Molecular Imaging and Biology</i> , 2022, 24, 950-958.	1.3	2
1936	Overview of therapeutic targets in management of dementia. <i>Biomedicine and Pharmacotherapy</i> , 2022, 152, 113168.	2.5	15
1938	Secular trends in the prevalence of dementia based on a communityâ€based complete enumeration in Japan: the Nakayama Study. <i>Psychogeriatrics</i> , 2022, 22, 631-641.	0.6	2
1939	Networkâ€based metaâ€analysis and the candidate gene association studies reveal novel ethnicityâ€specific variants in <sc> <i>MFSD3</i> </sc> and <sc> <i>MRPL43</i> </sc> associated with dementia with Lewy bodies. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 0, , .	1.1	1

#	ARTICLE	IF	CITATIONS
1940	Odor identification predicts the transition of patients with isolated <sc>RBD</sc> : A retrospective study. <i>Annals of Clinical and Translational Neurology</i> , 0, , .	1.7	2
1941	Recent advances in Lewy body dementia: A comprehensive review. <i>Disease-a-Month</i> , 2023, 69, 101441.	0.4	3
1942	Contribution of Memory Tests to Early Identification of Conversion from Amnesic Mild Cognitive Impairment to Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1397-1409.	1.2	5
1943	<sc>GRN</sc> Mutations Are Associated with Lewy Body Dementia. <i>Movement Disorders</i> , 2022, 37, 1943-1948.	2.2	5
1945	±±±Synuclein Seed Amplification in <sc>CSF</sc> and Brain from Patients with Different Brain Distributions of Pathological ±±±Synuclein in the Context of Co±±±Pathology and <sc>Non±±±LBD</sc> Diagnoses. <i>Annals of Neurology</i> , 2022, 92, 650-662.	2.8	19
1946	Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. <i>Parkinsonism and Related Disorders</i> , 2022, 100, 33-36.	1.1	5
1947	Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	24
1948	A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson±±±s disease with dementia. <i>Brain Communications</i> , 2022, 4, .	1.5	3
1949	Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	0
1950	Impact of the COVID-19 Pandemic and Lockdown on Anxiety, Depression and Nursing Burden of Caregivers in Alzheimer's Disease, Dementia With Lewy Bodies and Mild Cognitive Impairment in China: A 1-Year Follow-Up Study. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	6
1951	Frontal Atrophy and Executive Dysfunction Relate to Complex Numbers Impairment in Progressive Supranuclear Palsy. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1553-1566.	1.2	2
1952	Differential Neuropathology, Genetics, and Transcriptomics in Two Kindred Cases with Alzheimer±±±s Disease and Lewy Body Dementia. <i>Biomedicines</i> , 2022, 10, 1687.	1.4	2
1953	Intermittent theta burst stimulation for the treatment of autonomic dysfunction and depressive symptoms in dementia with Lewy bodies. <i>Asian Journal of Psychiatry</i> , 2022, , 103212.	0.9	1
1954	The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 111-116.	1.1	7
1955	Bidirectional Relationship Between Sleep Disturbances and Parkinson's Disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	8
1956	A Multimodal Neuroimaging and Neuropsychological Study of Visual Hallucinations in Alzheimer±±±s Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 133-149.	1.2	2
1957	Organized Registration for the Assessment of Dementia by the Nationwide General Consortium Toward Effective Treatment (ORANGE) Registry: Current Status and Perspectives of Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	1.2	0
1958	Prospective CERAD Neuropsychological Assessment in Patients With Multiple System Atrophy. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3

#	ARTICLE	IF	CITATIONS
1959	Update on the Cognitive Presentations of iNPH for Clinicians. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	0
1960	Neurocognitive health of older adults experiencing homelessness in Oakland, California. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3
1961	YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer's disease and frontotemporal lobar degeneration. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	6
1962	The large neuron involvement in the neostriatum in Lewy body diseases. <i>Neuropathology</i> , 2022, 42, 459-463.	0.7	0
1963	Predictive value of phospho-tau/total-tau ratio in amyloid-negative Mild Cognitive Impairment. <i>Neuroscience Letters</i> , 2022, 787, 136811.	1.0	3
1964	<sc>±</sc>Synuclein V15A</sc> Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid-Binding Property. <i>Movement Disorders</i> , 2022, 37, 2075-2085.	2.2	11
1965	Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes. <i>Brain</i> , 2022, 145, 4506-4518.	3.7	15
1967	From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias. <i>Arquivos De Neuro-Psiquiatria</i> , 2022, 80, 24-35.	0.3	0
1968	Neuropathology and emerging biomarkers in corticobasal syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 919-929.	0.9	27
1969	Automated Analysis of Drawing Process for Detecting Prodromal and Clinical Dementia. , 2022, , .		2
1970	The Effectiveness of Community Aging Care Centers on Global Function for People Living with Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 553-562.	1.2	2
1971	The gesture imitation test in dementia with Lewy bodies and Alzheimer's disease dementia. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
1973	Consistent Abnormalities in Metabolic Patterns of Lewy Body Dementias. <i>Movement Disorders</i> , 2022, 37, 1861-1871.	2.2	6
1974	Norovirus Intestinal Infection and Lewy Body Disease in an Older Patient with Acute Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8376.	1.8	1
1975	Selective Detection of Misfolded Tau From Postmortem Alzheimer's Disease Brains. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	16
1976	Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimer's disease in a multigenerational Colombian Family. <i>PLoS ONE</i> , 2022, 17, e0269955.	1.1	1
1977	Sleep Dysfunction in Movement Disorders: a Window to the Disease Biology. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 565-576.	2.0	6
1979	Late-onset mania in autopsy-confirmed Lewy body disease: A rare symptom of prodromal dementia with Lewy bodies?. <i>Bipolar Disorders</i> , 2022, 24, 683-684.	1.1	0

#	ARTICLE	IF	CITATIONS
1980	A Mini-Mental State Examination Formula May Help to Distinguish Alzheimer's Disease from Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 1119-1129.	1.2	1
1981	Headache-Associated Phantasmia as a Harbinger of Lewy Body Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2023, 35, 92-97.	0.9	0
1982	Glucocerebrosidase mutations and Parkinson disease. <i>Journal of Neural Transmission</i> , 2022, 129, 1105-1117.	1.4	19
1983	Developing a core outcome set (COS) for Dementia with Lewy bodies (DLB). <i>HRB Open Research</i> , 0, 5, 57.	0.3	1
1984	Factors Associated with Behavioral and Psychological Symptoms of Dementia during COVID-19. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10094.	1.2	2
1985	Investigating the power of eyes open resting state EEG for assisting in dementia diagnosis. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	6
1986	Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease. <i>Neurology</i> , 2022, 99, .	1.5	2
1987	Polysomnographic Predictors of Sleep, Motor, and Cognitive Dysfunction Progression in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 657-674.	2.0	5
1988	Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2022, 144, 603-614.	3.9	35
1989	Neuroprotective Trials in REM Sleep Behavior Disorder. <i>Neurology</i> , 2022, 99, 19-25.	1.5	20
1990	Differential effects of tau stage, Lewy body pathology, and substantia nigra degeneration on FDG-PET patterns in clinical AD. <i>Journal of Nuclear Medicine</i> , 0, , jnumed.122.264213.	2.8	3
1991	Lewy Body Disease Primate Model with $\alpha$ -Synuclein Propagation from the Olfactory Bulb. <i>Movement Disorders</i> , 2022, 37, 2033-2044.	2.2	6
1992	Promoting independence in Lewy body dementia through exercise: the PRIDE study. <i>BMC Geriatrics</i> , 2022, 22, .	1.1	1
1993	A circular RNA blood panel that differentiates Alzheimer's disease from other dementia types. <i>Biomarker Research</i> , 2022, 10, .	2.8	4
1994	Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies. <i>Neurology</i> , 0, , 10.1212/WNL.0000000000201166.	1.5	4
1995	Seeing the Woods for the Trees? Applying Diagnostic Criteria for Dementia with Lewy Bodies to Patients Presenting with Posterior Cortical Atrophy. <i>Alzheimer Disease and Associated Disorders</i> , 0, Publish Ahead of Print, .	0.6	0
1996	A Review on the Clinical Diagnosis of Multiple System Atrophy. <i>Cerebellum</i> , 2023, 22, 825-839.	1.4	6
1997	Advancing the Genetics of Lewy Body Disorders with Disease-Modifying Treatments in Mind. <i>Genetics &amp; Genomics Next</i> , 0, , 2200011.	0.8	0

#	ARTICLE	IF	CITATIONS
1998	Reproductive factors and cognitive impairment in natural menopausal women: A cross-sectional study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
1999	Metabolic connectivity of resting-state networks in alpha synucleinopathies, from prodromal to dementia phase. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	7
2000	A bibliometric analysis of neuroimaging biomarkers in Parkinson disease based on Web of Science. <i>Medicine (United States)</i> , 2022, 101, e30079.	0.4	3
2001	Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders. <i>Biomolecules</i> , 2022, 12, 1099.	1.8	3
2002	Neuropathological and Clinical Correlates of Lewy Body Disease Survival by Race and Ethnicity in the National Alzheimer's Coordinating Center. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 1339-1349.	1.2	3
2003	Real-World Testing of a Machine Learning-Derived Visual Scale for Tc99m TRODAT-1 for Diagnosing Lewy Body Disease: Comparison with a Traditional Approach Using Semiquantification. <i>Journal of Personalized Medicine</i> , 2022, 12, 1369.	1.1	0
2004	White matter hyperintensities in dementia with Lewy bodies are associated with poorer cognitive function and higher dementia stages. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
2005	Evaluation of <i>SORL1</i> in Lewy Body Dementia Identifies No Significant Associations. <i>Movement Disorders</i> , 2022, 37, 2312-2314.	2.2	0
2006	Macroscopic diagnostic clue for parkinsonism. <i>Neuropathology</i> , 2022, 42, 394-419.	0.7	3
2007	Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2099-2109.	2.2	3
2008	Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias. <i>Parkinsonism and Related Disorders</i> , 2022, 102, 94-100.	1.1	10
2009	Pisa syndrome in dementia with Lewy bodies: A Chinese multicenter study. <i>Parkinsonism and Related Disorders</i> , 2022, 103, 50-55.	1.1	0
2010	FDG-PET combined with learning vector quantization allows classification of neurodegenerative diseases and reveals the trajectory of idiopathic REM sleep behavior disorder. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 225, 107042.	2.6	11
2011	Montreal Cognitive Assessment predicts the short-term risk of Lewy body disease in isolated REM sleep behavior disorder with reduced MIBG scintigraphy. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	2
2012	Age-Related Perioperative Neurocognitive Disorders: Experimental Models and Druggable Targets. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 321-340.	4.2	7
2013	Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 141, 104856.	2.9	2
2014	Decreased delta-band event-related power in dementia with Lewy bodies with a mutation in the glucocerebrosidase gene. <i>Clinical Neurophysiology</i> , 2022, 143, 14-20.	0.7	2
2015	Cognitive stimulation and cognitive results in older adults: A systematic review and meta-analysis. <i>Archives of Gerontology and Geriatrics</i> , 2023, 104, 104807.	1.4	7

#	ARTICLE	IF	CITATIONS
2016	Long-acting paliperidone in Ekbomâ€™s syndrome in Lewy body dementia: A case report. Translational Neuroscience, 2022, 13, 201-210.	0.7	2
2017	Development and design of a diagnostic report to support communication in dementia: Coâ€™creation with patients and care partners. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	2
2018	Sex and gender differences in dementia. International Review of Neurobiology, 2022, , 179-233.	0.9	3
2019	What is new in nuclear medicine imaging for dementia. Noropsikiyatri Arsivi, 2022, , .	0.2	1
2020	White matter hyperintensity distribution differences in aging and neurodegenerative disease cohorts. Neurolmage: Clinical, 2022, 36, 103204.	1.4	9
2021	The Cognitive and Language Profile of Dementia with Lewy Bodies. American Journal of Alzheimer's Disease and Other Dementias, 2022, 37, 153331752211069.	0.9	3
2022	Autophagy in Lewy body diseases and multiple system atrophy. , 2022, , 227-244.		0
2023	Clinical aspects of diagnosis in dementia. , 2023, , 1-26.		0
2024	Distinguishing Lewy Body Dementia from Alzheimer's Disease using Machine Learning on Heterogeneous Data: A Feasibility Study. , 2022, , .		0
2025	Predicting cognitive decline in Parkinsonâ€™s disease using FDG-PETâ€™based supervised learning. Journal of Clinical Investigation, 2022, 132, .	3.9	9
2026	CSF Biomarkers of Alzheimer Disease in Patients With Concomitant Î±-Synuclein Pathology. Neurology, 2022, 99, .	1.5	6
2027	A Guide for the Differential Diagnosis of Multiple System Atrophy in Clinical Practice. Journal of Parkinson's Disease, 2022, 12, 2015-2027.	1.5	4
2028	Genetics and Pathogenesis of Parkinson's Syndrome. Annual Review of Pathology: Mechanisms of Disease, 2023, 18, 95-121.	9.6	49
2029	Association between prevalence rate of dementia with Lewy bodies and sleep characteristics in Chinese old adults. Frontiers in Human Neuroscience, 0, 16, .	1.0	1
2030	Alzheimerâ€™s Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers. Journal of Alzheimer's Disease, 2022, 90, 419-432.	1.2	3
2031	Determining Whether Sex and Zygosity Modulates the Association between APOE4 and Psychosis in a Neuropathologically-Confirmed Alzheimerâ€™s Disease Cohort. Brain Sciences, 2022, 12, 1266.	1.1	2
2032	CSF Î±-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies. Alzheimer Disease and Associated Disorders, 0, Publish Ahead of Print, .	0.6	0
2033	Sensory Loss and Risk of Dementia. Neuroscientist, 0, , 107385842211260.	2.6	5



#	ARTICLE	IF	CITATIONS
2034	Neuroleptic Sensitivity in Dementia with Lewy Body and Use of Pimavanserin in an Inpatient Setting: A Case Report. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	3
2035	Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology. <i>Neurology</i> , 2022, 99, .	1.5	3
2036	A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 363-380.	1.2	8
2037	Neural basis of impaired narrative discourse comprehension in prodromal and mild dementia with lewy bodies. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
2038	Predictive risk factors of phenoconversion in idiopathic REM sleep behavior disorder: the Italian study "FARPRESTO". <i>Neurological Sciences</i> , 2022, 43, 6919-6928.	0.9	6
2039	Optimal MoCA cutoffs for detecting biologically-defined patients with MCI and early dementia. <i>Neurological Sciences</i> , 2023, 44, 159-170.	0.9	7
2041	Prevalence of Comorbid Dementia in Late-life Depression and Bipolar Disorder: A Retrospective Inpatient Study. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 589-598.	1.2	3
2042	Neuroscience robotics for controlled induction and real-time assessment of hallucinations. <i>Nature Protocols</i> , 2022, 17, 2966-2989.	5.5	9
2043	Sleep disturbances in Lewy body dementia: A systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	9
2044	Dispersion-based cognitive intra-individual variability in dementia with Lewy bodies.. <i>Neuropsychology</i> , 2022, 36, 719-729.	1.0	7
2045	Structures of $\alpha$ -synuclein filaments from human brains with Lewy pathology. <i>Nature</i> , 2022, 610, 791-795.	13.7	124
2047	Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review. <i>BioMed Research International</i> , 2022, 2022, 1-17.	0.9	5
2048	Whole-exome sequencing reveals PSEN1 and ATP7B combined variants as a possible cause of early-onset Lewy body dementia: a case study of genotype-phenotype correlation. <i>Neurogenetics</i> , 0, , .	0.7	1
2049	Capturing Cognitive Aging in Vivo: Application of a Neuropsychological Framework for Emerging Digital Tools. <i>JMIR Aging</i> , 2022, 5, e38130.	1.4	6
2050	Characteristics of very late-onset schizophrenia-like psychosis as prodromal dementia with Lewy bodies: a cross-sectional study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	10
2052	The Bender Gestalt Test is useful for clinically diagnosing dementia with Lewy bodies: Analysis of its sensitivity, specificity, and clinical characteristics of the figure copy. <i>Applied Neuropsychology Adult</i> , 0, , 1-6.	0.7	1
2053	Cohort profile: the Norwegian Registry of Persons Assessed for Cognitive Symptoms (NorCog) " a national research and quality registry with a biomaterial collection. <i>BMJ Open</i> , 2022, 12, e058810.	0.8	5
2054	Comorbid Neurodegeneration in Primary Progressive Aphasia: Clinicopathological Correlations in a Single-Center Study. <i>Behavioural Neurology</i> , 2022, 2022, 1-14.	1.1	1

#	ARTICLE	IF	CITATIONS
2056	Utility of empathy informant report in FTD differential diagnosis. <i>Journal of the International Neuropsychological Society</i> , 0, , 1-7.	1.2	0
2057	Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 433-444.	1.2	2
2058	The presence and co-incidence of geriatric syndromes in older patients with mild-moderate Lewy body dementia. <i>BMC Neurology</i> , 2022, 22, .	0.8	5
2059	Intermediate-length CGG repeat expansion in NOTCH2NLC is associated with pathologically confirmed Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 120, 189-195.	1.5	3
2060	Increased PRR14 and VCAM-1 level in serum of patients with Parkinson's disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
2061	In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcome. <i>Fluids and Barriers of the CNS</i> , 2022, 19, .	2.4	3
2062	Aggression Towards Caregivers in Parkinson's Disease and Related Disorders: A Mixed Methods Study. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	0
2063	TREM2 risk variants are associated with atypical Alzheimer's disease. <i>Acta Neuropathologica</i> , 2022, 144, 1085-1102.	3.9	7
2064	Characteristics of Drawing Process Differentiate Alzheimer's Disease and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 693-704.	1.2	3
2065	Mental health care for older adults: recent advances and new directions in clinical practice and research. <i>World Psychiatry</i> , 2022, 21, 336-363.	4.8	49
2066	Serum Homocysteine, Vitamin B12, Folate, and Their Association with Mild Cognitive Impairment and Subtypes of Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 681-691.	1.2	9
2067	Preclinical and randomized clinical evaluation of the p38 $\beta$ kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. <i>Nature Communications</i> , 2022, 13, .	5.8	17
2068	Non-REM sleep with hypertonia in Parkinsonian Spectrum Disorders: A pilot investigation. <i>Sleep Medicine</i> , 2022, 100, 501-510.	0.8	5
2069	Survival and Causes of Death among People with Clinically Diagnosed Dementia with Lewy bodies: A Multicenter Cohort Study. <i>International Journal of Geriatric Psychiatry</i> , 0, , .	1.3	1
2070	Metric magnetic resonance imaging analysis reveals pronounced substantia-innominata atrophy in dementia with Lewy bodies with a psychiatric onset. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4
2071	Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder. <i>Movement Disorders</i> , 2023, 38, 57-67.	2.2	2
2072	Towards an understanding of the pathological basis of senile depression and incident dementia: Implications for treatment. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 620-632.	1.0	9
2073	Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 405-417.	1.2	2

#	ARTICLE	IF	CITATIONS
2074	Sex differences in clinical cognitive impairment with Lewy bodies: a Chinese multicenter study. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	3
2075	Identification of dementia and MCI cases in health information systems: An Italian validation study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	2
2076	Speech and language characteristics differentiate Alzheimer's disease and dementia with Lewy bodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	8
2077	Impact and Risk Factors of Limbic Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Change in an Oldest-Old Cohort. <i>Neurology</i> , 2023, 100, .	1.5	4
2078	Evidence-Based Evaluation and Management of Cognitive Impairment in Dementia With Lewy Bodies. <i>Psychiatric Annals</i> , 2022, 52, 404-409.	0.1	0
2079	Case Study 3: A 58-Year-Old Woman Referred for Evaluation of Suspected Alzheimer Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022, 34, 307-315.	0.9	0
2080	Temporal Variation in Disease Onset and Clinical Features of Lewy Body Disease in China. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1263-1275.	1.2	2
2081	â€™Itâ€™s just incredible the difference it has madeâ€™: family carersâ€™ experiences of a specialist Lewy body dementia Admiral Nurse service. <i>Age and Ageing</i> , 2022, 51, .	0.7	1
2082	Clinical Presentation, Diagnosis, and Pathogenesis of Dementia With Lewy Bodies. <i>Psychiatric Annals</i> , 2022, 52, 398-403.	0.1	0
2084	Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 953-964.	0.9	2
2085	Electroconvulsive therapy improves psychotic symptoms in patients with dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	4
2086	Dementia with Lewy bodies: Impact of coâ€™pathologies and implications for clinical trial design. <i>Alzheimer's and Dementia</i> , 2023, 19, 318-332.	0.4	15
2087	Rhythmic auditory cueing in atypical parkinsonism: A pilot study. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	2
2089	Motor Symptoms in Dementia With Lewy Bodies: Literature Review and Evidence-Based Management. <i>Psychiatric Annals</i> , 2022, 52, 415-422.	0.1	0
2090	Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	33
2091	Can CSF Biomarkers Decode Contributions of Combined A $\beta$ 2 Plaque, Tau Tangle, and I $\pm$ -Synuclein Pathology?. <i>Neurology</i> , 2022, 99, 877-878.	1.5	0
2092	Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort. <i>Neurology</i> , 2023, 100, .	1.5	23
2093	Validation and extension of the quick dementia rating system (QDRS). <i>Applied Neuropsychology Adult</i> , 0, , 1-8.	0.7	0

#	ARTICLE	IF	CITATIONS
2094	A proposal for a new concept in psychiatric phenomenology: The "Yume" (dreamy or) Tj ETQq0 0 0 rgBT /Overjock 10 Tf		
2096	Characteristics of initial symptoms in patients with dementia with Lewy body disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	5
2097	Diagnosis and Treatment of Cognitive and Neuropsychiatric Symptoms in Parkinson Disease and Dementia With Lewy Bodies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 1314-1332.	0.4	2
2098	Oral environment and cerebral blood flow in patients with neurodegenerative dementia: comparison of Alzheimer type dementia and dementia with Lewy bodies. <i>Psychogeriatrics</i> , 0, , .	0.6	1
2099	Management of Psychiatric Phenomena in Lewy Body Dementia. <i>Psychiatric Annals</i> , 2022, 52, 410-414.	0.1	0
2100	Management of Psychiatric Symptoms in Dementia. <i>Neurologic Clinics</i> , 2023, 41, 123-139.	0.8	3
2101	Diagnostic value of $\beta$ -synuclein seeding amplification assays in $\beta$ -synucleinopathies: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2022, 104, 99-109.	1.1	21
2102	(Dis)Connected Dots in Dementia with Lewy Bodies" A Systematic Review of Connectivity Studies. <i>Movement Disorders</i> , 2023, 38, 4-15.	2.2	10
2103	Cognitive Impairment in Older Adults. <i>Psychiatric Clinics of North America</i> , 2022, 45, 639-661.	0.7	12
2104	Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers. <i>JAMA Neurology</i> , 2022, 79, 1155.	4.5	12
2105	The Brain Health Platform: Combining Resilience, Vulnerability, and Performance to Assess Brain Health and Risk of Alzheimer's Disease and Related Disorders. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1817-1830.	1.2	4
2106	Optic radiation atrophy in Lewy body disease with visual hallucination on phase difference enhanced magnetic resonance images. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
2107	Impact prediction of translocation of the mitochondrial outer membrane 70 as biomarker in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
2108	The convergent and divergent patterns in brain perfusion between Alzheimer's disease and Parkinson's disease with dementia: An ASL MRI study. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	2
2109	A Group of Long Non-coding RNAs in Blood Acts as a Specific Biomarker of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2023, 60, 566-575.	1.9	3
2110	Cerebral microbleeds in dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2022, 104, 68-71.	1.1	1
2111	Automated differential diagnosis of dementia syndromes using FDG PET and machine learning. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4
2112	Moderating effect of cognitive reserve on brain integrity and cognitive performance. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4

#	ARTICLE	IF	CITATIONS
2113	From protein biomarkers to proteomics in dementia with Lewy Bodies. Ageing Research Reviews, 2023, 83, 101771.	5.0	4
2114	Liposome: A potential drug delivery vector to treat dementia. , 2023, , 149-168.		0
2115	Psychiatric causes of behavioural change in adults less than 65 years old. Singapore Medical Journal, 2022, 63, 456.	0.3	0
2116	Magnetic resonance imaging in Parkinson's disease with mild cognitive impairment, Parkinson's disease dementia, and dementia with Lewy bodies. , 2023, , 297-307.		0
2117	Molecular imaging evidence in favor or against PDD and DLB overlap. , 2023, , 275-295.		1
2118	Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring. Journal of Parkinson's Disease, 2022, 12, 2519-2530.	1.5	7
2119	Primary eyecare provision for people living with dementia: what do we need to know?. Australasian journal of optometry, The, 2023, 106, 711-725.	0.6	1
2120	Case report: Delusional infestation in dementia with Lewy bodies. Frontiers in Psychiatry, 0, 13, .	1.3	3
2121	Validity of the Brief Assessment of Impaired Cognition caseâ€finding instrument for identification of dementia subgroups and staging of dementia. European Journal of Neurology, 0, , .	1.7	1
2122	Disease progression in dementia with Lewy bodies: AÂlongitudinal study on clinical symptoms, quality of life and functional impairment. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	3
2123	Clinical Correlates of Cerebrospinal Fluid 14-3-3 Protein in Non-Prion Rapid Progressive Dementia. Journal of Alzheimer's Disease, 2022, , 1-10.	1.2	0
2124	CSF proteome profiling across the Alzheimerâ€s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nature Aging, 2022, 2, 1040-1053.	5.3	21
2125	Neocortical Lewy Body Pathology Parallels Parkinson's Dementia, but Not Always. Annals of Neurology, 2023, 93, 184-195.	2.8	15
2126	Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimerâ€s Disease in Clinical Practice. International Journal of Molecular Sciences, 2022, 23, 13488.	1.8	0
2127	Microbiomeâ€gutâ€brain dysfunction in prodromal and symptomatic Lewy body diseases. Journal of Neurology, 2023, 270, 746-758.	1.8	10
2128	A descriptive study of Parkinson disease and atypical parkinsonisms in the <i>Annals of the Pathological Autopsy Cases in Japan</i>. Neuropathology, 2023, 43, 297-305.	0.7	1
2129	Implication of EEG theta/alpha and theta/beta ratio in Alzheimerâ€s and Lewy body disease. Scientific Reports, 2022, 12, .	1.6	10
2130	Family Caregiver Comorbidities in Lewy Body Dementia Versus Alzheimer Disease and Associated Disorders. Alzheimer Disease and Associated Disorders, 0, Publish Ahead of Print, .	0.6	0

#	ARTICLE	IF	CITATIONS
2131	RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementiaâ€”an international Delphi consensus. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	7
2132	Clinicopathological diversity of semantic dementia: Comparisons of patients with earlyâ€”onset versus lateâ€”onset, leftâ€”sided versus rightâ€”sided temporal atrophy, and TDPâ€”type A versus type C pathology. <i>Neuropathology</i> , 0, , .	0.7	5
2133	Psychometric properties of the Autonomic Symptoms Checklist in the Lewy body disease module of the uniform dataset. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	2
2134	Current and Future Trends in Biomarkers for the Early Detection of Alzheimerâ€™s Disease in Asia: Expert Opinion. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 699-710.	1.2	3
2135	Delay in the diagnosis of dementia in urban India: Role of dementia subtype and age at onset. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	2
2136	Validity and reliability of the Turkish version of the ALBA screening instrument for Lewy body dementia in older adults. <i>Applied Neuropsychology Adult</i> , 0, , 1-6.	0.7	3
2137	Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation. <i>ACS Chemical Neuroscience</i> , 2022, 13, 3281-3290.	1.7	7
2138	The Proteome of Neuromelanin Granules in Dementia with Lewy Bodies. <i>Cells</i> , 2022, 11, 3538.	1.8	2
2139	Functional loss and worsening geriatric assessment parameters are more common in dementia with Lewy bodies than Alzheimer's disease. <i>Psychogeriatrics</i> , 0, , .	0.6	1
2140	Diverse limbic comorbidities cause limbic and temporal atrophy in lewy body disease. <i>Parkinsonism and Related Disorders</i> , 2022, 105, 52-57.	1.1	3
2141	C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients. <i>Neurobiology of Disease</i> , 2022, 175, 105927.	2.1	3
2142	Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2023, 106, 105226.	1.1	3
2143	Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	1.7	5
2144	What Are the Key Diagnostic Cognitive Impairment and Dementia Subtypes and How to Integrate all of the Diagnostic Data to Establish a Diagnosis?. <i>Clinics in Geriatric Medicine</i> , 2023, 39, 77-90.	1.0	1
2145	Mass Spectrometryâ€”Based Proteomics Analysis of Human Substantia Nigra From Parkinson's Disease Patients Identifies Multiple Pathways Potentially Involved in the Disease. <i>Molecular and Cellular Proteomics</i> , 2023, 22, 100452.	2.5	15
2146	Optimizing cCOG, a Webâ€”based tool, to detect dementia with Lewy Bodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	4
2147	Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study. <i>Neurobiology of Disease</i> , 2023, 176, 105937.	2.1	8
2148	The effect of antidepressant therapy on a patient with progressive supranuclear palsy accompanied by depression, anxiety and fluctuating dementia. <i>Asian Journal of Psychiatry</i> , 2023, 80, 103418.	0.9	0

#	ARTICLE	IF	CITATIONS
2149	Cerebrospinal fluid glucose is not altered in patients with dementia. <i>Clinical Biochemistry</i> , 2023, 112, 1-5.	0.8	0
2150	Tratamento da demência: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. <i>Dementia E Neuropsychologia</i> , 2022, 16, 88-100.	0.3	2
2151	Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. <i>Dementia E Neuropsychologia</i> , 2022, 16, 73-87.	0.3	1
2152	Diagnosis and management of Parkinson's disease dementia and dementia with Lewy bodies: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. <i>Dementia E Neuropsychologia</i> , 2022, 16, 73-87.	0.3	0
2153	Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. <i>Dementia E Neuropsychologia</i> , 2022, 16, 88-100.	0.3	1
2154	Dementia with Lewy bodies as a morphological substrate of new-onset psychosis in later life - a case report with clinicopathological correlation. <i>Psychiatrie Pro Praxi</i> , 2022, 23, 179-181.	0.0	0
2155	Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2023, 36, 267-281.	1.2	3
2157	One Minute of EEG Data Provides Sufficient and Reliable Data for Identifying Lewy Body Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 0, Publish Ahead of Print, .	0.6	0
2158	Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential. <i>Communications Biology</i> , 2022, 5, .	2.0	1
2159	Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort. <i>Neurology</i> , 2023, 100, e860-e873.	1.5	16
2160	How patients with dementia influence caregiver burden using the Dementia Assessment Sheet for Community-based Integrated Care System (DASC) and Zarit Caregiver Burden Interview (ZBI). <i>Psychogeriatrics</i> , 2023, 23, 157-163.	0.6	3
2161	Exploring the Sensitivity of Prodromal Dementia with Lewy Bodies Research Criteria. <i>Brain Sciences</i> , 2022, 12, 1594.	1.1	1
2162	Distribution of Lewy-related pathology in the brain, spinal cord, and periphery: the population-based Vantaa 85+ study. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	4
2165	Conversations in dementia with Lewy bodies: Resources and barriers in communication. <i>International Journal of Language and Communication Disorders</i> , 0, , .	0.7	0
2166	Bipolar spectrum disorders in neurologic disorders. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
2167	Lifelong constipation in Parkinson's disease and other clinically defined alpha-synucleinopathies: A population-based study in Southeast Minnesota. <i>Parkinsonism and Related Disorders</i> , 2023, 107, 105244.	1.1	4
2168	Illusory Responses across the Lewy Body Disease Spectrum. <i>Annals of Neurology</i> , 2023, 93, 702-714.	2.8	2
2169	Brain <sup>18</sup> F-FDG PET and an optimized cingulate island ratio to differentiate Lewy body dementia and Alzheimer's disease. <i>Journal of Neuroimaging</i> , 2023, 33, 256-268.	1.0	3

#	ARTICLE	IF	CITATIONS
2170	Baroreflex-sympathoneural dysfunction characterizes at-risk individuals with preclinical central Lewy body diseases. <i>Clinical Autonomic Research</i> , 0, .	1.4	1
2171	Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer's disease and primary tauopathies. <i>Acta Neuropathologica</i> , 2023, 145, 197-218.	3.9	12
2172	Effect of Amyloid on Cognitive Performance in Parkinson's Disease and Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2023, 38, 278-285.	2.2	3
2173	Plasma sphingolipid abnormalities in neurodegenerative diseases. <i>PLoS ONE</i> , 2022, 17, e0279315.	1.1	6
2174	The impact of integrated brain molecular PET measures on DLB cognitive phenotype and clinical course. <i>Brain</i> , 2022, 145, 4157-4159.	3.7	0
2177	Treatment needs of dementia with Lewy bodies according to patients, caregivers, and physicians: a cross-sectional, observational, questionnaire-based study in Japan. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	6
2178	Assessment of clinical features and coexisting geriatric syndromes in newly diagnosed dementia with Lewy bodies: a retrospective study in a tertiary geriatrics setting in Turkey. <i>European Geriatric Medicine</i> , 0, .	1.2	1
2179	Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy. <i>Neurology</i> , 2023, 100, .	1.5	10
2180	Axonal degeneration in the anterior insular cortex is associated with Alzheimer's co-pathology in Parkinson's disease and dementia with Lewy bodies. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	5
2181	Functional brain networks in the evaluation of patients with neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2023, 19, 73-90.	4.9	17
2182	Costs of dementia with lewy bodies: A Chinese multicenter cross-sectional study. <i>International Journal of Geriatric Psychiatry</i> , 2023, 38, .	1.3	1
2183	Gut microbiota in dementia with Lewy bodies. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	7
2184	Case Report: Depression – dementia with Lewy bodies in the elderly: The importance of differential diagnosis. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
2185	Electroconvulsive therapy as a potential therapeutic option in psychiatric-onset prodromal dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2023, 38, .	1.3	1
2186	Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: A retrospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004124.	3.9	2
2187	Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson's Disease (PD) and dementia with Lewy bodies (DLB). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1090-1102.	3.3	11
2188	A Study on Some Language Impairments in Patients with Lewy Body Spectrum Disorders. <i>Zahedan Journal of Researches in Medical Sciences</i> , 2022, 25, .	0.1	0
2189	CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease. <i>Neurology</i> , 2023, 100, .	1.5	5



#	ARTICLE	IF	CITATIONS
2190	Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions. <i>Parkinsonism and Related Disorders</i> , 2023, 107, 105285.	1.1	12
2191	Dopaminergic connectivity reconfiguration in the dementia with Lewy bodies continuum. <i>Parkinsonism and Related Disorders</i> , 2023, 108, 105288.	1.1	4
2192	Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging. <i>Insights Into Imaging</i> , 2023, 14, .	1.6	5
2193	MRS in neurodegenerative dementias, prodromal syndromes and atâ€risk states: A systematic review of the literature. <i>NMR in Biomedicine</i> , 2023, 36, .	1.6	3
2194	EEG Entropy in REM Sleep as a Physiologic Biomarker in Early Clinical Stages of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 1557-1572.	1.2	5
2195	Neuropsychological Changes in Isolated REM Sleep Behavior Disorder: A Systematic Review and Meta-analysis of Cross-sectional and Longitudinal Studies. <i>Neuropsychology Review</i> , 2024, 34, 41-66.	2.5	2
2198	A blood mRNA panel that differentiates Alzheimerâ€™s disease from other dementia types. <i>Journal of Neurology</i> , 0, , .	1.8	1
2199	Comprehensive geriatric assessment is of value when diagnosing cognitive disorders in older patients and beyond. <i>European Geriatric Medicine</i> , 0, , .	1.2	0
2200	The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1371.	1.8	3
2201	Optical coherence tomography and angiography in Alzheimer's disease and other cognitive disorders. <i>European Journal of Ophthalmology</i> , 2023, 33, 1706-1717.	0.7	2
2203	Lateâ€onset panic disorder as the initial presentation in autopsyâ€confirmed dementia with Lewy bodies. <i>Psychiatry and Clinical Neurosciences</i> , 2023, 77, 242-244.	1.0	1
2204	Different peripheral expression patterns of the nicotinic acetylcholine receptor in dementia with Lewy bodies and Alzheimerâ€™s disease. <i>Immunity and Ageing</i> , 2023, 20, .	1.8	4
2205	Neuropsychological test performance of former American football players. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	5
2206	Characterising the prodromal phase in dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2023, 107, 105279.	1.1	2
2207	Morphological differences between the two major subtypes of multiple system atrophy with cognitive impairment. <i>Parkinsonism and Related Disorders</i> , 2023, 107, 105273.	1.1	1
2208	MDS-UDPRS-III in the diagnosis of idiopathic Normal Pressure Hydrocephalus and identification of candidates for Ventriculo-Peritoneal Shunting surgery. Results from a retrospective large cohort of patients. <i>Journal of the Neurological Sciences</i> , 2023, 445, 120536.	0.3	1
2209	Distress associated with recurrent complex visual hallucinations in Dementia with Lewy Bodies: The application of adapted cognitive behavioural therapy (CBT). , 2020, 1, 47-57.		1
2210	Ethics in Geriatric Mental Health. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
2211	Dementia and Mild Neurocognitive Disorders. , 2022, , .		0
2212	Schizophrenia Spectrum and Other Psychotic Disorders. , 2022, , .		0
2213	Genomics in Geriatric Psychiatry. , 2022, , .		0
2215	Individual and Group Psychotherapy. , 2022, , .		0
2216	Sexuality and Aging. , 2022, , .		0
2217	Use of the Laboratory in the Diagnostic Workup of Older Adults. , 2022, , .		0
2218	Anxiety, Obsessive-Compulsive, and Trauma-Related Disorders. , 2022, , .		1
2219	Working With Families of Older Adults. , 2022, , .		0
2220	Somatic Symptom and Related Disorders. , 2022, , .		0
2222	Neuropsychological Assessment of Late-Life Cognitive Disorders. , 2022, , .		0
2223	Sleep and Circadian Rhythm Sleep-Wake Disorders. , 2022, , .		0
2224	Bipolar and Related Disorders. , 2022, , .		0
2225	The Psychiatric Interview of Older Adults. , 2022, , .		0
2227	Substance-Related and Addictive Disorders. , 2022, , .		0
2229	Electroconvulsive Therapy and Other Forms of Brain Stimulation. , 2022, , .		0
2230	Depressive Disorders. , 2022, , .		0
2231	Physiological and Clinical Considerations of Geriatric Patient Care. , 2022, , .		0
2232	Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
2234	Use of Technology in Geriatric Psychiatry. , 2022, , .		0
2235	Agitation in Older Adults. , 2022, , .		0
2236	Clinical Psychiatry in the Nursing Home. , 2022, , .		0
2237	Global neuropathologic severity of Alzheimerâ€™s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. Molecular Neurodegeneration, 2022, 17, .	4.4	13
2238	FMR1 deletion in rats induces hyperactivity with no changes in striatal dopamine transporter availability. Scientific Reports, 2022, 12, .	1.6	3
2239	A Case Report of Treatment-Resistant Agitation in Dementia with Lewy Bodies: Medical Marijuana as an Alternative to Antipsychotics. Journal of Palliative Medicine, 0, , .	0.6	1
2240	Sex Differences in Dementia. Current Topics in Behavioral Neurosciences, 2022, , .	0.8	4
2241	MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies. Npj Parkinson's Disease, 2023, 9, .	2.5	5
2242	Cortical Thickness and Brain Glucose Metabolism in Healthy Aging. Journal of Clinical Neurology		

#	ARTICLE	IF	CITATIONS
2253	Parkinson disease primer, part 1: diagnosis. Canadian Family Physician, 2023, 69, 20-24.	0.1	4
2254	Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases. Movement Disorders, 2023, 38, 496-501.	2.2	2
2255	Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson's disease dementia. Translational Neurodegeneration, 2023, 12, .	3.6	8
2256	Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder. Brain Communications, 2022, 5, .	1.5	4
2257	Dysphagia in elderly with dementia. Japanese Journal of Geriatrics, 2023, 60, 1-10.	0.0	1
2258	The theoretical problems of "prodrome" and "phenocconversion" in neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 155-167.	1.0	0
2259	Circadian disruption and sleep disorders in neurodegeneration. Translational Neurodegeneration, 2023, 12, .	3.6	20
2261	Mortality Risks and Causes of Death by Dementia Types in a Japanese Cohort with Dementia: NCGG-STORIES. Journal of Alzheimer's Disease, 2023, 92, 487-498.	1.2	3
2262	Costs During the Last Five Years of Life for Patients with Clinical and Pathological Confirmed Diagnosis of Lewy Body Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 92, 457-466.	1.2	0
2263	Steeper memory decline after COVID-19 lockdown measures. Alzheimer's Research and Therapy, 2023, 15, .	3.0	3
2264	Demographic and Neuropsychologic Profiles of Patients with Neurodegenerative Dementia: Results from A Tertiary Referral University Hospital. European Journal of Geriatrics and Gerontology, 2023, 5, 59-65.	0.1	0
2265	Aphasic mild cognitive impairment in prodromal dementia with Lewy bodies. Frontiers in Neurology, 0, 14, .	1.1	3
2266	Baseline Predictors of Longitudinal Cognitive Outcomes in Persons with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2023, 52, 91-107.	0.7	0
2267	Degeneration of nigrostriatal dopaminergic neurons in the early to intermediate stage of dementia with Lewy bodies and Parkinson's disease. Journal of the Neurological Sciences, 2023, 449, 120660.	0.3	1
2268	Diagnosis of vascular parkinsonism: A new tool for gait hypokinesia occurring in older persons. Parkinsonism and Related Disorders, 2023, 109, 105360.	1.1	0
2269	Sex differences in brain metabolic connectivity architecture in probable dementia with Lewy bodies. Neurobiology of Aging, 2023, 126, 14-24.	1.5	2
2270	Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee. Clinical Neurophysiology, 2023, 150, 131-175.	0.7	37
2271	The unique neuropathological vulnerability of the human brain to aging. Ageing Research Reviews, 2023, 87, 101916.	5.0	4

#	ARTICLE	IF	CITATIONS
2272	Evaluation and Management of Dementia. , 2022, , 112-128.		0
2273	A bibliometric analysis of the application of imaging in sleep in neurodegenerative disease. Frontiers in Aging Neuroscience, 0, 15, .	1.7	2
2275	Mindfulness and Care Experience in Family Caregivers of Persons Living with Dementia. Journal of Alzheimer's Disease Reports, 2023, 7, 151-164.	1.2	0
2277	Mobility and associations with levels of cerebrospinal fluid amyloid $\hat{1}^2$ and tau in a memory clinic cohort. Frontiers in Aging Neuroscience, 0, 15, .	1.7	1
2278	Examining the Validity and Utility of Montreal Cognitive Assessment Domain Scores for Early Neurocognitive Disorders. Journal of the American Medical Directors Association, 2023, 24, 314-320.e2.	1.2	3
2281	Comparison Between <sup>18</sup> F-Florapronol and <sup>18</sup> F-Florbetaben Imaging in Patients		

#	ARTICLE	IF	CITATIONS
2296	A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1974-1987.	3.3	8
2297	Neurocognitive Disorders. , 2023, , 407-435.		0
2298	Redefining Bradykinesia. <i>Movement Disorders</i> , 2023, 38, 551-557.	2.2	12
2299	Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	64
2300	Orthostatic hypotension in dementia with Lewy bodies: a meta-analysis of prospective studies. <i>Clinical Autonomic Research</i> , 0, , .	1.4	2
2301	±Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid: A Systematic Review and Meta-Analysis. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 737-747.	0.8	9
2302	Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. <i>Brain</i> , 2023, 146, 2557-2569.	3.7	20
2303	Overview of late-onset psychoses. <i>International Psychogeriatrics</i> , 2024, 36, 28-42.	0.6	2
2304	Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	4
2305	The Importance of Dopamine Deficiency Evaluation in Non-Alzheimer Disease Dementias. <i>American Journal of Case Reports</i> , 0, 24, .	0.3	1
2306	Identification of key genes and signaling pathways associated with dementia with Lewy bodies and Parkinson's disease dementia using bioinformatics. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	3
2307	Burden of Illness Among Patients with Psychosis due to Dementia with Lewy Bodies and Other Dementias. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2023, 38, 153331752311635.	0.9	0
2309	Different MAPT haplotypes influence expression of total MAPT in postmortem brain tissue. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	5
2311	Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	4
2312	Synaptic Density and Glucose Consumption in Patients with <sup>11</sup>C<sup>18</sup>F<sup>18</sup>F<sup>18</sup>F PET<sup>18</sup>F PET Study. <i>Movement Disorders</i> , 2023, 38, 796-805.	2.2	6
2313	±Synuclein oligomers and fibrils: partners in crime in synucleinopathies. <i>Neural Regeneration Research</i> , 2023, 18, 2332-2342.	1.6	3
2314	Clinical symptoms in mild cognitive impairment with Lewy bodies: Frequency, time of onset, and discriminant ability. <i>European Journal of Neurology</i> , 2023, 30, 1585-1593.	1.7	2
2315	A Preliminary Comparison of the Methylome and Transcriptome from the Prefrontal Cortex Across Alzheimer's Disease and Lewy Body Dementia. <i>Journal of Alzheimer's Disease Reports</i> , 2023, 7, 279-297.	1.2	3

#	ARTICLE	IF	CITATIONS
2316	Indication for molecular testing by multiplex ligationâ€dependent probe amplification in parkinsonism. <i>European Journal of Neurology</i> , 0, , .	1.7	0
2317	Prevalence and outcomes of rapidly progressive dementia: a retrospective cohort study in a neurologic unit in China. <i>BMC Geriatrics</i> , 2023, 23, .	1.1	1
2318	Î±-Synuclein conformers reveal link to clinical heterogeneity of Î±-synucleinopathies. <i>Translational Neurodegeneration</i> , 2023, 12, .	3.6	4
2319	The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1988-2035.	3.3	2
2321	Analysis of positron emission tomography hypometabolic patterns and neuropsychiatric symptoms in patients with dementia syndromes. <i>CNS Neuroscience and Therapeutics</i> , 0, , .	1.9	0
2322	Plasma phospho-tau in Alzheimerâ€™s disease: towards diagnostic and therapeutic trial applications. <i>Molecular Neurodegeneration</i> , 2023, 18, .	4.4	22
2323	Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions. <i>Current Treatment Options in Neurology</i> , 2023, 25, 93-119.	0.7	1
2324	Misfolded Î±-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder. <i>Neurology</i> , 2023, 100, .	1.5	21
2325	Comparison of the telephoneâ€Montreal Cognitive Assessment (Tâ€MoCA) and Telephone Interview for Cognitive Status (TICS) as screening tests for early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 4599-4608.	0.4	2
2326	Former participation in professional football as an occupation in patients with isolated REM sleep behavior disorder leading to a synucleinopathy: a caseâ€control study. <i>Journal of Neurology</i> , 2023, 270, 3234-3242.	1.8	3
2327	Case 33. Hallucinations May Be the Clue. , 2023, , 145-148.		0
2328	On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimerâ€™s disease and Lewy body disease. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	1.7	3
2329	Cognitive Impairment in Neurodegenerative Movement Disorders. <i>Seminars in Neurology</i> , 2023, 43, 081-094.	0.5	0
2330	Advances in the Diagnosis and Management of Psychotic Symptoms in Neurodegenerative Diseases: A Narrative Review. <i>Journal of Geriatric Psychiatry and Neurology</i> , 0, , 089198872311643.	1.2	0
2331	Brainstem atrophy in dementia with Lewy bodies compared with progressive supranuclear palsy and Parkinsonâ€™s disease on MRI. <i>BMC Neurology</i> , 2023, 23, .	0.8	3
2333	Optimized Cingulate Island Sign in Discriminating Dementia With Lewy Bodies From Alzheimer Disease. <i>Clinical Nuclear Medicine</i> , 2023, 48, 400-403.	0.7	0
2334	Neuropsychological evaluation of phenoconversion risk in <sc>REM</sc> sleep behaviour disorder: A scoping review. <i>Journal of Sleep Research</i> , 0, , .	1.7	2
2335	Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	4

#	ARTICLE	IF	CITATIONS
2336	JNK Activation in Alzheimer's Disease Is Driven by Amyloid $\beta^2$ and Is Associated with Tau Pathology. <i>ACS Chemical Neuroscience</i> , 0, , .	1.7	5
2337	Clinical update on dementia with Lewy bodies for primary care NPs. <i>Nurse Practitioner</i> , 2023, 48, 22-29.	0.2	1
2338	Voxel-Based and Surface-Based Morphometry Analysis in Patients with Pathologically Confirmed Argrophilic Grain Disease and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 93, 379-387.	1.2	4
2339	Identification of a Putative $\beta$ -synuclein Radioligand Using an in silico Similarity Search. <i>Molecular Imaging and Biology</i> , 2023, 25, 704-719.	1.3	2
2340	Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 802-813.	1.7	9
2341	Association of APOE $\epsilon$ 4/ $\epsilon$ 4 with fluid biomarkers in patients from the PUMCH dementia cohort. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	1.7	2
2342	Validation study of "Sant'À-Cerveau", a digital tool for early cognitive changes identification. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	1
2343	A short and simple bedside test to detect cognitive fluctuations in patients with dementia with Lewy bodies. <i>Acta Neurologica Belgica</i> , 2023, 123, 803-806.	0.5	0
2344	<sc>LRRK2</sc> and Parkinson's disease: from genetics to targeted therapy. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 850-864.	1.7	5
2345	Cognitive heterogeneity in Parkinson's disease: A mechanistic view. <i>Neuron</i> , 2023, 111, 1531-1546.	3.8	10
2346	Evaluating the association between genetically proxied ACE inhibition and dementias. <i>Alzheimer's and Dementia</i> , 2023, 19, 3894-3901.	0.4	3
2347	Clinical characteristics and potential association to Parkinson's disease and dementia with Lewy bodies in patients with major depressive disorder who received maintenance electroconvulsive therapy: a retrospective chart review study. <i>BMC Psychiatry</i> , 2023, 23, .	1.1	1
2348	Superior Global Cognition in Oldest-Old Is Associated with Resistance to Neurodegenerative Pathologies: Results from The 90+ Study. <i>Journal of Alzheimer's Disease</i> , 2023, 93, 561-575.	1.2	1
2349	Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, 82, 438-451.	0.9	4
2350	Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson's disease and atypical Parkinsonian syndromes. <i>Journal of Neural Transmission</i> , 2023, 130, 839-846.	1.4	3
2351	A simple method to evaluate the pentagon copy test of the Mini-Mental State Examination for the differentiation of dementia with Lewy bodies. <i>Applied Neuropsychology Adult</i> , 0, , 1-7.	0.7	0
2353	Blood $\beta$ -synuclein is related to amyloid PET positivity in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2023, 19, 4896-4907.	0.4	1
2354	Ecological validity of cognitive fluctuations in dementia with Lewy bodies. <i>Journal of the International Neuropsychological Society</i> , 2024, 30, 35-46.	1.2	5



#	ARTICLE	IF	CITATIONS
2355	The brain-first vs. body-first model of Parkinson's disease with comparison to alternative models. Journal of Neural Transmission, 2023, 130, 737-753.	1.4	10
2357	Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy. Journal of Neuropathology and Experimental Neurology, 2023, 82, 457-466.	0.9	2
2358	Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 2023, 10, 980-986.	0.8	2
2359	Neuropsychological Comparison of Patients With Alzheimer's Disease and Dementia With Lewy Bodies.		

#	ARTICLE	IF	CITATIONS
2499	Case report: Anti-ARHGAP26 autoantibodies in atypical dementia with Lewy bodies. , 0, 2, .		0
2510	Organische psychische Störungen/Neurokognitive Störungen. , 2023, , 137-172.		0
2514	Dopaminergic Nerve Terminal Imaging Across the Spectrum of Aging, Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder, Parkinsonism and Dementia. , 2023, , 109-125.		0
2515	FDG PET Imaging Evaluation of Neurodegenerative Dementias. , 2023, , 57-71.		0
2516	What Is Neurodegeneration?. , 2023, , 1-13.		0
2517	Balance Measures Derived from Insole Sensor Differentiate Prodromal Dementia with Lewy Bodies. , 2023, , .		0
2522	â€˜How Does Your Dementia Affect You?â€™. , 2023, , 45-81.		0
2530	Lewy Body Dementia: An Overview of Promising Therapeutics. Current Neurology and Neuroscience Reports, 2023, 23, 581-592.	2.0	1
2532	Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	23
2536	Synaptic PET Imaging in Neurodegeneration. , 2023, , 157-167.		0
2549	Synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 175-202.	1.0	0
2551	Brain Hemisphere Dissimilarity, a Self-Supervised Learning Approach for alpha-synucleinopathies prediction with FDG PET. , 2023, , .		0
2557	Acute psychiatric problems in movement disorders. International Review of Movement Disorders, 2023, , 49-84.	0.1	0
2558	Neurodegenerative Erkrankungen und VerÄnderungen des künstlerischen Ausdrucks. , 2023, , 29-42.		0
2582	Neuroimaging determinants of cognitive impairment in the memory clinic: how important is the vascular burden?. Journal of Neurology, 0, , .	1.8	0
2584	The effects of different acetylcholinesterase inhibitors on EEG patterns in patients with Alzheimerâ€™s disease: A systematic review. Neurological Sciences, 0, , .	0.9	0
2599	Antidementiva. , 2023, , 637-689.		0
2605	Comparison of CSF and plasma NfL and pNfH for Alzheimerâ€™s disease diagnosis: a memory clinic study. Journal of Neurology, 2024, 271, 1297-1310.	1.8	1

#	ARTICLE	IF	CITATIONS
2617	qEEG Methods to Probe Abnormal Brain Rhythms Related to Quiet Vigilance in Patients with Dementia Due to Alzheimer's, Parkinson's, and Lewy Body Diseases. <i>Neuromethods</i> , 2024, , 67-89.	0.2	0
2621	Sleep Disturbances in Autoimmune Encephalitis. , 2023, , 741-755.		0
2683	Differentiating anti-LGON5 disease and Lewy body dementia: a systematic review. <i>Journal of Neurology</i> , 2024, 271, 1707-1716.	1.8	0
2687	A general clinical overview of the non-motor symptoms in Parkinson's disease: Neuropsychiatric symptoms. <i>International Review of Neurobiology</i> , 2024, , 59-97.	0.9	0
2704	Expanding the phenotype of psychiatric-onset prodromal dementia with Lewy bodies. <i>Journal of Neurology</i> , 2024, 271, 2125-2128.	1.8	0
2709	Estimating motor progression trajectory pursuant to temporal dynamic status of cardiac denervation in Parkinson's disease. <i>Journal of Neurology</i> , 2024, 271, 2019-2030.	1.8	0
2721	Maladie de Parkinson. , 2023, , 520-526.		0
2784	Case report: Environmental adjustment for visual hallucinations in dementia with Lewy bodies based on photo assessment of the living environment. <i>Frontiers in Psychiatry</i> , 0, 15, .	1.3	0
2786	Lewy Body Dementia. , 2024, , .		0